Halozyme Therapeutics Annual Report 2022

FY2022 Annual Report · Halozyme Therapeutics

Loading PDF…

2022
Annual Report

Dear Fellow Shareholders:

2022 was a transformative year for
Halozyme. We delivered record revenue
from our ENHANZE® business and
extended our drug delivery leadership
and expanded our commercial portfolio
with the acquisition of Antares Pharma.
We had many successes and learnings
this year and together, as One Team, we
demonstrated operational excellence
throughout the organization for the
beneﬁt of patients around the world.
Halozyme’s successes were marked by
strong growth in revenue and proﬁts as
we strengthened our partnerships and
enhanced our capabilities to support
current and new partners with ENHANZE®
and an innovative auto-injector
technology platform. All of this and more,
delivers on our commitment to our
stakeholders, including our shareholders.

RECORD GROWTH
FOR HALOZYME
Our strong performance across the
business, including the successful
integration of Antares Pharma, drove
another year of record revenue, with
$660.1 million, representing 49% year-
over-year growth. Revenue from
royalties in 2022 also achieved record
levels, increasing 77% to $360.5 million,
primarily driven by strong adoption of our
ENHANZE® partner products DARZALEX®
Faspro and Phesgo® and the addition of
the auto-injector royalty revenue.

Our leadership in drug delivery with a
commercial portfolio has augmented
our growth potential, diversiﬁed our
revenue streams and extended our
revenue durability. We look forward
to further strengthening our position
as the drug delivery partner of choice
for pharmaceutical and biotechnology
companies with ENHANZE® and our
auto-injector technology platforms.

As a proﬁtable biopharma company, we
have a strong balance sheet and continue
to generate cash that has supported
our commitment to our strategic capital
allocation strategy, including returning
capital to our shareholders. In 2022, we
completed $350 million of our 3-year $750
million dollar share repurchase plan that
was approved by the Board of Directors
in December 2021. As part of this plan, we
expect to complete another $150 million
of share repurchases in 2023, pending
market conditions and other factors.

Halozyme is well-positioned to embark on
our next chapter of accelerating ﬁnancial
growth to drive shareholder value.

PARTNER SUCCESS
WITH ENHANZE®

With an established leadership in drug
delivery, we have ﬁve globally-approved
partner products utilizing ENHANZE®
available in more than 100 countries. More
than 600,000 patients have received
commercial products utilizing ENHANZE®.
We currently have twelve pharma and
biotech partners with access to our
ENHANZE® drug delivery technology and
work closely with our partners to support
the development of their innovative
products in combination with ENHANZE®.

Our ENHANZE® development pipeline is
robust and diverse. There were signiﬁcant
achievements and successes with our
partners related to our ENHANZE®
technology in 2022, including:
• argenx’s submission of a Marketing
Authorization Application to the
European Medicines Agency and the
FDA acceptance of its Biologics License
Application for SC efgartigimod for the
treatment of adults with generalized
myasthenia gravis with a PDUFA date
of June 20, 2023.

• Roche’s submission of a Marketing
Authorization Application to the
European Medicines Agency and
the FDA acceptance of its Biologics
License Application for SC atezolizumab
with ENHANZE® across all approved
indications of IV Tecentriq® with a
PDUFA date of September 15, 2023.
• Roche’s initiation of a Phase 3 study

evaluating ocrelizumab with ENHANZE®
in subjects with multiple sclerosis.
• Janssen’s initiation of a Phase 3 study
of lazertinib and amivantamab with
ENHANZE® in patients with epidermal
growth factor receptor mutated
advanced or metastatic non-small cell
lung cancer (PALOMA-3).

• Bristol Myers Squibb’s initiation of a
Phase 3 study to compare the drug
levels of nivolumab with ENHANZE®
administered subcutaneously
versus intravenous administration in
participants with melanoma following
complete resection (CheckMate-6GE).
• Takeda’s positive topline results from a
pivotal Phase 3 trial evaluating HYQVIA®
(Immunoglobulin infusion 10% (Human)
with ENHANZE®), for maintenance
treatment of chronic inﬂammatory
demyelinating polyradiculoneuropathy.

• Eight partner products are in or have
completed Phase 1 development.

2 partner products with
ENHANZE® pending
completion of regulatory
review and potential for
approval in 2023

4 Phase 3 study data
readouts by collaboration
partners in 2023 from two
products utilizing ENHANZE®

Helen Torley, President and Chief Executive Ofﬁcer

Halozyme is continuing to enhance our
capabilities to support current and new
partners utilizing our ENHANZE® and
auto-injector technologies, with the goal
of reducing the burden of treatment for
patients and providing new options for
patients with the goal of driving long-
term, durable growth.

CONTINUED
OPERATIONAL
EXCELLENCE
Just as our vision remains to deliver
disruptive solutions that signiﬁcantly
improve patient experiences and bring
the potential to positively inﬂuence
outcomes for emerging and established
therapies, we have remained dedicated
to delivering on our commitment to
corporate citizenship. Sustainability and
environmental consciousness have been
critical to our decision-making as the
organization has grown and expanded our
footprint. This core responsibility, together
with our drive for continuous learning
and development, drove our efforts
to transform our internal and external
environment. In 2022, we successfully
executed multiple actions to progress
our ESG ambition:

• Continued to build a diverse team of
employees who are passionate about
and committed to positively impacting
the lives of patients and their families.
This dedication has resulted in a diverse
and inclusive employee base consisting
of 43.8% female and 30.5% non-white/
Caucasian employees as of December
2022. We value and celebrate the unique
talents, backgrounds, and perspectives
each employee contributes to achieving
our mission and corporate objectives.
Our diverse and inclusive culture is
key to attracting, developing, and
retaining top talent within the globally
competitive biotechnology industry.

• As Halozyme welcomed two new ofﬁce
sites, we expanded our approach to
employee engagement. These efforts
include a focus on supporting the
Halozyme team culture and connectivity
through events and activities to support
the local community. These initiatives
achieved strong participation in both
engagement and community events.
• We are committed to protecting our

data assets and systems’ conﬁdentiality,
integrity and availability. In 2022,
an industry leading management
consulting ﬁrm assessed the security
controls for our integrated business
between Halozyme and Antares
following the acquisition. That
assessment helped us create a robust
and comprehensive cybersecurity plan
of action for 2023 and beyond.

• Implemented a global Environment

Health and Safety program to support
integration initiatives. The program
also includes a Global Policy rollout
with site-speciﬁc procedures. We also
initiated a Laboratory Waste-to-Energy
program to reduce waste from our labs
and prevent it from entering the landﬁll
while leveraging it as a raw material to
produce renewed energy.

Our goal is to achieve
NetZero energy usage at
our company headquarters
by 2030

Approximately 85 percent
of our waste, by volume,
is recycled

All our initiatives, progress and
accomplishments are possible because of
Halozyme’s One Team commitment. One
Team is all about exceptional collaboration
and accountability as we execute on our
mission for all of our stakeholders.

The dedication and commitment I have
seen this past year have been astounding,
and the motivation to enhance the patient
experience is reﬂected across every facet
of our business.

I am grateful to all of our stakeholders,
including our employees, partners, board
of directors and shareholders for your
support and commitment in 2022.

Best regards,

HELEN TORLEY, M.B. Ch. B., M.R.C.P.
PRESIDENT & CEO

include

to shareholders

FORWARD LOOKING STATEMENTS
Statements set forth in this annual report and
letter
forward-looking
statements including, without limitation, statements
concerning the Company’s expected future ﬁnancial
performance, plans to repurchase shares under
its share repurchase program and expectations
concerning its partners’ development programs and
potential approvals of partnered products. These
forward-looking statements are typically, but not
always, identiﬁed through use of the words “believe,”
“enable,” “may,” “will,” “could,” “intends,” “estimate,”
“anticipate,” “plan,” “predict,” “probable,” “potential,”
“possible,” “should,” “continue,” and other words of
similar meaning and involve risk and uncertainties
that could cause actual results to differ materially
from those in the forward-looking statements. Actual
results could differ materially from the expectations
contained in these forward-looking statements as a
result of several factors, including unexpected levels of
revenues, expenditures and costs, unexpected delays
in the execution of the Company’s share repurchase
program, or unexpected results or delays in the
development, regulatory review or commercialization
of the Company’s partnered or proprietary products.
These and other factors that may result in differences
are discussed in greater detail in the Company’s
most recently ﬁled Annual Report on Form 10-K
ﬁled with the Securities and Exchange Commission.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF

1934

For the fiscal year ended December 31, 2022
OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT

OF 1934

For the transition period from to

Commission File Number 001-32335

_________________________
HALOZYME THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
___________________________

Delaware
(State or other jurisdiction of incorporation or organization)

88-0488686
(I.R.S. Employer Identification No.)

12390 El Camino Real
San Diego
CA
(Address of principal executive offices)

92130
(Zip Code)

(858) 794-8889
(Registrant’s telephone number, including area code)

Title of Each Class

Securities registered under Section 12(b) of the Act:
Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, $0.001 Par Value

HALO

The NASDAQ Stock Market, LLC

Securities registered under Section 12(g) of the Act:
None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities

Act. ☒ Yes ☐ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the

Act. ☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller
reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller
reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer

Non-accelerated filer

Smaller reporting company Emerging growth company

☒

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant has filed a report on and attestation to its management’s assessment of the
effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by
the registered public accounting firm that prepared or issued its audit report. ☒

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the

registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-
based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to
§240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange

Act). ☐ Yes ☒ No

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of June 30,
2022 was approximately $5.1 billion based on the closing price on the NASDAQ Global Select Market reported for such date. Shares
of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common
stock have been excluded in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is
not necessarily a conclusive determination for other purposes.

The number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 135,366,862 as of

February 14, 2023.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive Proxy Statement to be filed subsequent to the date hereof with the Securities and Exchange
Commission pursuant to Regulation 14A in connection with the registrant’s 2023 Annual Meeting of Stockholders are incorporated by
reference into Part III of this Annual Report.

HALOZYME THERAPEUTICS, INC.

INDEX

Summary of Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART I

Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Mine Safety Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART II
Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(Reserved) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . .
Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure . . . . . . . . . . . .
Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART III

Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters . . .

Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . . . . . . . . . . .

Principal Accounting Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.

Item 5.

Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 9C.

Item 10.

Item 11.

Item 12.

Item 13.

Item 14.

Item 15.

Exhibits, Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 16. . . Form 10-K Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

SIGNATURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART IV

Page
3

8
25
42
43
43
43

44
46
47
60
60
60
61
63
63

Summary of Risk Factors

Our business is subject to a number of risks and uncertainties, including those described in the section labeled “Risk
Factors” in “Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations” of this
Quarterly Report. These risks include the following:

Risks Related To Our Business

•

If our partnered or proprietary product candidates do not receive and maintain regulatory approvals, or if approvals are
not obtained in a timely manner, such failure or delay would substantially impair our ability to generate revenues.

Use of our partnered or proprietary products and product candidates could be associated with adverse events or product
recalls.

If our contract manufacturers or vendors are unable or unwilling for any reason to manufacture and supply to us bulk
rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our
partners for use in the production of Hylenex or other proprietary or partnered products and product candidates, our
and our partners’ product development or commercialization efforts could be delayed or suspended and our business
results of operations and our collaborations could be harmed.

• We rely on third parties to perform necessary services for our products including services related to the distribution,
invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration,
storage and transportation of our products. If anything should impede their ability to meet their commitments this
could impact our business performance.

•

If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a
key collaboration agreement, is terminated for any reason, our business could suffer.

Hylenex and our partners’ ENHANZE® products and product candidates rely on the rHuPH20 enzyme, and any
adverse development regarding rHuPH20 could substantially impact multiple areas of our business, including current
and potential ENHANZE collaborations, as well as any proprietary programs.

Our business strategy is focused on growth of our ENHANZE technology, our auto-injector technology, our
commercial products and potential growth through acquisition. Currently, ENHANZE is the largest revenue driver and
as a result there is a risk for potential negative impact from adverse developments. Future expansion of our strategic
focus to additional applications of our ENHANZE technology or by acquiring new technologies may require the use of
additional resources, result in increased expense and ultimately may not be successful.

Our partnered or proprietary product candidates may not receive regulatory approvals or their development may be
delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory requirements or safety
concerns. If we or our partners fail to obtain, or have delays in obtaining, regulatory approvals for any product
candidates, our business, financial condition and results of operations may be materially adversely affected or delayed.

Our third-party partners are responsible for providing certain proprietary materials that are essential components of our
partnered products and product candidates, and any failure to supply these materials could delay the development and
commercialization efforts for these partnered products and product candidates and/or harm our collaborations. Our
partners are also responsible for distributing and commercializing their products, and any failure to successfully
commercialize their products could materially adversely affect our revenues.

If we or our partners fail to comply with regulatory requirements applicable to promotion, sale and manufacturing of
approved products, regulatory agencies may take action against us or them, which could harm our business.

Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely
impact our future business and operations.

•

Business interruptions resulting from pandemics or similar public health crises could cause a disruption of the
development of our and our partnered product candidates and commercialization of our approved and our partnered
products, impede our ability to supply bulk rHuPH20 to our ENHANZE partners or procure and sell our proprietary
products and otherwise adversely impact our business and results of operations.

• We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such

funds.

• We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the

applicable debt agreements may cause repayment obligations to accelerate.

•

The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition
and operating results.

Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise
depress the price of our common stock.

If proprietary or partnered product candidates are approved for commercialization but do not gain market acceptance
resulting in commercial performance below that which was expected or projected, our business may suffer.

Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents
and other proprietary rights.

Developing, manufacturing and marketing pharmaceutical products for human use involves significant product
liability risks for which we may have insufficient insurance coverage.

If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly
announced or otherwise expected, the commercialization of our partners products may be delayed and, as a result, , our
business, financial condition, and results of operations may be adversely affected or delayed.

Future acquisitions could disrupt our business and impact our financial condition.

Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.

Risks Related To Ownership of Our Common Stock

•

Our stock price is subject to significant volatility.

Future transactions where we raise capital may negatively affect our stock price.

Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us
more difficult.

Risks Related to Our Industry

•

Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the
extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our
or our partnered product sales, introductions or modifications.

Because some of our and our partners’ products and product candidates are considered to be drug/device combination
products, the approval and post-approval requirements that we and they are required to comply with can be more
complex.

• We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to
comply, or have not fully complied, with such laws, we could face civil, criminal and administrative penalties,
damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal
healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment
or restructuring of our operations, any of which could adversely affect our ability to operate.

• We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may
result in substantial expense, delay and/or cessation of certain development and commercialization of our products.

• We may incur significant liability if it is determined that we are promoting or have in the past promoted the “off-label”
use of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with
the FDA’s requirements.

•

For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required
to comply with regulatory requirements related to controlled substances, which will require the expenditure of
additional time and will incur additional expenses to maintain compliance and may subject us to additional penalties
for noncompliance, which could inhibit successful commercialization.

Patent protection for biotechnology inventions and for inventions generally is subject to significant scrutiny. If patent
laws or the interpretation of patent laws change, our business may be adversely impacted because we may lose the
ability to enforce our intellectual property rights against competitors who develop and commercialize products based
on our discoveries.

If third-party reimbursement and customer contracts are not available, our proprietary and our partnered products may
not be accepted in the market resulting in commercial performance below that which was expected or projected.

The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from
third-party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us
and our partners to sell our products at lower prices, and impact access to our and our partners’ products, resulting in
less revenue to us.

• We face competition and rapid technological change that could result in the development of products by others that are

competitive with our proprietary and partnered products, including those under development.

General Risks

•

If we are unable to attract, hire and retain key personnel our business could be negatively affected.

Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.

Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and
reputation.

This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of the “safe harbor”
provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as
amended. All statements, other than statements of historical fact, included herein, including without limitation those regarding
our future product development and regulatory events and goals, product collaborations, our business intentions and financial
estimates and anticipated results, are, or may be deemed to be, forward-looking statements. Words such as “expect,”
“anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “think,” “may,” “could,” “will,” “would,” “should,”
“continue,” “potential,” “likely,” “opportunity,” “project” and similar expressions or variations of such words are intended
to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual
Report. Additionally, statements concerning future matters such as the development or regulatory approval of new partner
products, enhancements of existing products or technologies, timing and success of the launch of new products by us and our
partners, third party performance under key collaboration agreements, the ability to successfully integrate Antares Pharma,
Inc. into our business, the ability of our bulk drug and device part manufacturers to provide adequate supply for our partners,
revenue, expense, cash burn levels and our ability to make timely repayments of debt, anticipated amounts and timing of share
repurchases, anticipated profitability and expected trends and other statements regarding our plans and matters that are not
historical are forward-looking statements.

Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such
statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are
inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and
outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such
differences in results and outcomes include without limitation those discussed under the heading “Risk Factors” in Part I, Item
1A below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these
forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or
update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual
Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt
to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and
prospects.

References to “Halozyme,” “the Company,” “we,” “us,” and “our” refer to Halozyme Therapeutics, Inc. and its wholly
owned subsidiary, Halozyme, Inc., Antares Pharma Inc., and Antares Pharma Inc.’s wholly-owned subsidiaries, Antares
Pharma IPL AG and Antares Pharma AG. References to “Notes” refer to the Notes to Consolidated Financial Statements
included herein (refer to Part II, Item 8).

PART I

Item 1.

Business

Overview

Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive

solutions with the goal of improving the patient experience and potentially outcomes.

Our proprietary enzyme, rHuPH20, is used to facilitate the subcutaneous (“SC”) delivery of injected drugs and fluids. We
license our technology to biopharmaceutical companies to collaboratively develop products that combine our ENHANZE® drug
delivery technology (“ENHANZE”) with the partners’ proprietary compounds.

Our first commercially approved product, Hylenex® recombinant (“Hylenex”), and our ENHANZE partners’ approved
products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is
the active ingredient in Hylenex, that works by breaking down hyaluronan (“HA”), a naturally occurring carbohydrate that is a
major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing
for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and
other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the
delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with
biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of
administration. In the development of proprietary intravenous (“IV”) drugs combined with our ENHANZE technology, data
have been generated supporting the potential for ENHANZE to reduce patient treatment burden as a result of shorter duration of
SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared to
weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already administered
subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more flexible
treatment options such as home administration by a healthcare professional or potentially the patient or caregiver. Lastly,
certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent life of
the product beyond the patent expiry of the proprietary IV drug.

We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-
La Roche, Inc. (“Roche”), Takeda Pharmaceuticals International AG and Baxalta US Inc (“Takeda”), Pfizer Inc. (“Pfizer”),
Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company
(“BMS”), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca
PLC)(“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (“Horizon”), ViiV Healthcare (the global specialist HIV
Company majority owned by GlaxoSmithKline) (“ViiV”) and Chugai Pharmaceutical Co, Ltd (“Chugai”). In addition to
receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone
payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-
formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of
one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen
collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved
products will depend on the ability of our partners, in some areas supported by Halozyme, to develop, manufacture, secure and
maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Through our recent acquisition of Antares Pharma, Inc. (“Antares”), we also develop, manufacture and commercialize, for
ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a
result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED®, TLANDO® and
NOCDURNA®. We have commercialized auto-injector products with several pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (“Teva”), Covis Group S.a.r.l. (“Covis”) and Otter Pharmaceuticals, LLC (“Otter”). We have
development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (“Idorsia”) and Pfizer.

Our principal offices and research facilities are located at 12390 El Camino Real, San Diego, CA 92130. Our telephone

number is (858) 794-8889 and our e-mail address is info@halozyme.com. Our website address is www.halozyme.com.
Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on
Form 10-K. Our periodic and current reports that we filed with the SEC are available on our website at www.halozyme.com,
free of charge, as soon as reasonably practicable after we have electronically filed such material with, or furnished them to, the
SEC, including our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any
amendments to those reports.

Our Technology

rHuPH20 can be applied as a drug delivery platform to increase dispersion and absorption of other injected drugs and
fluids, potentially reducing treatment burden. For example, rHuPH20 has been used to convert drugs that must be delivered
intravenously into SC injections or to reduce the number of SC injections needed for effective therapy. When ENHANZE
technology is applied subcutaneously, the rHuPH20 acts locally and transiently, with a tissue half-life of less than 30
minutes. HA at the local site reconstitutes its normal density within two days and, therefore, the effect of rHuPH20 on the
architecture of the SC space is temporary.

Through our recent acquisition of Antares, our technology also includes pressure-assisted auto-injector technology. The
pressure-assisted auto-injector technology is a form of parenteral drug delivery that continues to gain acceptance and demand
among the medical and patient community. Encompassing a variety of sizes and designs, our technology operates by using
pressure to force the drug, in solution or suspension, through the skin and deposits the drug into the SC or intramuscular tissue.
We have designed disposable, pressure-assisted auto-injector devices to address acute and chronic medical needs, such as
rheumatoid arthritis and psoriasis, allergic reactions, migraine headaches, testosterone deficiency and maternal health. Our
current platforms include the VIBEX® and the VIBEX® QuickShot® disposable pressure-assisted auto-injection systems, the
Vai™ auto-injector and disposable pen injection systems. Our auto-injectors offer a does capacity ranging from 0.5 mL to 2.25
mL. They are designed for speed and patient comfort and accommodate for highly viscous drug products. They are
customizable for fill volumes and needle lengths to meet our partners’ needs for reliability requirements, including for
emergency use applications.

Our Strategy

We are a leader in converting IV biologics to SC delivery and extending the dosing interval of SC drugs, using our
commercially-validated ENHANZE technology. Our ENHANZE technology also has the potential for SC delivery of small
molecules, including those developed as long-acting injectables and other therapies that might benefit from larger dose/larger
volume SC delivery. We collaborate with leading pharmaceutical and biotechnology companies to help them develop products
that combine our ENHANZE technology with their proprietary compounds. We target large, attractive markets, where
ENHANZE-enabled SC delivery has the potential to deliver competitive differentiation and other important benefits to our
partners, such as larger injection volumes administered rapidly, extended dosing intervals, and reduced treatment burden and
healthcare costs. In addition, ENHANZE has been demonstrated to enable the combination of two therapeutic antibodies in a
single injection, as well as the development of new co-formulation intellectual property. We leverage our strategic, technical,
regulatory and alliance management skills in support of our partners' efforts to develop new subcutaneously delivered products.
We currently have twelve collaborations with five currently approved products and additional product candidates in
development using our ENHANZE technology. We intend to work with our existing partners to expand our collaborations to
add new targets and develop targets and product candidates under the terms of the operative collaboration agreements. We will
also continue our efforts to enter into new collaborations to derive additional revenue from our proprietary technology.

We also support leading pharmaceutical companies by assisting in the development of, and supplying, auto-injector
devices and auto-injector drug combination products. We leverage our engineering, regulatory and manufacturing skills to
support our partners’ plans. We intend to extend the range of auto-injectors available to current and new partners, initiating
development of a high volume auto-injector, and further extend the number of partners by gaining more partners for the current
auto-injectors.

Product and Product Candidates

The following table summarizes our marketed proprietary products and product candidates under development and our

marketed partnered products and product candidates under development with our partners:

Proprietary Products and Product Candidates

Hylenex Recombinant (hyaluronidase human injection)

We market and sell Hylenex recombinant which is a formulation of rHuPH20 that facilitates SC administration for
achieving hydration, increases the dispersion and absorption of other injected drugs and, in SC urography, to improve
resorption of radiopaque agents. Hylenex recombinant is currently the number one prescribed branded hyaluronidase.

XYOSTED (testosterone enanthate) Injection

We market and sell in the U.S. our proprietary product XYOSTED injection for SC administration of testosterone
replacement therapy (“TRT”) in adult males for conditions associated with a deficiency or absence of endogenous testosterone
(primary or hypogonadism). XYOSTED is the only FDA-approved SC testosterone enanthate product for once-weekly, at-
home self-administration and is approved and marketed in three dosage strengths, 50 mg, 75 mg and 100 mg. Safety and
efficacy of XYOSTED in males less than 18 years old have not been established.

NOCDURNA (desmopressin acetate) Sublingual Tablets

We market and sell NOCDURNA in the U.S., which is the first and only sublingual tablet indicated for the treatment of
nocturia due to nocturnal polyuria (“NP”) in adults who awaken at least two times per night to urinate. In the NOCDURNA
clinical trials, NP was defined as night-time urine production exceeding one-third of the 24-hour urine production.
NOCDURNA is a sublingual tablet, marketed in two dosage strengths, that dissolves quickly under the tongue without water
and has been shown in clinical studies to reduce nighttime urination by nearly one-half (in patients who average three nighttime
bathroom visits.) We license NOCDURNA from Ferring. In October 2022, we sent a notice to Ferring that we are terminating
the NOCDURNA license agreement with an effective termination date in October 2023.

TLANDO (testosterone undecanoate) Oral Formulation

TLANDO is a twice daily oral formulation of testosterone indicated for testosterone replacement therapy in adult males
for conditions associated with a deficiency or absence of endogenous testosterone (primary or hypogonadotropic
hypogonadism). TLANDO was granted FDA approval in March 2022. In June 2022, we announced the commercial launch of
TLANDO. Safety and efficacy of TLANDO in males less than 18 years old have not been established.

ATRS - 1902

We have an ongoing program to develop a proprietary drug device combination product for the endocrinology market, for
patients who require additional supplemental hydrocortisone, identified as ATRS-1902. The development program uses a novel
proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.

In June 2021, we submitted an IND application with the FDA for the initiation of a Phase 1 clinical study of ATRS-1902
for adrenal crisis rescue. The IND application includes the protocol for an initial clinical study to compare the pharmacokinetic
profile of our novel formulation of hydrocortisone versus Solu-Cortef®, which is an anti-inflammatory glucocorticoid and is the
current standard of care for the management of acute adrenal crises.

In July 2021, the FDA accepted our IND for ATRS-1902 enabling us to initiate our Phase 1 clinical study. The Phase 1
clinical study, designed to evaluate the safety, tolerability and pharmacokinetics (“PK”) of a liquid stable formulation of
hydrocortisone, was initiated in September 2021. The study was a cross-over design to establish the PK profile of ATRS-1902
(100 mg) compared to Solu-Cortef (100 mg), the reference-listed drug, in 32 healthy adults.

In January 2022, we announced the positive results from the Phase 1 clinical study and were granted Fast Track
designation by the FDA. The positive results supported the advancement of our ATRS-1902 development program to a pivotal
study for the treatment of acute adrenal insufficiency using our Vai novel proprietary rescue pen platform to deliver a liquid
stable formulation of hydrocortisone.

Partnered Products

ENHANZE Collaborations

Roche Collaboration

In December 2006, we and Roche entered into a collaboration and license agreement under which Roche obtained a
worldwide license to develop and commercialize product combinations of rHuPH20 and up to twelve Roche target compounds
(the Roche Collaboration). Under this agreement, Roche elected a total of eight targets, two of which are exclusive.

In September 2013, Roche launched a SC formulation of Herceptin (trastuzumab) (Herceptin® SC) in Europe for the
treatment of patients with HER2-positive breast cancer followed by launches in additional countries. This formulation utilizes
our ENHANZE technology and is administered in two to five minutes, compared to 30 to 90 minutes with the standard IV
form. In September 2018, we announced that Roche received approval from Health Canada for Herceptin SC for the treatment
of patients with HER2-positive breast cancer. In February 2019, we announced that Roche received approval from the U.S.
Food and Drug Administration (“FDA”) for Herceptin SC under the brand name Herceptin Hylecta™ (trastuzumab and
hyaluronidase-oysk). In April 2019, Roche made Herceptin Hylecta available in the U.S. In October 2022, Roche
Pharmaceuticals China announced the approval of Herceptin in China for the treatment of patients with early-stage and
metastatic HER2-positive breast cancer.

In June 2020, the FDA approved the fixed-dose combination of Perjeta® (pertuzumab) and Herceptin for SC injection
(Phesgo™) utilizing ENHANZE technology for the treatment of patients with HER2-positive breast cancer. In December 2020,
the European Commission (“EC”) also approved Phesgo for the treatment of patients with early and metastatic HER2-positive
breast cancer. In July 2022, Roche submitted the Initial Marketing Application (“IMA”) for the fixed-dose combination of
Perjeta (pertuzumab) and Herceptin for SC injection (Phesgo) to Center for Drug Evaluation (“CDE”) in China. In September
2022, Chugai Pharmaceutical Co., Ltd. (a Member of the Roche Group) announced the submission of a new NDA in Japan for
fixed-dose SC combination of pertuzumab and trastuzumab (same monoclonal antibodies as in Perjeta and Herceptin) with
ENHANZE. This application is based on data from two clinical studies including the results from the global Phase 3 FeDeriCa
study in patients with HER2-positive breast cancer.

In June 2014, Roche launched MabThera® SC in Europe for the treatment of patients with common forms of non-
Hodgkin lymphoma (NHL) followed by launches in additional countries. This formulation utilizes our ENHANZE technology
and is administered in approximately five minutes compared to the approximately 1.5 to 4 hour IV infusion. In May 2016,
Roche announced that the European Medicines Agency (“EMA”) approved Mabthera SC to treat patients with chronic
lymphocytic leukemia (“CLL”). In June 2017, the FDA approved Genentech’s RITUXAN HYCELA®, a combination of
rituximab using ENHANZE technology (approved and marketed under the MabThera SC brand in countries outside the U.S.
and Canada), for CLL and two types of NHL, follicular lymphoma and diffuse large B-cell lymphoma. In March 2018, Health
Canada approved a combination of rituximab and rHuPH20 (approved and marketed under the brand name RITUXAN® SC) for
patients with CLL. In November 2022, Roche submitted the IMA for Mabthera SC to CDE in China.

In September 2017, we entered into an agreement with Roche to develop and commercialize one additional exclusive
target using ENHANZE technology. The upfront license payment may be followed by event-based payments subject to Roche’s
achievement of specified development, regulatory and sales-based milestones. In addition, Roche will pay royalties to us if
products under the collaboration are commercialized.

In October 2018, we entered into an agreement with Roche for the right to develop and commercialize one additional
exclusive target and an option to select two additional targets within four years using ENHANZE technology. The upfront
license payment may be followed by event-based payments subject to Roche’s achievement of specified development,
regulatory and sales-based milestones. In addition, Roche will pay royalties to us if products under the collaboration are
commercialized. Roche subsequently returned the rights for the first exclusive target.

In December 2018, Roche initiated a Phase 1b/2 study in patients with non-small cell lung cancer for TECENTRIQ®
(atezolizumab) using ENHANZE technology. In December 2020, Roche initiated a Phase 3 study in patients with non-small
cell lung cancer (NSCLC) for TECENTRIQ using ENHANZE technology. In August 2022, Roche announced that the Phase 3
study met its co-primary endpoints, showing non-inferior levels of Tecentriq in the blood (pharmacokinetics), when injected
subcutaneously, compared with IV infusion, in cancer immunotherapy-naïve patients with advanced or metastatic NSCLC for
whom prior platinum therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq. In
November 2022, Roche submitted a Biologics License Application (“BLA”) to the FDA and a Marketing Authorization
Application (“MAA”) to the EMA for SC formulation of Tecentriq (atezolizumab) with ENHANZE across all approved
indications of IV Tecentriq. In January 2023, FDA accepted the BLA for the SC formulation of Tecentriq with the official
PDUFA goal date of September 15, 2023.

In August 2019, Roche initiated a Phase 1 study evaluating OCREVUS® (ocrelizumab) with ENHANZE technology in
subjects with multiple sclerosis. In April 2022, Roche initiated a Phase 3 study evaluating OCREVUS with ENHANZE
technology in subjects with multiple sclerosis.

In October 2019, Roche nominated a new undisclosed exclusive target to be studied using ENHANZE technology. In

November 2021, Roche initiated a Phase 1 study with the undisclosed target and ENHANZE.

Takeda Collaboration

In September 2007, we and Takeda entered into a collaboration and license agreement under which Takeda obtained a
worldwide, exclusive license to develop and commercialize product combinations of rHuPH20 with GAMMAGARD LIQUID
(HYQVIA®) (the Takeda Collaboration). HYQVIA is indicated for the treatment of primary immunodeficiency disorders
associated with defects in the immune system.

In May 2013, the EC granted Takeda marketing authorization in all European Union (“EU”) Member States for the use of
HYQVIA (solution for SC use) as replacement therapy for adult patients with primary and secondary immunodeficiencies.
Takeda launched HYQVIA in the first EU country in July 2013 and has continued to launch in additional countries.

In September 2014, HYQVIA was approved by the FDA for treatment of adult patients with primary immunodeficiency
in the U.S. HYQVIA is the first SC immune globulin (IG) treatment approved for adult primary immunodeficiency patients
with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per
infusion in most patients, to deliver a full therapeutic dose of IG.

In May 2016, Takeda announced that HYQVIA received a marketing authorization from the EC for a pediatric indication,
which was launched in Europe to treat primary and certain secondary immunodeficiencies. In September 2020, Takeda
announced that the EMA approved a label update for HYQVIA broadening its use and making it the first and only facilitated
SC immunoglobulin replacement therapy in adults, adolescents and children with an expanded range of secondary
immunodeficiencies (SID).

In October 2021, Takeda initiated a Phase 1 single-dose, single-center, open-label, three-arm study to assess the
tolerability and safety of immune globulin SC (human), 20% solution with ENHANZE (TAK-881) at various infusion rates in
healthy adult subjects.

In July 2022, Takeda announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA, for maintenance
treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and Takeda confirmed its intention to submit
regulatory applications in the United States and European Union in its fiscal year 2022. In July 2022, Takeda filed a
supplemental Biologics License Application (sBLA) for the potential expanded use of HYQVIA for pediatric indication for
primary immunodeficiency.

Pfizer Collaboration

In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the
worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprietary biologics in
primary care and specialty care indications. Pfizer has elected five targets and has returned two targets.

Janssen Collaboration

In December 2014, we and Janssen entered into a collaboration and license agreement, under which Janssen has the
worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Janssen proprietary biologics
directed to up to five targets. Targets may be selected on an exclusive basis. Janssen has elected CD38 as the first target on an
exclusive basis. Janssen has initiated several Phase 3 studies, Phase 2 studies and Phase 1 studies of DARZALEX®
(daratumumab), directed at CD38, using ENHANZE technology in patients with amyloidosis, smoldering myeloma and
multiple myeloma.

In February 2019, Janssen’s development partner, Genmab, announced positive Phase 3 trial results from the COLUMBA
study evaluating SC DARZALEX in comparison to IV DARZALEX in patients with relapsed or refractory multiple myeloma.
DARZALEX SC® (utilizing ENHANZE technology) was found to be non-inferior to DARZALEX IV with regard the co-
primary endpoints of Overall Response Rate and Maximum Trough concentration. In May 2020, we announced that Janssen
received US FDA approval and launched the commercial sale of DARZALEX FASPRO® in four regimens across five
indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or
refractory patients. As a fixed-dose formulation, DARZALEX FASPRO can be administered over three to five minutes,
significantly less time than DARZALEX IV which requires multi-hour infusions. In June 2020, we announced that Janssen
received European marketing authorization and launched the commercial sale of DARZALEX SC utilizing ENHANZE in the
EU. Subsequent to these approvals, Janssen received several additional regulatory approvals for additional indications and
patient populations in US, EU, Japan and China. Beginning with the US, in January 2021, Janssen received FDA approval for
DARZALEX FASPRO in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed multiple
myeloma patients who are eligible for autologous stem cell transplant. In January 2021, Janssen received accelerated approval
from the FDA for DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for
the treatment of adult patients with newly diagnosed AL amyloidosis (not recommended for the treatment of patients with AL
amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials). In
July 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with pomalidomide and dexamethasone

(D-Pd) for patients with multiple myeloma after first or subsequent relapse. In July 2021, Janssen received FDA approval for
DARZALEX FASPRO in combination with D-Pd for patients with multiple myeloma after first or subsequent relapse. In
November 2021, Janssen received FDA approval for DARZALEX FASPRO in combination with Kyprolis® (carfilzomib) and
dexamethasone for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
In the EU, in June 2021, we announced that Janssen received marketing authorization from the EC for DARZALEX SC in two
new indications, in combination with D-VCd in newly diagnosed adult patients with AL amyloidosis and in combination with
D-Pd in adult patients with relapsed or refractory multiple myeloma. In Japan in March 2021, Janssen announced approval from
Japan’s Ministry of Health, Labour and Welfare (MHLW) for the SC formulation of DARZALEX (known as DARZQURO) in
Japan for the treatment of multiple myeloma, and in May 2021 Janssen commenced commercial sale in Japan. In August 2021,
Janssen received approval of DARZQURO for systemic AL amyloidosis in Japan. In China in October 2021, Janssen’s
DARZALEX FASPRO was approved by the China National Medical Products Administration (NMPA) for the treatment of
primary light chain amyloidosis, in combination with D-VCd in newly diagnosed patients.

In December 2019, Janssen elected EGFR and cMET as a bispecific antibody (amivantamab) target on an exclusive basis,
which is being studied in solid tumors. In November 2020, Janssen initiated a Phase 1 study of amivantamab and ENHANZE.
In September 2022, Janssen initiated a Phase 3 study of lazertinib and amivantamab with ENHANZE in patients with epidermal
growth factor receptor (EGFR)-mutated advanced or metastatic non-small cell lung cancer (PALOMA-3). In November 2022,
Janssen initiated a Phase 2 study of amivantamab with ENHANZE in multiple regimens in patients with advanced or metastatic
solid tumors including epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (PALOMA-2).

In July 2021, Janssen elected the target HIV reverse transcriptase limited to non-nucleoside reverse transcriptase
inhibitors. In December 2021, Janssen initiated a Phase 1 clinical trial combining rilpivirine and ENHANZE. Janssen and ViiV
are exploring the possibility of an ultra-long acting version of CABENUVA using ENHANZE.

AbbVie Collaboration

In June 2015, we and AbbVie entered into a collaboration and license agreement, under which AbbVie has the worldwide
license to develop and commercialize products combining our rHuPH20 enzyme with AbbVie proprietary biologics directed to
up to nine targets. Targets may be selected on an exclusive basis. AbbVie elected one target on an exclusive basis, TNF alpha,
for which it has discontinued development and returned the target.

Lilly Collaboration

In December 2015, we and Lilly entered into a collaboration and license agreement, under which Lilly has the worldwide
license to develop and commercialize products combining our rHuPH20 enzyme with Lilly proprietary biologics. Lilly
currently has the right to select up to three targets. Targets may be selected on an exclusive basis. Lilly has elected two targets
on an exclusive basis and one target on a semi-exclusive basis.

BMS Collaboration

In September 2017, we and BMS entered into a collaboration and license agreement, which became effective in
November 2017, under which BMS had the worldwide license to develop and commercialize products combining our rHuPH20
enzyme with BMS products directed at up to eleven targets. Targets may be selected on an exclusive basis or non-exclusive
basis. BMS has designated multiple immuno-oncology targets including programmed death 1 (PD-1) and has an option to select
3 additional targets by November 2024. In October 2019, BMS initiated a Phase 1 study of relatlimab, an anti-LAG 3 antibody,
in combination with nivolumab using ENHANZE technology. In May 2021, BMS initiated a Phase 3 of nivolumab using
ENHANZE technology, for patients with advanced or metastatic clear cell renal cell carcinoma (CheckMate-67T), leveraging
data and insights from Phase 1/2 CA209-8KX study in patients with solid tumors. In June 2022, BMS nominated a new
undisclosed target. In August 2022, BMS initiated a Phase 3 trial to compare the drug levels of nivolumab with ENHANZE
administered subcutaneously vs IV administration
in participants with melanoma following complete resection
(CheckMate-6GE). BMS plans to initiate a Phase 3 trial in early 2023 to demonstrate the drug exposure levels of nivolumab
and relatlimab fixed-dose combination with ENHANZE is not inferior than intravenous administration in participants with
previously untreated metastatic or unresectable melanoma (RELATIVITY-127).

Alexion Collaboration

In December 2017, we and Alexion entered into a collaboration and license agreement, under which Alexion has the
worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Alexion’s portfolio of
products directed at up to four exclusive targets and has access to utilize ENHANZE with up to three exclusive targets.

argenx Collaboration

In February 2019, we and argenx entered into an agreement for the right to develop and commercialize one exclusive
target, the human neonatal Fc receptor FcRn, which includes argenx's lead asset efgartigimod (ARGX-113), and an option to
select two additional targets using ENHANZE technology. In May 2019, argenx nominated a second target to be studied using

ENHANZE technology, a human complement factor C2 associated with the product candidate ARGX-117, which is being
developed to treat severe autoimmune diseases in Multifocal Motor Neuropathy (MMN). In October 2020, we and argenx
entered into an agreement to expand the collaboration relationship. Under the newly announced expansion, argenx gained the
ability to exclusively access our ENHANZE technology for three additional targets for a total of up to six targets under the
existing and newly expanded collaboration.

In July 2019, argenx dosed the first subject in a phase 1 clinical trial evaluating the safety, pharmacokinetics and
pharmacodynamics of efgartigimod (ARGX-113), using ENHANZE technology. In December 2019, argenx reported that based
on data from the phase 1 study and internal company analysis, a one minute injection administered every 2 weeks may be
possible. In December 2020, argenx initiated a Phase 3 study of ARGX-113 using ENHANZE technology for patients with
immune thrombocytopenia (ITP), an immune disorder in which the blood does not clot normally. In January 2021, argenx
initiated a Phase 3 study of ARGX-113 using ENHANZE technology in pemphigus vulgaris and foliaceus (PV), a rare
autoimmune disease that causes painful blisters on the skin and mucous membranes. In February 2021, argenx initiated a Phase
3 study of ARGX-113 using ENHANZE technology for patients with chronic inflammatory demyelinating polyneuropathy
(CIDP) and initiated a Phase 3 study of ARGX-113 using ENHANZE technology in myasthenia gravis (MG), an autoimmune
disorder of the musculoskeletal system caused by IgG autoantibodies. In December 2021, argenx announced the FDA approval
of efgartigimod (VYVGARTTM) for the treatment of generalized myasthenia gravis for the IV dosing regimen. In March 2022,
argenx announced that data from argenx’s phase 3 ADAPT-SC study evaluating SC efgartigimod (1000mg efgartigimod-PH20)
for the treatment of generalized myasthenia gravis (gMG) achieved the primary endpoint of total IgG reduction from baseline at
day 29, demonstrating statistical non-inferiority to VYVGART (efgartigimod alfa-fcab) IV formulation in gMG patients. In
June 2022, argenx initiated a study, BALLAD, evaluating Efgartigimod with ENHANZE in bullous pemphigoid. In September
2022, argenx announced the submission of a BLA to the US FDA for SC efgartigimod for the treatment of adults with gMG. In
November 2022, argenx announced the acceptance of the BLA application for SC efgartigimod in gMG with a priority review
and a Prescription Drug User Free Act (“PDUFA”) date of March 20, 2023. In January 2023, argenx announced the review time
was extended by the FDA to June 20, 2023 to allow the FDA sufficient time to review. Argenx has also submitted a marketing
authorization application to the European Medicines Agency for SC efgartigimod for the treatment of adults with gMG with an
anticipated regulatory approval decision in the fourth quarter of 2023.

Horizon Collaboration

In November 2020, we and Horizon entered into a global collaboration and license agreement that gives Horizon
exclusive access to ENHANZE technology for SC formulation of medicines targeting IGF-1R. Horizon intends to use
ENHANZE to develop a SC formulation of TEPEZZA® (teprotumumab-trbw), indicated for the treatment of thyroid eye
disease, a serious, progressive and vision-threatening rare autoimmune disease, potentially shortening drug administration time,
reducing healthcare practitioner time and offering additional flexibility and convenience for patients. In March 2021, Horizon
completed dosing in a Phase 1 study exploring the SC formulation of TEPEZZA. The trial was a small, single-dose Phase 1
pharmacokinetic trial which included evaluation of ENHANZE technology for a SC formulation. In March 2022, Horizon
announced the completion of a Phase 1 trial for the TEPEZZA SC program.

ViiV Healthcare Collaboration

In June 2021, we entered into a global collaboration and license agreement with ViiV. The license gives ViiV exclusive
access to our ENHANZE technology for four specific small and large molecule targets for the treatment and prevention of HIV.
These targets are integrase inhibitors, reverse transcriptase inhibitors limited to nucleoside reverse transcriptase inhibitors
(NRTI) and nucleoside reverse transcriptase translocation inhibitors (NRTTIs), capsid inhibitors and broadly neutralising
monoclonal antibodies (bNAbs), that bind to the gp120 CD4 binding site. In December 2021, ViiV initiated enrollment of a
Phase 1 study to evaluate cabotegravir administered subcutaneously with ENHANZE. In February 2022, ViiV initiated
enrollment of a Phase 1 study to evaluate the safety and pharmacokinetics of N6LS, a broadly neutralizing antibody,
administered subcutaneously with ENHANZE technology. In June 2022, ViiV initiated enrollment of a Phase 1 single dose
escalation study to evaluate pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously
with ENHANZE technology.

Chugai Collaboration

In March 2022, we entered into a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. The
license gives Chugai exclusive access to ENHANZE drug delivery technology for an undisclosed target. Chugai intends to
explore the potential use of ENHANZE for a Chugai drug candidate. In May 2022, Chugai initiated a Phase 1 study to evaluate
the pharmacokinetics, pharmacodynamics, and safety of targeted antibody administered subcutaneously with ENHANZE.

NIH CRADA

In June 2019, we announced a Cooperative Research and Development Agreement (“CRADA”) with the National
Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC), part of National Institute of Health (NIH),

enabling the VRC’s use of ENHANZE technology to develop SC formulations of VRC07-523LS and N6LS broadly
neutralizing antibodies (bnAbs) against HIV for HIV treatment. In April 2021, we were notified that the first patient was dosed
with N6LS and rHuPH20 in VRC 609 Phase 1 dose-escalation study to evaluate safety, tolerability, and pharmacokinetics of
N6LS using ENHANZE technology. In October 2022, the VRC 609 Phase 1 study was completed.

CAPRISA

In September 2020, we entered into a collaboration with the Centre for the AIDS Programme of Research in South Africa
(CAPRISA), a non-profit company, to evaluate safety, tolerability and pharmacokinetics of a human monoclonal antibody
(CAP256V2LS) in HIV-negative and HIV-positive women in South Africa. In October 2020, we were notified that the first
patient was dosed with CAP256V2LS and rHuPH20 in CAPRISA 012B Phase 1 dose-escalation study to evaluate safety,
tolerability, and pharmacokinetics of CAP256V2LS alone and in combination with VRC07-523LS using ENHANZE
technology. In January 2021, we were notified the first patient was dosed with CAP256V2LS and rHuPH20 in combination
with VRC07-523LS and rHuPH20 in CAPRISA 012B Phase 1 study. VRC07-523LS broadly neutralizing antibody was
supplied by the NIH/VRC under a research collaboration with CAPRISA. In June 2022, we received final study reports for
CAPRISA 012B Phase 1 study and concluded our collaboration with CAPRISA.

Device and Other Drug Product Collaborations

Teva License, Development and Supply Agreements

In July 2006, we entered into an exclusive license, development and supply agreement with Teva for an epinephrine auto-
injector product to be marketed in the U.S. and Canada. Pursuant to the agreement, Teva is obligated to purchase all of its
delivery device requirements from us. We received an upfront cash payment and a milestone payment upon FDA product
approval. We also receive a negotiated purchase price for each device sold, as well as royalties on Teva’s commercial sales of
the product. The agreement will continue until the expiration of the last to expire patent that is filed no later than 12 months
after FDA approval. We have multiple patents that have been granted by the United States Patent and Trademark Office
(“USPTO”) that cover this product, the latest of which will expire in 2033. We have and plan to continue to file patent
applications covering this product. We are the exclusive supplier of the device, which we developed, for Teva’s generic
Epinephrine Injection USP products, indicated for emergency treatment of severe allergic reactions including those that are life
threatening (anaphylaxis) in adults and certain pediatric patients. Teva’s Epinephrine Injection, utilizing our patented VIBEX®
injection technology, was approved by the FDA as a generic drug product with an AB rating, meaning that it is therapeutically
equivalent to the branded products EpiPen® and EpiPen Jr® and therefore, subject to state law, substitutable at the pharmacy.
We supply the device and Teva is responsible for the drug, assembly and packaging, distribution and commercialization of the
finished product, for which we also receive royalties on Teva’s net sales.

In December 2007, we entered into a license, development and supply agreement with Teva under which we developed
and will supply a disposable pen injector for two therapeutic products: exenatide and teriparatide. Under the agreement, we
received an upfront payment and development milestones, and are entitled to receive royalties on net product sales by Teva in
territories where commercialized. On February 25, 2022, Teva notified us that it was terminating the exenatide program and
related agreement due to a lack of commercial viability. The termination was effective August 23, 2022.

We are the exclusive supplier of the multi-dose pen, which we developed, used in Teva’s generic teriparatide injection
product. In 2020, Teva launched Teriparatide Injection, the generic version of Eli Lilly’s branded product Forsteo® featuring
our multi-dose pen platform, for commercial sale in several countries outside of the U.S. Under an exclusive development,
license and supply agreement with Teva, we are responsible for the manufacturing and supply of the multi-dose pen used in
Teva’s generic teriparatide product and Teva is responsible for the sale and distribution of the product. We are compensated for
devices sold to Teva and we are entitled to receive royalties on net product sales by Teva in the territories.

In November 2012, we entered into a license, supply and distribution agreement with Teva for an auto-injector product
containing sumatriptan for the treatment of migraines. Teva is responsible for the manufacture, supply, commercialization and
distribution of the drug, and Halozyme is responsible for the manufacture and supply of the device and assembly and packaging
of the finished product. We are compensated at cost for product shipment to Teva and Teva distributes the product in the U.S.
Teva also received an option for distribution rights in other territories. In addition, net profits are shared equally between
Halozyme and Teva. The term of the agreement continues seven years from commercial launch, which was in June 2016, with
automatic one-year renewals unless terminated sooner by either party in accordance with the terms of the agreement.

Covis Agreements

In September 2014, we entered into a development and license agreement with Covis, to develop and supply a SC auto-
injector system for use with Makena, a progestin drug (hydroxyprogesterone caproate) indicated to reduce the risk of preterm
birth in women pregnant with one baby and who spontaneously delivered one preterm baby in the past. Under the agreement,
we were granted an exclusive, worldwide, royalty-bearing license, with the right to sublicense, to certain intellectual property
rights, including know-how, patents and trademarks. Covis is responsible for the clinical development and preparation,

submission and maintenance of all regulatory applications, and is responsible for the manufacture and supply of the drug to be
used in the product, and to market, distribute and sell the product.

In March 2018, we entered into a manufacturing agreement with Covis for the exclusive supply of the device, a variation
of our VIBEX QuickShot SC auto-injector developed by us, and fully assembled and packaged final finished product of the
Makena SC auto-injector. We receive a contracted price per unit on each product manufactured and royalties based on net sales
of products commencing on product launch in a particular country.

In October 2020, Covis received notice that the FDA proposed to withdraw approval of Makena (hydroxyprogesterone
caproate injection). Covis requested a public hearing in an effort to maintain patient access to Makena as a treatment option to
reduce pre-term birth. In October 2022 the hearing resulted in the FDA Advisory Committee recommending that Makena
should not remain on the market.

Pfizer Agreement

In August 2018, we entered into a development agreement with Pfizer to jointly develop a combination drug device rescue
pen utilizing the QuickShot auto-injector and an undisclosed Pfizer drug. We are continuing to evaluate the next steps for this
program.

Idorsia Agreement

In November 2019, we entered into a global agreement with Idorsia to develop a novel, drug-device product containing
selatogrel. A new chemical entity selatogrel is being developed for the treatment of a suspected acute myocardial infarction
(AMI) in adult patients with a history of AMI. Idorsia will pay for the development of the combination product and will be
responsible for applying for and obtaining global regulatory approvals for the product. The parties intend to enter into a separate
commercial license and supply agreement pursuant to which Antares will provide fully assembled and labelled product to
Idorsia at cost plus mark-up. Idorsia will then be responsible for global commercialization of the product, pending FDA or
foreign approval. Halozyme will be entitled to receive royalties on net sales of the commercial product.

Ferring Agreement

In October 2020, we entered into an exclusive license and commercial supply agreement with Ferring for the marketed
product NOCDURNA (desmopressin acetate) in the U.S. Under the terms of the license agreement, we paid Ferring an upfront
payment of $5.0 million upon execution and paid an additional $2.5 million on October 1, 2021. Ferring is eligible for tiered
royalties and additional commercial milestone payments potentially totaling up to $17.5 million based on our net sales of
NOCDURNA in the U.S. In October 2022, we sent a notice to Ferring that we are terminating the NOCDURNA license
agreement with an effective termination date in October 2023.

Lipocine Agreement

In October 2021, we entered into an exclusive license agreement with Lipocine for the product TLANDO (testosterone
undecanoate) in the U.S. In June 2022, we announced the commercial launch of TLANDO. Under the terms of the license
agreement, we paid Lipocine an upfront payment of $11.0 million. Lipocine is eligible for additional milestone payments up to
$10.0 million and tiered royalty and commercial milestones based on net sales of TLANDO in the U.S. We will be responsible
for the manufacturing and commercialization of TLANDO.

Otter Agreement

In December 2021, we entered into a supply agreement with Otter to manufacture the VIBEX auto-injection system
device, designed and developed to incorporate a pre-filled syringe for delivery of methotrexate, assemble, package, label and
supply the final OTREXUP product and related samples to Otter at cost plus mark-up. Otter is responsible for manufacturing,
formulation and testing of methotrexate and the corresponding pre-filled syringe for assembly with the device manufactured by
us, along with the commercialization and distribution of OTREXUP. OTREXUP is a SC methotrexate injection for once
weekly self-administration with an easy-to-use, single dose, disposable auto-injector, indicated for adults with severe active
rheumatoid arthritis (“RA”), children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant
psoriasis. Further, we entered into a license agreement with Otter in which we granted Otter a worldwide, exclusive, fully paid-
up license to certain patents relating to OTREXUP that may also relate to our other products for Otter to commercialize and
otherwise exploit OTREXUP in the field as defined in the license agreement.

For a further discussion of the collaboration agreements, refer to Note 2, Summary of Significant Accounting Policies -

Revenues under Collaborative Agreements.

Patents and Intellectual Proprietary Rights

Patents and other intellectual proprietary rights are essential to our business. Our success will depend in part on our ability
to obtain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary

rights of third parties. Our strategy is to actively pursue patent protection in the U.S. and certain foreign jurisdictions for
technology that we believe to be proprietary to us and that offers us a potential competitive advantage.

Halozyme Patent Portfolio

Our Halozyme patent portfolio includes patents in the U.S., Europe and other countries in the world and we also have
numerous pending patent applications. In general, patents have a term of 20 years from the application filing date or earlier
claimed priority date. Our issued patents will expire between 2023 and 2039. We continue to file and prosecute patent
applications to strengthen and grow our patent portfolio pertaining to our recombinant human hyaluronidase and other drugs
and drug delivery devices, which cover primarily compositions of matter, formulations, methods of use and devices. We have
multiple patents and patent applications throughout the world pertaining to our recombinant human hyaluronidase and methods
of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued European patent which expires in
2024, which we believe cover the products and product candidates under our existing collaborations and Hylenex recombinant.
In addition, we have, under prosecution throughout the world, multiple patent applications that relate specifically to individual
product candidates under development, the expiration of which can only be definitely determined upon maturation into our
issued patents. We believe our patent filings represent a barrier to entry for potential competitors looking to utilize these
hyaluronidases.

Other Proprietary Rights

In addition to patents, we rely on trade secrets, proprietary know-how, regulatory exclusivities and continuing
technological innovation to protect our products and technologies. We protect our trade secrets, proprietary know-how and
innovation, in part, by maintaining physical security of our sites and electronic security of our information technology systems
and utilizing confidentiality and proprietary information agreements. Our policy is to require our employees, directors,
consultants, advisors, partners, outside scientific partners and sponsored researchers, other advisors and other individuals and
entities to execute confidentiality agreements upon the start of employment, consulting or other contractual relationships with
us. These agreements provide that all confidential information developed or made known to the individual or entity during the
course of the relationship is to be kept confidential and not disclosed to third parties except in specific circumstances. In the
case of employees and some other parties, the agreements provide that all discoveries and inventions conceived by the
individual will be our exclusive property. In certain instances, partners with which we have entered into development
agreements may have rights to certain technology developed in connection with such agreements. Despite the use of these
agreements and our efforts to protect our intellectual property, there is a risk of unauthorized use or disclosure of information.
Furthermore, our trade secrets may otherwise become known to, or underlying technology may be independently developed by,
our competitors.

We also file trademark applications to protect the names of our products and product candidates. These applications may
not mature to registration and may be challenged by third parties. We are pursuing trademark protection in a number of
different countries around the world.

Research and Development Activities

Our research and development expenses consist primarily of costs associated with the product development, quality and
regulatory work required to maintain the ENHANZE platform, expenses associated with testing of new auto-injectors, activities
and support for our partners in their development and manufacturing of product candidates performed on behalf of our partners,
compensation and other expenses for research and development personnel, supplies and materials, facility costs and
amortization and depreciation. We charge all research and development expenses to operations as they are incurred. Prior to our
November 2019 restructuring, our research and development activities were primarily focused on the development of
PEGPH20.

Manufacturing

ENHANZE

We do not have our own manufacturing facility for our product and our partners’ products and product candidates, or the

capability to package our products. We have engaged third parties to manufacture bulk rHuPH20 and Hylenex.

We have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and
Catalent Indiana LLC (Catalent) to produce supplies of bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under
current Good Manufacturing Practices (cGMP) for clinical and commercial uses. Catalent currently produces bulk rHuPH20 for
use in Hylenex and collaboration product candidates. Avid currently produces bulk rHuPH20 for use in collaboration products.
We rely on their ability to successfully manufacture these batches according to product specifications. It is important for our
business for Catalent and Avid to (i) retain their status as cGMP-approved manufacturing facilities; (ii) successfully scale up
bulk rHuPH20 production; and/or (iii) manufacture the bulk rHuPH20 required by us and our partners for use in our proprietary
and collaboration products and product candidates. In addition to supply obligations, Avid and Catalent will also provide
support for data and information used in the chemistry, manufacturing and controls sections for FDA and other regulatory
filings.

We have a commercial manufacturing and supply agreement with Patheon Manufacturing Services, LLC (Patheon) under

which Patheon will provide the final fill and finishing steps in the production process of Hylenex recombinant.

Devices

We also use third parties to manufacture our auto-injector technology products and product candidates, including the
products and related components we supply to our partners. For our products and product candidates, we verify that they are
manufactured in accordance with FDA’s cGMPs for drug products and FDA’s current Quality System Regulations (“QSRs”)
for medical devices and equivalent provisions in the EU and elsewhere, which are required as part of the overall obligations
necessary, in the EU for instance, to obtain a CE-mark. We enter into quality agreements with our third-party manufacturers
which require compliance with cGMPs, QSRs and foreign equivalents, to the extent applicable. We use third-party service
providers to assemble and package our products and product candidates under our direction. We monitor and evaluate
manufacturers and suppliers to assess compliance with regulatory requirements and our internal quality standards and
benchmarks. We perform quality reviews of manufacturing for all of our product candidates and products, and quality releases
for all of our product candidates and products that we sponsor or commercialize.

We use third-party manufacturers to manufacture and supply certain components, drugs, final assembly and finished
product. Below is a summary of our key production, manufacturing, assembly and packaging arrangements with third-party
manufacturers for products commercialized by us and our partners:

•

Phillips-Medisize Corporation (“Phillips”), an international outsource provider of design and manufacturing
services, produces commercial quantities of components of our QuickShot auto-injector device for XYOSTED,
our QuickShot auto-injector device for the Makena product with Covis, and our VIBEX epinephrine auto-injector
product with Teva.

ComDel Innovation, Inc. (“ComDel”), a domestic provider of integrated solutions for product development,
tooling, and manufacturing, produces commercial quantities of components for the VIBEX sumatriptan auto-
injector product and for the teriparatide pen product with Teva.

Jabil Healthcare, an international manufacturing development company produces commercial quantities of
components of our VIBEX auto-injector device for the OTREXUP product for Otter and the VIBEX epinephrine
auto-injector product with Teva.

Fresenius Kabi supplies commercial quantities of pre-filled syringes of testosterone for XYOSTED.

Sharp Corporation (“Sharp”), an international contract packaging company, assembles and packages XYOSTED,
Sumatriptan Injection USP and the Makena auto-injector products, and the OTREXUP auto-injector product for
Otter.

Pfizer supplies the active pharmaceutical ingredient (“API”) for TLANDO.

NextPharma, an international pharmaceutical manufacturing company, supplies the bulk capsule product for
TLANDO.

PCI Pharma Services (“PCI”), an international contract packaging company, bottles and packages TLANDO.

Sales, Marketing and Distribution

We have two teams of sales specialists, one that provide hospital and surgery center customers with the information
needed to obtain formulary approval for, and support utilization of, Hylenex recombinant and one that supports the promotion
of our testosterone products XYOSTED and TLANDO. Our commercial activities also include marketing and related services
and commercial support services such as commercial operations, managed markets and commercial analytics. We also employ
third-party vendors, such as advertising agencies, market research firms and suppliers of marketing and other sales support
related services to assist with our commercial activities.

We sell XYOSTED, TLANDO and Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell
Hylenex to hospitals and XYOSTED and TLANDO to other end-user customers. We engage Integrated Commercialization
Solutions (ICS), a division of AmerisourceBergen Specialty Group, a subsidiary of AmerisourceBergen, to act as our exclusive
distributor for commercial shipment and distribution of Hylenex recombinant to our customers in the United States. We also
contract with numerous wholesale distributors,
(“McKesson”) and
AmerisourceBergen Corporation to distribute our other proprietary products (including XYOSTED and TLANDO) to retail
pharmacies as well as the Veterans Administration and other governmental agencies

including Cardinal, McKesson Corporation

In addition to shipping and distribution services, these distributors and third-party logistics provider, Cardinal Health 105,
Inc., also known as Specialty Pharmaceutical Services (“Cardinal”) provide us with other key services related to logistics,
warehousing, returns and inventory management, sales reports, contract administration and chargebacks processing and
accounts receivable management. We also use a division of Cardinal for sample administration. In addition, we utilize these
third parties to perform various other services for us relating to regulatory monitoring, including call center management,
adverse event reporting, safety database management and other product maintenance services. In exchange for these services,
we pay fees to certain distributors based on a percentage of wholesale acquisition cost. We have also contracted with several
specialty pharmacies to support fulfillment of certain prescriptions. In addition, we use third parties to perform various other
services for us relating to regulatory monitoring, including adverse event reporting, safety database management and other
product maintenance services.

Competition

The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong
emphasis on proprietary therapeutics. We face competition from a number of sources, some of which may target the same
indications as our product or product candidates, including large pharmaceutical companies, smaller pharmaceutical companies,
biotechnology companies, academic institutions, government agencies and private and public research institutions, many of
which have greater financial resources, drug development experience, sales and marketing capabilities, including larger, well
established sales forces, manufacturing capabilities, experience in obtaining regulatory approvals for product candidates and
other resources than us.

ENHANZE

Our ENHANZE technology may face increasing competition from alternate approaches and/or emerging technologies to
deliver medicines SC. In addition, our partners face competition in the commercialization of the product candidates for which
the partners seek marketing approval from the FDA and other regulatory authorities.

Hylenex Recombinant

Hylenex recombinant is currently the only FDA approved recombinant human hyaluronidase on the market. The
competitors for Hylenex recombinant include, but are not limited to, Bausch Health Companies, Inc.’s product, Vitrase®, an
ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.’s product, Amphadase®, a bovine (bull) hyaluronidase.

XYOSTED and TLANDO

In the U.S., there are several different formulations for TRT including intramuscular injection, transdermal patches and gels,
oral formulations and nasal gels. Competition in the U.S. testosterone replacement market includes transdermal solutions such
as AbbVie’s Androgel® 1% and 1.62%, Perrigo’s generic Androgel® Topical Gel, 1.62%, Eli Lilly’s Axiron®, Endo’s
Testim® and Fortesta® (and the authorized generic) and Allergan plc’s (“Allergan”) Androderm®. Other forms of TRT include
injectables such as Endo’s Aveed®, Pfizer’s Depo®-Testosterone, and several generic oil testosterone products sold by Actavis,
Sandoz, Viatris Inc., Teva and others, as well as Testopel® pellets by Endo and JATENZO®, an oral formulation, by Tolmar,
and Kyzatrex, an oral formulation by Marius Pharmaceuticals.

Devices

We have a wide range of competitors depending upon the branded or generic marketplace, the therapeutic product
category, and the product type, including dosage strengths and route of administration. Our competitors include established
specialty pharmaceutical companies, major brand name and generic manufacturers of pharmaceuticals such as Teva, Viatris, Eli
Lilly and Endo, as well as a wide range of medical device companies that sell a single or limited number of competitive
products or participate in only a specific market segment. Our competitors also include third party contract medical device
design and development companies such as Scandinavian Health Ltd., Ypsomed AG, West Pharmaceutical and Owen Mumford
Ltd. Many of our competitors have greater financial and other resources than we have, such as more commercial resources,
larger research and development staffs and more extensive marketing and manufacturing organizations. Smaller or early stage
emerging companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies.

Government Regulations

The FDA and comparable regulatory agencies in foreign countries regulate the manufacture and sale of the
pharmaceutical products that we or our partners have developed or that our partners currently are developing. The FDA has
established guidelines and safety standards that are applicable to the laboratory and preclinical evaluation and clinical
investigation of therapeutic products and stringent regulations that govern the manufacture and sale of these products. The
process of obtaining regulatory approval for a new therapeutic product usually requires a significant amount of time and
substantial resources.

Regulatory obligations continue post-approval and include the reporting of adverse events when a drug is utilized in the
broader patient population. Promotion and marketing of drugs is also strictly regulated, with penalties imposed for violations of
FDA regulations, the Lanham Act and other federal and state laws, including the federal anti-kickback statute.

We currently intend to continue to seek, through our partners, approval to market products and product candidates in
foreign countries, which may have regulatory processes that differ materially from those of the FDA. Our partners may rely
upon independent consultants to seek and gain approvals to market our proposed products in foreign countries or may rely on
other pharmaceutical or biotechnology companies to license our proposed products. We cannot guarantee that approvals to
market any of our partners’ products can be obtained in any country. Approval to market a product in any one foreign country
does not necessarily indicate that approval can be obtained in other countries.

From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory
provisions governing the approval, manufacturing and marketing of drug products. In addition, FDA regulations and guidance
may be revised or reinterpreted by the agency or reviewing courts in ways that may significantly affect our business and
development of our partners’ product candidates and any products that we may commercialize. It is impossible to predict
whether additional legislative changes will be enacted, or FDA regulations, guidance or interpretations changed, or what the
impact of any such changes may be.

Information about our Executive Officers

Information concerning our executive officers, including their names, ages and certain biographical information can be
found in Part III, Item 10, Directors, Executive Officers and Corporate Governance. This information is incorporated by
reference into Part I of this report.

Human Capital Management

The experience, expertise and dedication of our employees drive the progress and accomplishments of Halozyme.

As of February 14, 2023, we had 393 full-time employees. None of our employees are unionized and we believe our

employee relations to be good.

Recognizing the value of our employees and the contributions they make in achieving our business objectives and overall
success, we focus on creating and providing an inclusive and safe work environment where employees are respected and
rewarded for their contributions, work together as one team, have opportunities to grow and develop their careers, and support
the communities in which we work. We also believe this approach to human capital management is essential to attracting and
retaining employees in the highly competitive biotechnology and pharmaceutical labor market. To achieve this supportive
working environment, our human capital management efforts focus on:

Corporate Values and Ethics:

The foundation of our human capital management strategy is contained in our corporate values statement and our Code of
Conduct and Ethics (the “Code of Conduct”), both of which provide uniform guidance to all our employees regarding
expectations for proper workplace behavior. Our corporate values emphasize respecting and valuing fellow team members and
acting with integrity and honesty to uphold the highest ethical standards. We believe these values provide an environment in
which all employees can feel proud and motivated to contribute their valued talents to achieving corporate goals and objectives.
Our values also emphasize empowering employees and personal accountability as a means to fulfill our commitments to
patients, partners, shareholders and each other.

Our Board of Directors adopted and regularly reviews the Code of Conduct, which applies to all of our employees,
officers and directors. Adherence to the Code of Conduct helps ensure that all employees can feel a part of an organization that
emphasizes adherence to laws and policies covering the industry in which we work. Our Code of Conduct also emphasizes each
employee’s accountability for making decisions and taking actions in a highly ethical manner with a focus on honesty, fairness
and integrity and treating all fellow employees in a respectful and inclusive manner. We have established a reporting hotline
that enables employees to file anonymous reports of any suspected violations of the Code of Conduct. We believe that
providing an ethical environment in which to work is vital to our efforts to attract, retain and develop our employees.

Diversity and Inclusion:

We seek to build and maintain a diverse team of employees that is passionate about and committed to having a positive
impact on the lives of patients and their families. We value and celebrate the unique talents, backgrounds and perspectives each
employee contributes to achieving our mission and corporate objectives. In support of this philosophy, we adopted the
Biotechnology Innovation Organization’s principles on workforce development, diversity and inclusion. Our diverse and
inclusive culture is key to attract, develop and retain our talent pool within the globally competitive biotechnology industry. Our
dedication to these principles has resulted in a diverse and inclusive employee base consisting of 45% female and 31% non-
white/Caucasian employees as of February 14, 2023.

As an equal opportunity employer, we strive to attract and connect with diverse talent who best match our core values and
who will be successful and thrive at Halozyme. Our recruiting team partners with hiring managers and we select diverse
interview panels to help provide insight at every stage of the process to identify the best possible candidate – whether internal
or external – to fill open roles in the company. We evaluate our recruitment and retention efforts based on a variety of metrics,
including offer acceptance rate, time-to-hire, turnover and diversity of our employees.

Professional Development for Employees at All Levels:

We are firmly committed to employee development as an essential driver of our future growth and overall success of
Halozyme. We understand that high performing employees are always seeking a challenge and reaching for ways to broaden,
deepen and develop their skills and grow professionally. To support our employees, we conduct an individual development plan
process to give employees the opportunity and accountability to document their career goals and discuss the actions necessary
to achieve those goals. We have two internal training programs: our senior leader development program is focused on
advancing business acumen and leadership skills and our learning and development curriculum for the entire organization is
focused on personal, professional, team and leadership development opportunities and grounded in our established leadership
attributes which identify the knowledge, skills, abilities and behaviors that contribute to individual and organizational
performance. In addition, everyone attends or participates in compliance, harassment prevention, and safety training and we
offer education assistance for college and university courses, training seminars and educational conference attendance
opportunities to all employees.

To monitor progress, we review our succession plan for key senior management positions as part of our annual talent

review and identify development opportunities to help ensure potential successor readiness.

Employee Engagement:

Building trust and a high performing culture is a top priority for Halozyme. We achieve this by providing a platform for
employees to give feedback, collaborate on solutions, and discuss how to make changes to help improve our experience at
work. Over the years, we have regularly conducted employee engagement surveys to better understand what we do well and
where there are opportunities for improvement.

Based on the insights gained from past surveys, we have focused on strengthening cross-functional teamwork including
how teams communicate and how we hold each other accountable. Examples of specific actions we have taken in response to
employee survey feedback include all-employee training on cross-functional teamwork and a learning series to equip employees
to give and receive constructive feedback.

We hold frequent all-employee meetings that serve as an open forum to share progress on strategy and corporate goals as
well as potential at-risk areas, celebrate achievements, and share best practices and learnings. Beginning in 2020 and continuing
into 2023 we have increased the frequency of our all-employee meetings from monthly to semi-monthly while transitioning
from work-from-home to a hybrid workplace to keep employees well-informed, connected and to provide them with a setting to
ask questions and discuss solutions.

Management tracks and assesses retention and attrition and interviews departing employees in order to identify any

addressable trends.

Compensation & Benefits:

Our compensation and benefits programs, with oversight from the Compensation Committee of our Board of Directors, are
designed to attract, retain and reward employees through competitive salaries, annual bonus eligibility, long-term incentive
awards, Employee Stock Purchase Plan, a 401(k) Plan, healthcare and insurance benefits, health savings and flexible spending
accounts, paid time off, family leave, and employee assistance programs. Each year we conduct surveys to benchmark our
salaries and benefits and confirm we are satisfied with the competitiveness of our total compensation offering. We also provide
a variety of peer-to-peer and corporate recognition programs to celebrate and recognize our employees for their hard work and
contributions.

Employee Health and Safety:

We are dedicated to promoting the health and safety of our employees because we believe it fosters employee
productivity and job performance. We have developed and implemented annual workplace safety training which is intended to
remind our employees of workplace safety procedures that may be useful in the event of emergency situations and to assist our
employees in helping to prevent workplace accidents. We have a Safety Operations Team which meets on a quarterly basis to
review workplace safety and adherence to safety policies. This team reports safety metrics and results of ongoing initiatives to
the CEO semi-annually and the Board annually. Further, our Code of Conduct emphasizes our commitment to preventing
unlawful employment discrimination and workplace harassment including mandatory, on-going sexual harassment training and
provides a mechanism for reporting any violations of this policy.

Our response to COVID-19:

Because we take the health and safety of our employees, their families and our local communities very seriously, we
continued case monitoring, contact tracing and notifications as required, diagnostic testing and enhanced safety protocols to
ensure business continuity and risk of transmission is minimized.

Corporate Citizenship:

We believe in supporting the community in which we work and provide our employees multiple opportunities to

contribute to the community, including providing company-wide community service days/volunteerism supporting:

•

Patient advocacy/healthcare;

Health disparities;

STEM education;

Humanitarian services (e.g., food drives, home builds, meal services);

Environment (e.g., lagoon cleanup events, park restoration); and

Children in underserved communities (e.g. school supply drives, holiday adopt-a-family).

Item 1A.

Risk Factors

Risks Related To Our Business

Approval from the FDA or equivalent health authorities is necessary to design, develop, test, manufacture and market
pharmaceutical products and medical devices in the U.S. and the other countries in which we anticipate doing business have
similar requirements. The process for obtaining FDA and other regulatory approvals is extensive, time-consuming, risky and
costly, and there is no guarantee that the FDA or other regulatory bodies will approve any applications that may be filed with
respect to any of our partnered or proprietary product candidates, or that the timing of any such approval will be appropriate for
the desired product launch schedule for a product candidate. We and our partners may provide guidance as to the timing for the
filing and acceptance of such regulatory approvals, but such filings and approvals may not occur when we or our partners
expect, or at all. The FDA or other foreign regulatory agency may refuse or delay approval of our partnered or proprietary
product candidates for failure to collect sufficient clinical or animal safety data and require additional clinical or animal safety
studies which may cause lengthy delays and increased costs to our or our partners’ development programs. Any such issues
associated with rHuPH20 could have an adverse impact on future development of our partners’ products which include
rHuPH20, future sales of Hylenex recombinant, or our ability to maintain our existing ENHANZE collaborations or enter into
new ENHANZE collaborations.

We and our partners may not be successful in obtaining approvals for any additional potential products in a timely

manner, or at all.

Refer to the risk factor titled “Our partnered or proprietary product candidates may not receive regulatory approvals or
their development may be delayed for a variety of reasons, including delayed or unsuccessful clinical trials, regulatory
requirements or safety concerns” for additional information relating to the approval of product candidates.

Additionally, even with respect to products which have been approved for commercialization, in order to continue to
manufacture and market pharmaceutical products, we or our partners must maintain our regulatory approvals. If we or any of
our partners are unsuccessful in maintaining the required regulatory approvals, our revenues would be adversely affected.

Use of our partnered or proprietary and the products and product candidates could be associated with adverse events or
product recalls.

As with most pharmaceutical products, our partnered or proprietary products and product candidates could be associated
with adverse events which can vary in severity (from minor reactions to death) and frequency (infrequent to very common) or
product recalls. Adverse events associated with the use of our partnered or proprietary products or product candidates may be
observed at any time, including in clinical trials or when a product is commercialized, and any such adverse events may
negatively affect our or our partners’ ability to obtain or maintain regulatory approval or market such products and product
candidates. Adverse events such as toxicity or other safety issues associated with the use of our partnered or proprietary
products and product candidates could require us or our partners to perform additional studies or halt development or
commercialization of these products and product candidates or expose us to product liability lawsuits which will harm our
business. For example, we experienced a clinical hold on patient enrollment and dosing in our phase 2 study of PEGPH20 in
patients with PDA (a discontinued program), which was not resolved until we implemented steps to address an observed
possible difference in TE event rates between the arms of the study. We or our partners may be required by regulatory agencies
to conduct additional animal or human studies regarding the safety and efficacy of our pharmaceutical products or product
candidates which we have not planned or anticipated. There can be no assurance that we or our partners will resolve any issues
related to any product or product candidate adverse events to the satisfaction of the FDA or any regulatory agency in a timely
manner or ever, which could harm our business, prospects and financial condition.

To the extent that a product fails to conform to its specifications or comply with the applicable laws or regulations, we or
our partners may be required to or may decide to voluntarily recall the product or regulatory authorities may request or require
that we recall a product even if there is no immediate potential harm to a patient. Any recall of our products or their components
that we supply to our partners could materially adversely affect our business by rendering us unable to sell those products or
components for some time and by adversely affecting our reputation. Recalls are costly and take time and effort to administer.
Even if a recall only initially relates to a single product, product batch, or a portion of a batch, recalls may later be expanded to
additional products or batches or we or our partners may incur additional costs and need to dedicate additional efforts to
investigate and rule out the potential for additional impacted products or batches. Moreover, if any of our partners recall a
product due to an issue with a product or component that we supplied, they may claim that we are responsible for such issue
and may seek to recover the costs related to such recall or be entitled to certain contractual remedies from us. Recalls may
further result in decreased demand for our partnered or proprietary products, could cause our partners or distributors to return
products to us for which we may be required to provide refunds or replacement products, or could result in product shortages.
Recalls may also require regulatory reporting and prompt regulators to conduct additional inspections of our or our partners’ or

contractors’ facilities, which could result in findings of noncompliance and regulatory enforcement actions. A recall could also
result in product liability claims by individuals and third-party payers. In addition, product liability claims or other safety issues
could result in an investigation of the safety or efficacy of our products, our manufacturing processes and facilities, or our
marketing programs conducted by the FDA or the authorities of the EU member states and other jurisdictions. Such
investigations could also potentially lead to a recall of our products or more serious enforcement actions, limitations on the
indications for which they may be used, or suspension, variation, or withdrawal of approval. Any such regulatory action by the
FDA, the EMA or the competent authorities of the EU member states could lead to product liability lawsuits as well.

If our contract manufacturers or vendors are unable to or unwilling for any reason to manufacture and supply to us bulk
rHuPH20 or other raw materials, reagents, components or devices in the quantity and quality required by us or our
partners for use in the production of Hylenex or our other proprietary or partnered products and product candidates, our
and our partners’ product development and commercialization efforts could be delayed or stopped and our business
results of operations and our collaborations could be harmed.

We rely on a number of third parties in our supply chain for the supply and manufacture of our partnered and proprietary
products and the availability of such products depends upon our ability to procure the raw materials, components, packaging
materials and finished products from these third parties, several of which are currently our single source for the materials
necessary for certain of our products. We have entered into supply agreements with numerous third-party suppliers. For
example, we have existing supply agreements with contract manufacturing organizations Avid Bioservices, Inc. (Avid) and
Catalent Indiana LLC (Catalent) to produce bulk rHuPH20. These manufacturers each produce bulk rHuPH20 under cGMP for
use in Hylenex recombinant, and for use in partnered products and product candidates. We rely on their ability to successfully
manufacture bulk rHuPH20 according to product specifications. In addition to supply obligations, our contract manufacturers
will also provide support for the chemistry, manufacturing and controls sections for FDA and other regulatory filings. We also
rely on vendors to supply us with raw materials to produce reagents and other materials for bioanalytical assays used to support
our partners’ clinical trials. We also have a commercial manufacturing and supply agreement with Patheon under which
Patheon provides the final fill and finishing steps in the production process of Hylenex recombinant. If any of our contract
manufacturers or vendors: (i) is unable to retain its status as an FDA approved manufacturing facility; (ii) is unable to otherwise
successfully scale up production to meet corporate or regulatory authority quality standards; (iii) is unable to procure the labor,
raw materials, reagents or components necessary to produce our proprietary products, including bulk rHuPH20 and Hylenex
recombinant our bioanalytical assays or our partnered products or (iv) fails to manufacture and supply our partnered and
proprietary products, including bulk rHuPH20 in the quantity and quality required by us or our partners for use in Hylenex and
partnered products and product candidates for any other reason, our business will be adversely affected. In addition, a
significant change in such parties’ or other third party manufacturers’ business or financial condition could adversely affect
their abilities or willingness to fulfill their contractual obligations to us. We have not established, and may not be able to
establish, favorable arrangements with additional bulk rHuPH20 manufacturers and suppliers of the ingredients necessary to
manufacture bulk rHuPH20 should the existing manufacturers and suppliers become unavailable or in the event that our
existing manufacturers and suppliers are unable or unwilling to adequately perform their responsibilities. We have attempted to
mitigate the impact of a potential supply interruption through the establishment of excess bulk rHuPH20 inventory where
possible, but there can be no assurances that this safety stock will be maintained or that it will be sufficient to address any
delays, interruptions or other problems experienced by any of our contract manufacturers. Any delays, interruptions or other
problems regarding the ability or willingness of our contract manufacturers to supply bulk rHuPH20 or the ability or
willingness of other third-party manufacturers, to supply other raw materials or ingredients necessary to produce our other
proprietary or partnered products on a timely basis could: (i) cause the delay of our partners’ clinical trials or otherwise delay or
prevent the regulatory approval of our partners’ product candidates; (ii) delay or prevent the effective commercialization of
proprietary or partnered products and product candidates; and/or (iii) cause us to breach contractual obligations to deliver bulk
rHuPH20 to our partners. Such delays could damage our relationship with our partners, and they could have a material adverse
effect on royalties and thus our business and financial condition. Additionally, we rely on third parties to manufacture, prepare,
fill, finish, package, store and ship our proprietary and partnered products and product candidates on our behalf. If the third
parties we identify fail to perform their obligations, the progress of partners’ clinical trials could be delayed or even suspended
and the commercialization of our partnered or proprietary products could be delayed or prevented.

In addition, our Minnetonka, Minnesota facility supports our administrative functions, product development and quality
operations and is intended to eventually provide additional manufacturing and warehousing capabilities in the future. If we
begin manufacturing and producing commercial products in the future, we will be subject to relevant risks comparable to those
of our third-party manufacturers. For example, we may not be able to begin product manufacturing and production due to a
number of different reasons including, but not limited to, an ability to obtain necessary supplies and materials, labor and
expertise. To the extent we rely on our ability to manufacture and ship any of our proprietary and partnered products, our
inability to do so could have a material adverse impact on our business, financial condition and results of operations.

We rely on third parties to perform necessary services for our products including services related to the distribution,
invoicing, rebates and contract administration, co-pay program administration, sample distribution and administration,
storage and transportation of our products. If anything should impede their ability to meet their commitments this could
impact our business performance.

Depending on the product, we have retained third-party service providers to perform a variety of functions related to the
distribution, invoicing, rebates and contract administration, co-pay program administration, sample distribution and
administration, storage and transportation of our products, key aspects of which are out of our direct control. We place
substantial reliance on these providers as well as other third-party providers that perform services for us, including, depending
on the product, entrusting our inventories of products to their care and handling. We also may rely on third parties to administer
our drug price reporting and rebate payments and contracting obligations under federal programs. Despite our reliance on third
parties, we have responsibilities for compliance with the applicable legal and program requirements. By example, in certain
states, we are required to hold licenses to distribute our products in these states and must comply with the associated state laws.
Moreover, if these third-party service providers fail to meet expected deadlines, or otherwise do not carry out their contractual
duties to us or encounter physical damage or a natural disaster at their facilities, our ability to deliver products to meet
commercial demand would be significantly impaired. In addition, we may use third parties to perform various other services for
us relating to regulatory monitoring, including adverse event reporting, safety database management and other product
maintenance services. If our employees or any third-party service providers fail to comply with applicable laws and regulations,
we and/or they may face regulatory or False Claims Act enforcement actions. Moreover, if the quality or accuracy of the data
maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we
and/or they could be subject to regulatory sanctions. We do not currently have the internal capacity to perform these important
commercial functions, and we may not be able to maintain commercial arrangements for these services on reasonable terms.

If we or any party to a key collaboration agreement fail to perform material obligations under such agreement, or if a key
collaboration agreement, is terminated for any reason, our business could suffer.

We have entered into multiple collaboration agreements under which we may receive significant future payments in the
form of milestone payments, target designation fees, maintenance fees and royalties. We are heavily dependent on our partners
to develop and commercialize product candidates subject to our collaborations in order for us to realize any financial benefits,
including revenues from milestones, royalties and product sales from these collaborations. Our partners may not devote the
attention and resources to such efforts that we would ourselves, change their clinical development plans, promotional efforts or
simultaneously develop and commercialize products in competition to those products we have licensed to them. Any of these
actions may not be visible to us immediately and could negatively impact our ability to forecast and our ability to achieve the
benefits and revenue we receive from such collaboration. In addition, in the event that a party fails to perform under a key
collaboration agreement, or if a key collaboration agreement is terminated, the reduction in anticipated revenues could
negatively impact our operations. In addition, the termination of a key collaboration agreement by one or more of our partners
could have a material adverse impact on our ability to enter into additional collaboration agreements with new partners on
favorable terms, if at all. In certain circumstances, the termination of a key collaboration agreement would require us to revise
our corporate strategy going forward and may lead us to reevaluate the applications and value of our technology.

Hylenex and our partners’ ENHANZE products and product candidates rely on the rHuPH20 enzyme, and any adverse
development regarding rHuPH20 could substantially impact multiple areas of our business, including current and potential
ENHANZE collaborations, as well as any proprietary programs.

rHuPH20 is a key technological component of Hylenex and our ENHANZE technology and most of our ENHANZE
partnered products and product candidates, including the current and future products and product candidates under our
ENHANZE collaborations. We derive a substantial portion of our revenues from our ENHANZE collaborations. Therefore, if
there is an adverse development for rHuPH20 (e.g., an adverse regulatory determination relating to rHuPH20, if we are unable
to obtain sufficient quantities of rHuPH20, if we are unable to obtain or maintain material proprietary rights to rHuPH20 or if
we discover negative characteristics of rHuPH20), multiple areas of our business, including current and potential collaborations,
as well as proprietary programs would be substantially impacted. For example, elevated anti-rHuPH20 antibody titers were
detected in the registration trial for HYQVIA as well as in a former partner’s product in a Phase 2 clinical trial with rHuPH20,
but have not been associated, in either case, with any adverse events. We monitor for antibodies to rHuPH20 in our
collaboration and proprietary programs, and although we do not believe at this time that the incidence of non-neutralizing anti-
rHuPH20 antibodies in either the HYQVIA program or the former partner’s program will have a significant impact on our
proprietary product and our partners’ product and product candidates, there can be no assurance that there will not be other such
occurrences in the foregoing programs or that concerns regarding these antibodies will not also be raised by the FDA or other
health authorities in the future, which could result in delays or discontinuations of our Hylenex commercialization activities, the
development or commercialization activities of our ENHANZE partners, or deter our entry into additional ENHANZE
collaborations with third parties.

Our business strategy is focused on growth of our ENHANZE technology, our auto-injector technology, our commercial
products and potential growth through acquisition. Currently, ENHANZE is the largest revenue driver and as a result
there is a risk for potential negative impact from adverse developments. Future expansion of our strategic focus to
additional applications of our ENHANZE technology or by acquiring new technologies may require the use of additional
resources, result in increased expense and ultimately may not be successful.

We routinely evaluate our business strategy, and may modify this strategy in the future in light of our assessment of unmet
medical needs, growth potential, resource requirements, regulatory issues, competition, risks and other factors. As a result of
these strategic evaluations, we may focus our resources and efforts on one or a few programs or fields and may suspend or
reduce our efforts on other programs and fields. For example, in the fourth quarter of 2019, we decided to focus our resources
on our ENHANZE technology and our commercial product, Hylenex. By focusing primarily on these areas, we increase the
potential impact on us if one of those partner programs does not successfully complete clinical trials, achieve commercial
acceptance or meet expectations regarding sales and revenue. We may also expand our strategic focus by seeking new
therapeutics applications of our technology or by acquiring new technologies which may require the use of additional resources,
increased expense and would require the attention of senior management. For example, in May 2022, we acquired Antares as a
means to diversify the sources of our revenues. There can be no assurance that our investment in Antares or any such future
investment of resources in new technologies will ultimately result in additional approved proprietary or partnered products or
commercial success of new therapeutic applications of our technology.

Clinical testing of pharmaceutical products is a long, expensive and uncertain process, and the failure or delay of a clinical
trial can occur at any stage, including the patient enrollment stage. Even if initial results of preclinical and nonclinical studies or
clinical trial results are promising, our partners may obtain different results in subsequent trials or studies that fail to show the
desired levels of dose safety and efficacy, or we or our partners may not obtain applicable regulatory approval for our products
for a variety of other reasons. Preclinical, nonclinical, and clinical trials for proprietary or partnered product candidates could be
unsuccessful, which would delay or preclude regulatory approval and commercialization of the product candidates. In the U.S.
and other jurisdictions, regulatory approval can be delayed, limited or not granted for many reasons, including, among others:

•

during the course of clinical studies, the final data from later Phase 3 studies may differ from data observed in
early phase clinical trials, and clinical results may not meet prescribed endpoints for the studies or otherwise
provide sufficient data to support the efficacy of our partners’ product candidates;

clinical and nonclinical test results may reveal inferior pharmacokinetics, adverse events or unexpected safety
issues associated with the use of our partners’ product candidates;

regulatory review may not find that the data from preclinical testing and clinical trials justifies approval;

regulatory authorities may require that we or our partners change our studies or conduct additional studies which
may significantly delay or make continued pursuit of approval commercially unattractive;

a regulatory agency may reject our and our partners’ trial data or disagree with their interpretations of either
clinical trial data or applicable regulations;

a regulatory agency may require additional safety monitoring and reporting through Risk Evaluation and
Mitigation Strategies including conditions to assure safe use programs and we or a partner may decide to not
pursue regulatory approval for a such a product;

a regulatory agency may not approve our manufacturing processes or facilities, or the processes or facilities of our
partners, our contract manufacturers or our raw material suppliers;

failure of our or our partners’ contract research organization, or CRO, to properly perform the clinical trial in
accordance with the written protocol, our contractual obligations with them or applicable regulatory requirements;

a regulatory agency may identify problems or other deficiencies in our existing manufacturing processes or
facilities, or the existing processes or facilities of our partners, our contract manufacturers or our raw material
suppliers;

a regulatory agency may change its formal or informal approval requirements and policies, act contrary to
previous guidance, adopt new regulations or raise new issues or concerns late in the approval process; or

a proprietary or partnered product candidate may be approved only for indications that are narrow or under
conditions that place the product at a competitive disadvantage, which may limit the sales and marketing activities
for such product candidate or otherwise adversely impact the commercial potential of a product.

If a proprietary or partnered product candidate is not approved in a timely fashion or approval is not obtained on
commercially viable terms, or if development of any product candidate is terminated due to difficulties or delays encountered in
the regulatory approval process, it could have a material adverse impact on our business, financial condition and results of
operation and we would become more dependent on the development of other proprietary or partnered product candidates and/
or our ability to successfully acquire other technologies. There can be no assurances that we or our any partnered product
candidate will receive regulatory approval in a timely manner, or at all. There can be no assurance that partners will be able to
gain clarity as to the FDA’s requirements or that the requirements may be satisfied in a commercially feasible way, in which
case our ability to enter into collaborations with third parties or explore other strategic alternatives to exploit an opportunity will
be limited or may not be possible.

We anticipate that certain proprietary or partnered products will be marketed, and perhaps manufactured, in foreign
countries. The process of obtaining regulatory approvals in foreign countries is subject to delay and failure for the reasons set
forth above, as well as for reasons that vary from jurisdiction to jurisdiction. The approval process varies among countries and
jurisdictions and can involve additional testing. The time required to obtain approval may differ from that required to obtain
FDA approval. Foreign regulatory agencies may not provide approvals on a timely basis, if at all. Approval by the FDA does
not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory
authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or by the FDA.

Our development and commercialization partners are responsible for providing certain proprietary materials that are
essential components of our partnered products and product candidates. For example, Roche is responsible for producing the
Herceptin and MabThera required for its subcutaneous products and Takeda is responsible for producing the GAMMAGARD
LIQUID for its product HYQVIA. If a partner, or any applicable third party service provider of a partner, encounters difficulties
in the manufacture, storage, delivery, fill, finish or packaging of the partnered product or product candidate or component of
such product or product candidate, such difficulties could (i) cause the delay of clinical trials or otherwise delay or prevent the
regulatory approval of partnered product candidates; and/or (ii) delay or prevent the effective commercialization of partnered
products. Such delays could have a material adverse effect on our business and financial condition. We also rely on our partners
to commercialize and distribute their products and if they are unsuccessful in commercializing their products, the resulting
royalty revenue we would receive may be lower than expected.

Any approved products, along with the manufacturing processes, post-approval clinical data requirements, labeling,
advertising and promotional activities for these products, are subject to continual requirements and review by the FDA, state
and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer and the manufacturing
facilities to continual review and periodic inspections. We, our partners and our respective contractors, suppliers and vendors,
will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising,
promotion and sales of drug products, required submissions of safety and other post-market information and reports,
registration requirements, cGMP regulations (including requirements relating to quality control and quality assurance, as well as
the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to
physicians and recordkeeping requirements. Further, because some of our proprietary and partnered products and product
candidates are drug/device combination products, we and our partners will have to comply with extensive regulatory
requirements than would otherwise be required for products that are not combination products. Regulatory agencies may
change existing requirements or adopt new requirements or policies. We, our partners and our respective contractors, suppliers
and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.

In particular, regulatory requirements applicable to pharmaceutical products make the substitution of suppliers and
manufacturers costly and time consuming. We have minimal internal manufacturing capabilities and are, and expect to be in the
future, substantially dependent on contract manufacturers and suppliers for the manufacture of our products and for their active
and other ingredients. The disqualification of these manufacturers and suppliers through their failure to comply with regulatory
requirements could negatively impact our business because the delays and costs in obtaining and qualifying alternate suppliers
(if such alternative suppliers are available, which we cannot assure) could delay our or our partners’ clinical trials or otherwise
inhibit our or partners’ ability to bring approved products to market, which would have a material adverse effect on our
business and financial condition. Likewise, if we, our partners and our respective contractors, suppliers and vendors involved in
sales and promotion of our products do not comply with applicable laws and regulations, for example off-label or false or
misleading promotion, this could materially harm our business and financial condition.

Failure to comply with regulatory requirements may result in adverse regulatory actions including but not limited to, any

of the following:

•

restrictions on our or our partners’ products or manufacturing processes;

warning letters;

withdrawal of our or our partners’ products from the market;

voluntary or mandatory recall;

fines;

suspension or withdrawal of regulatory approvals;

suspension or termination of any of our partners’ ongoing clinical trials;

refusal to permit the import or export of our or our partners’ products;

refusal to approve pending applications or supplements to approved applications that we submit;

product seizure;

injunctions; or

imposition of civil or criminal penalties.

Failure to successfully integrate the Antares business, or failure of the Antares business to perform could adversely
impact our stock price and future business and operations.

In May 2022, we completed the acquisition of Antares. Our integration of the Antares business into our operations will be
a complex and time-consuming process that may not be successful. The primary areas of focus for successfully combining the
business of Antares with our operations may include, among others: retaining and integrating key employees, integrating
information, communications and other systems, and managing the growth of the combined company.

Even if we successfully integrate the business of Antares into our operations, we may not realize the anticipated benefits.
We acquired Antares with the expectation that the acquisition will result in various benefits for the combined company,
including providing an opportunity for increased revenues through growth of device revenue and commercial products and
development of a new high volume auto-injector. Increased competition, unresolvable technical issues and/or deterioration in
business conditions may limit our ability to grow this business. As such, we may not be able to realize the benefits anticipated
in connection with the acquisition.

Public health crises such as pandemics or similar outbreaks could adversely impact our business and results of operations
by, among other things, disrupting the development of our and our partnered product candidates and commercialization of our
and our partnered approved products, causing disruptions in the operations of our third-party contract manufacturing
organizations upon whom we rely for the production and supply of our proprietary products, including Hylenex and the bulk
rHuPH20 we supply to our partners, and causing other disruptions to our operations.

For example, the COVID-19 pandemic led to the implementation of various responses, including government-imposed
quarantines, travel restrictions and other public health safety measures. The extent to which future pandemics impact our
operations and/or those of our partners will depend on future developments, which are highly uncertain and unpredictable,
including the duration or recurrence of outbreaks, potential future government actions, new information that will emerge
concerning the severity and impact of that pandemic and the actions to contain the pandemic or address its impact in the short
and long term, among others.

The business disruptions associated with a global pandemic could impact the business, product development priorities and
operations of our partners, including potential delays in manufacturing their product candidates or approved products. For
example, clinical trial conduct may be impacted in geographies affected by a pandemic. The progress or completion of these
clinical trials could be adversely impacted by the pandemic. Additionally, interruption or delays in the operations of the FDA,
the EMA and other similar foreign regulatory agencies, or changes in regulatory priorities to focus on the pandemic, may affect
required regulatory review, inspection, clearance and approval timelines. Disruptions such as these could result in delays in the
development programs of our partnered products or impede the commercial efforts for approved products, resulting in potential
reductions or delays in our revenues from partner royalty or milestone payments.

We rely on many third parties to source active pharmaceutical ingredient and drug products, manufacture and assemble
our devices, distribute finished products and provide various logistics activities in order to manufacture and sell our partnered
and proprietary products. For example, we rely on third-party manufacturers to manufacture the bulk rHuPH20 that we supply
to our partners for their commercial products and product candidates, as well as our commercial product Hylenex. If any such
third party manufacturer is adversely impacted by a pandemic and related consequences, including staffing shortages,
production slowdowns and disruptions in delivery systems, availability of raw materials, reagents or components or if they
divert resources or manufacturing capacity to accommodate the development of coronavirus treatments or vaccines, our supply
chain may be disrupted, limiting our ability to sell Hylenex or supply bulk rHuPH20 to our partners. Any such disruptions to
the operations of the third parties upon whom we rely to manufacture and sell our partnered and proprietary products could
result in reductions or delays in our revenues.

We may need to raise additional capital in the future and there can be no assurance that we will be able to obtain such
funds.

We may need to raise additional capital in the future to fund our operations for general corporate purposes if we do not
achieve the level of revenues we expected. Our current cash reserves and expected revenues may not be sufficient for us to fund
general operations and conduct our business at the level desired. In addition, if we engage in acquisitions of companies,
products or technologies in order to execute our business strategy, we may need to raise additional capital. We may raise
additional capital in the future through one or more financing vehicles that may be available to us including (i) new
collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings; (iv) other
equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities.

If we are required to raise additional capital in the future, it may not be available on favorable financing terms within the
time required, or at all. If additional capital is not available on favorable terms when needed, we will be required to raise capital
on adverse terms or significantly reduce operating expenses through the restructuring of our operations or deferral of strategic
business initiatives. If we raise additional capital through a public offering of securities or equity, a substantial number of
additional shares of our common stock may be issued, which will dilute the ownership interest of our current investors and may
negatively affect our stock price.

We currently have significant debt and expect to incur additional debt. Failure by us to fulfill our obligations under the
applicable debt agreements may cause repayment obligations to accelerate.

The aggregate amount of our consolidated indebtedness, net of debt discount, as of December 31, 2022 was $1,506.1
million, which includes $13.5 million in aggregate principal amount of the 2024 Convertible Notes and $805.0 million in
aggregate principal amount of the 2027 Convertible Notes and $720.0 million in aggregate principal of the 2028 Convertible
Notes, net of unamortized debt discount of $0.1 million, $14.4 million and $17.9 million for the 2024 Convertible Notes, 2027
Convertible Notes and 2028 Convertible Notes, respectively.

Our indebtedness may:

• make it difficult for us to satisfy our financial obligations, including making scheduled principal and interest payments

on our indebtedness;

•

limit our ability to borrow additional funds for working capital, capital expenditures, acquisitions or other general
corporate purposes;

limit our ability to use our cash flow or obtain additional financing for future working capital, capital expenditures,
acquisitions, share repurchases or other general business purposes;

require us to use a portion of our cash flow from operations to make debt service payments;

limit our flexibility to plan for, or react to, changes in our business and industry;

place us at a competitive disadvantage compared to our less leveraged competitors; and

increase our vulnerability to the impact of adverse economic and industry conditions.

In addition, our 2022 Credit Agreement includes certain affirmative and negative covenants, that, among other things,
may restrict our ability to: create liens on assets; incur additional indebtedness; make investments; make acquisitions and other
fundamental changes; and sell and dispose of property or assets. The 2022 Credit Agreement also includes financial covenants
requiring us to maintain, measured as of the end of each fiscal quarter, a maximum consolidated net leverage ratio of 4.75 to
1.00 initially, which declines to 4.00 to 1.00 over the term of the loan facility, and a minimum consolidated interest coverage
ratio of 3.00 to 1.00. The 2022 Credit Agreement also contains customary representations and warranties and events of default.
Complying with the covenants contained in the 2022 Credit Agreement could make it more difficult for us to execute our
business strategy. Further, in the event of default by us under the 2022 Credit Agreement, the lenders would be entitled to
exercise their remedies thereunder, including the right to accelerate the debt, upon which we may be required to repay all
amounts then outstanding under the 2022 Credit Agreement which would harm our financial condition.

Our ability to make payments on our existing or any future debt will depend on our future operating performance and
ability to generate cash and may also depend on our ability to obtain additional debt or equity financing. It will also depend on
financial, business or other factors affecting our operations, many of which are beyond our control. We will need to use cash to
pay principal and interest on our debt, thereby reducing the funds available to fund operations, strategic initiatives and working
capital requirements. If we are unable to generate sufficient cash to service our debt obligations, an event of default may occur
under any of our debt instruments which could result in an acceleration of such debt upon which we may be required to repay
all the amounts outstanding under some or all of our debt instruments. Such an acceleration of our debt obligations could harm
our financial condition. From time to time, we may seek to retire or repurchase our outstanding debt through cash purchases
and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. Any such
repurchases or exchanges would be on such terms and at such prices as we determine, and will depend on current market
conditions, our liquidity needs, any restrictions in our contracts and other factors. The amounts involved in such transactions
could be material.

The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and
operating results.

In the event the conditional conversion feature of the Convertible Notes is triggered, holders of the Convertible Notes will
be entitled to convert the notes at any time during specified periods at their option. If one or more holders elect to convert their
notes, we would be required to settle a portion or all of our conversion obligation in cash, which could adversely affect our
liquidity. Even if holders of the Convertible Notes do not elect to convert their notes, we are required under applicable
accounting rules to reclassify all or a portion of the outstanding principal of the notes as a current rather than long-term liability
when the conditional conversion feature is triggered, which results in a material reduction of our net working capital. For
example, as of December 31, 2022, the conditional conversion feature was triggered and our 2024 Convertible Notes are
classified as a current liability.

Conversion of our Convertible Notes may dilute the ownership interest of existing stockholders or may otherwise depress the
price of our common stock.

The conversion of some or all of our Convertible Notes, to the extent we deliver shares upon conversion, will dilute the
ownership interests of existing stockholders. Any sales in the public market of the Convertible Notes or our common stock
issuable upon conversion of the Convertible Notes could adversely affect prevailing market prices of our common stock. In
addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of
the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of
our common stock could depress the price of our common stock.

Assuming that existing or future proprietary or partnered product candidates obtain the necessary regulatory approvals for
commercial sale, a number of factors may affect the market acceptance of these newly-approved products, including, among
others:

•

the degree to which the use of these products is restricted by the approved product label;

the price of these products relative to other therapies for the same or similar treatments;

the extent to which reimbursement for these products and related treatments will be available from third party
payers including government insurance programs and private insurers;

the introduction of generic or biosimilar competitors to these products;

the perception by patients, physicians and other members of the health care community of the effectiveness and
safety of these products for their prescribed treatments relative to other therapies for the same or similar
treatments;

the ability and willingness of our partners to fund sales and marketing efforts; and

the effectiveness of the sales and marketing efforts of our partners.

If these proprietary or partnered products do not gain or maintain market acceptance or experience reduced sales resulting
in commercial performance below that which was expected or projected, the revenues we expect to receive from these products
will be diminished which could harm our ability to fund future operations, including conduct acquisitions, execute our planned
share repurchases, or affect our ability to use funds for other general corporate purposes and cause our business to suffer.

In addition, our proprietary or partnered product candidates will be restricted to the labels approved by FDA and
applicable regulatory bodies, and these restrictions may limit the marketing and promotion of the ultimate products. If the
approved labels are restrictive, the sales and marketing efforts for these products may be negatively affected.

Our ability to license our ENHANZE and device technologies to our partners depends on the validity of our patents and
other proprietary rights.

Patents and other proprietary rights are essential to our business. Our success will depend in part on our ability to obtain
and maintain patent protection for our inventions, to preserve our trade secrets and to operate without infringing the proprietary
rights of third parties. We have multiple patents and patent applications throughout the world pertaining to our recombinant
human hyaluronidase and methods of use and manufacture, including an issued U.S. patent which expires in 2027 and an issued
European patent which expires in 2024, which we believe cover the products and product candidates under our existing
collaborations, and Hylenex. Although we believe our patent filings represent a barrier to entry for potential competitors
looking to utilize these hyaluronidases, upon expiration of our patents other pharmaceutical companies may (if they do not
infringe our other patents) seek to compete with us by developing, manufacturing and selling biosimilars to the active drug
ingredient in our ENHANZE technology used by our partners in combination with their products. Any such loss of patent
protection or proprietary rights could lead to a reduction or loss of revenues, incentivize one or more of our key ENHANZE
partners to terminate their relationship with us and impact our ability to enter into new collaboration and license agreements.

Developing, manufacturing and marketing pharmaceutical products for human use involves significant product liability
risks for which we may have sufficient insurance coverage.

The development, manufacture, testing, marketing and sale of pharmaceutical products and medical devices involves the
risk of product liability claims by consumers and other third parties. Product liability claims may be brought by individuals
seeking relief for themselves, or by groups seeking to represent a class of injured patients. Further, third-party payers, either
individually or as a putative class, may bring actions seeking to recover monies spent on one of our products. Although we
maintain product liability insurance coverage, product liability claims can be high in the pharmaceutical industry, and our
insurance may not sufficiently cover our actual liabilities. If product liability claims were to be made against us, it is possible
that the liabilities may exceed the limits of our insurance policy, or our insurance carriers may deny, or attempt to deny,
coverage in certain instances. If a lawsuit against us is successful, then the insurance coverage may not be sufficient and could
materially and adversely affect our business and financial condition. Furthermore, various distributors of pharmaceutical
products require minimum product liability insurance coverage before purchase or acceptance of products for distribution.
Failure to satisfy these insurance requirements could impede our ability to achieve broad distribution of our proposed products,
and higher insurance requirements could impose additional costs on us. In addition, since many of our partnered product
candidates include the pharmaceutical products of a third party, we run the risk that problems with the third-party
pharmaceutical product will give rise to liability claims against us. Product liability claims can also result in additional
regulatory consequences including, but not limited to, investigations and regulatory enforcement actions, as well as recalls,
revocation or approvals, or labeling, marketing or promotional restrictions or changes. Product liability claims could also harm
our reputation and the reputation of our products, adversely affecting our ability to market our products successfully. In
addition, defending a product liability lawsuit is expensive and can divert the attention of our key employees from operating our
business. Such claims can also impact our ability to initiate or complete clinical trials.

If our partners do not achieve projected development, clinical, or regulatory goals in the timeframes publicly
announced or otherwise expected, the commercialization of our partners products may be delayed and, as a result, , our
business, financial condition , and results of operations may be adversely affected or delayed.

From time to time, our collaborators may publicly articulate the estimated timing for the accomplishment of certain
scientific, clinical, regulatory and other product development goals. The accomplishment of any goal is typically based on
numerous assumptions, and the achievement of a particular goal may be delayed for any number of reasons both within and
outside of our and our collaborators’ control. If scientific, regulatory, strategic or other factors cause a collaboration partner to
not meet a goal, regardless of whether that goal has been publicly articulated or not, our stock price may decline rapidly. Stock
price declines may also trigger direct or derivative shareholder lawsuits. As with any litigation proceeding, the eventual
outcome of any legal action is difficult to predict. If any such lawsuits occur, we will incur expenses in connection with the
defense of these lawsuits, and we may have to pay substantial damages or settlement costs in connection with any resolution
thereof. Although we have insurance coverage against which we may claim recovery against some of these expenses and costs,
the amount of coverage may not be adequate to cover the full amount or certain expenses and costs may be outside the scope of
the policies we maintain. In the event of an adverse outcome or outcomes, our business could be materially harmed from
depletion of cash resources, negative impact on our reputation, or restrictions or changes to our governance or other processes
that may result from any final disposition of the lawsuit. Moreover, responding to and defending pending litigation significantly
diverts management’s attention from our operations.

In addition, the consistent failure to meet publicly announced milestones may erode the credibility of our management

team with respect to future milestone estimates.

Future acquisitions could disrupt our business and impact our financial condition.

In order to augment and extend our revenue we acquired Antares in May 2022 and we may decide to acquire additional
businesses, products and technologies. As we have limited experience in evaluating and completing acquisitions, our ability as
an organization to make such acquisitions is unproven. Acquisitions could require significant capital infusions and could
involve many risks, including, but not limited to, the following:

•

we may have to issue additional convertible debt or equity securities to complete an acquisition, which would
dilute our stockholders and could adversely affect the market price of our common stock;

an acquisition may negatively impact our results of operations because it may require us to amortize or write down
amounts related to goodwill and other intangible assets, or incur or assume substantial debt or liabilities, or it may
cause adverse tax consequences, substantial depreciation or deferred compensation charges;

we may encounter difficulties in assimilating and integrating the business, products, technologies, personnel or
operations of companies that we acquire;

certain acquisitions may impact our relationship with existing or potential partners who are competitive with the
acquired business, products or technologies;

acquisitions may require significant capital infusions and the acquired businesses, products or technologies may
not generate sufficient value to justify acquisition costs;

we may take on liabilities from the acquired company such as debt, legal liabilities or business risk which could be
significant;

an acquisition may disrupt our ongoing business, divert resources, increase our expenses and distract our
management;

acquisitions may involve the entry into a geographic or business market in which we have little or no prior
experience; and

key personnel of an acquired company may decide not to work for us.

If any of these risks occurred, it could adversely affect our business, financial condition and operating results. There is no
assurance that we will be able to identify or consummate any future acquisitions on acceptable terms, or at all. If we do pursue
any future acquisitions, it is possible that we may not realize the anticipated benefits from such acquisitions or that the market
will not view such acquisitions positively.

Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.

Our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In
preparing our financial statements, we estimate the amount of tax that will become payable in each of such places.
Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including changes in
the mix of our profitability between different tax jurisdictions, the results of examinations and audits of our tax filings, our
inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in
tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or
our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.

In addition, on September 30, 2021, we determined, based on our facts and circumstances, that it was more likely than not
that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation
allowance against our deferred tax assets was released. This resulted in substantially and disproportionately increasing our
reported net income and our earnings per share compared to our operating results for 2021. Historical and future comparisons to
these amounts are not, and will not be, indicative of actual profitability trends for our business. Starting in 2022, we recorded
income tax expense at an estimated tax rate that approximate statutory tax rates, resulting a reduction in our net income and net
income per share.

Risks Related To Ownership of Our Common Stock

Our stock price is subject to significant volatility.

We participate in a highly dynamic industry which often results in significant volatility in the market price of common
stock irrespective of company performance. The high and low sales prices of our common stock during the twelve months
ended December 31, 2022 were $59.46 and $31.36, respectively. In addition to the other risks and uncertainties described
elsewhere in this Annual Report on Form 10-K and all other risks and uncertainties that are either not known to us at this time
or which we deem to be immaterial, any of the following factors may lead to a significant drop in our stock price:

•

the presence of competitive products to those being developed by our partners;

•

failure (actual or perceived) of our partners to devote attention or resources to the development or
commercialization of partnered products or product candidates licensed to such partner;

a dispute regarding our failure, or the failure of one of our partners, to comply with the terms of a collaboration
agreement;

the termination, for any reason, of any of our collaboration agreements;

the sale of common stock by any significant stockholder, including, but not limited to, direct or indirect sales by
members of management or our Board of Directors;

the resignation, or other departure, of members of management or our Board of Directors;

general negative conditions in the healthcare industry;

pandemics or other global crises;

general negative conditions in the financial markets;

the cost associated with obtaining regulatory approval for any of our proprietary or partnered product candidates;

the failure, for any reason, to secure or defend our intellectual property position;

the failure or delay of applicable regulatory bodies to approve our proprietary or partnered product candidates;

identification of safety or tolerability issues associated with our proprietary or partnered products or product
candidates;

failure of our or our partners’ clinical trials to meet efficacy endpoints;

suspensions or delays in the conduct of our or our partners’ clinical trials or securing of regulatory approvals;

adverse regulatory action with respect to our proprietary or partnered products and product candidates such as loss
of regulatory approval to commercialize such products, clinical holds, imposition of onerous requirements for
approval or product recalls;

our failure, or the failure of our partners, to successfully commercialize products approved by applicable
regulatory bodies such as the FDA;

our failure, or the failure of our partners, to generate product revenues anticipated by investors;

disruptions in our clinical or commercial supply chains, including disruptions caused by problems with a bulk
rHuPH20 contract manufacturer or a fill and finish manufacturer for any product or product collaboration
candidate;

the sale of additional debt and/or equity securities by us;

our failure to obtain financing on acceptable terms or at all;

a restructuring of our operations;

an inability to execute our share repurchase program in the time and manner we expect due to market, business,
legal or other considerations; or

a conversion of the Convertible Notes into shares of our common stock.

Future transactions where we raise capital may negatively affect our stock price.

We are currently a “Well-Known Seasoned Issuer” and may file automatic shelf registration statements at any time with
the SEC. Sales of substantial amounts of shares of our common stock or other securities under any future shelf registration
statements could lower the market price of our common stock and impair our ability to raise capital through the sale of equity
securities.

Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more
difficult.

Anti-takeover provisions in our charter documents, the Indentures and Delaware law may make an acquisition of us more
difficult. First, our Board of Directors is classified into three classes of directors. Under Delaware law, directors of a
corporation with a classified board may be removed only for cause unless the corporation’s certificate of incorporation provides
otherwise. Our amended and restated certificate of incorporation, does not provide otherwise. In addition, our bylaws limit who
may call special meetings of stockholders, permitting only stockholders holding at least 50% of our outstanding shares to call a
special meeting of stockholders. Our amended and restated certificate of incorporation does not include a provision for
cumulative voting for directors. Under cumulative voting, a minority stockholder holding a sufficient percentage of a class of
shares may be able to ensure the election of one or more directors. Finally, our bylaws establish procedures, including advance
notice procedures, with regard to the nomination of candidates for election as directors and stockholder proposals.

These provisions in our charter documents may discourage potential takeover attempts, discourage bids for our common
stock at a premium over market price or adversely affect the market price of, and the voting and other rights of the holders of,
our common stock. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect
directors other than the candidates nominated by our Board of Directors.

Further, in connection with our Convertible Notes issuances, we have entered into indentures, dated as of November 18,
2019, of March 1, 2021 and August 18, 2022 (the“Indentures”) with The Bank of New York Mellon Trust Company, N.A., as
trustee. Certain provisions in the Indentures could make it more difficult or more expensive for a third party to acquire us. For
example, if a takeover would constitute a fundamental change, holders of the Convertible Notes will have the right to require us
to repurchase their Convertible Notes in cash. In addition, if a takeover constitutes a make-whole fundamental change, we may
be required to increase the conversion rate for holders who convert their Convertible Notes in connection with such takeover. In
addition, a change of control constitutes an event of default under our 2022 Credit Agreement. Such event of default could
result in the administrative agent or the lender parties thereto declaring the unpaid principal, all accrued and unpaid interest, and
all other amounts owing or payable under the 2022 Credit Agreement to be immediately due and payable. In either case, and in
other cases, our obligations under the Convertible Notes and the Indentures could increase the cost of acquiring us or otherwise
discourage a third party from acquiring us or removing incumbent management

In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware

General Corporation Law, which may prohibit large stockholders from consummating a merger with, or acquisition of, us.

These provisions may deter an acquisition of us that might otherwise be attractive to stockholders.

Risks Related to Our Industry

Our or our partnered products must receive regulatory approval before they can be sold, and compliance with the
extensive government regulations is expensive and time consuming and may result in the delay or cancellation of our or our
partnered product sales, introductions or modifications.

Extensive industry regulation has had, and will continue to have, a significant impact on our business. All pharmaceutical
and medical device companies, including ours, are subject to extensive, complex, costly and evolving regulation by the health
regulatory agencies including the FDA (and with respect to controlled drug substances, the U.S. Drug Enforcement
Administration (DEA)) and equivalent foreign regulatory agencies and state and local/regional government agencies. The
Federal Food, Drug and Cosmetic Act, the Controlled Substances Act and other domestic and foreign statutes and regulations
govern or influence the testing, manufacturing, packaging, labeling, storing, recordkeeping, safety, approval, advertising,
promotion, sale and distribution of our products and our partners’ products and product candidates. We are dependent on
receiving FDA and other governmental approvals, including regulatory approvals in jurisdictions outside the United States,
prior to manufacturing, marketing and shipping our products. Consequently, there is always a risk that the FDA or other
applicable governmental authorities, including those outside the United States, will not approve our or our partners’ products or
may impose onerous, costly and time-consuming requirements such as additional clinical or animal testing. Regulatory
authorities may require that our partners’ change our studies or conduct additional studies, which may significantly delay or
make continued pursuit of approval commercially unattractive to our partners. For example, the approval of the HYQVIA BLA
was delayed by the FDA until we and our partner provided additional preclinical data sufficient to address concerns regarding
non-neutralizing antibodies to rHuPH20 that were detected in the registration trial. Although these antibodies have not been
associated with any known adverse clinical effects, and the HYQVIA BLA was ultimately approved by the FDA, the FDA or
other foreign regulatory agency may, at any time, halt our and our partners’ development and commercialization activities due
to safety concerns. In addition, even if our proprietary or partnered products are approved, regulatory agencies may also take
post-approval action limiting or revoking our or our partners’ ability to sell these products. Any of these regulatory actions may
adversely affect the economic benefit we may derive from our proprietary or our partnered products and therefore harm our
financial condition.

Under certain of these regulations, in addition to our partners, we and our contract suppliers and manufacturers are subject
to periodic inspection of our or their respective facilities, procedures and operations and/or the testing of products by the FDA,
the DEA and other authorities, which conduct periodic inspections to confirm that we and our contract suppliers and
manufacturers are in compliance with all applicable regulations. The FDA also conducts pre-approval and post-approval
reviews and plant inspections to determine whether our systems, or our contract suppliers’ and manufacturers’ processes, are in
compliance with cGMP and other FDA regulations. If our partners, we, or our contract suppliers and manufacturers, fail these
inspections, our partners may not be able to commercialize their products in a timely manner without incurring significant
additional costs, or at all.

In addition, the FDA imposes a number of complex regulatory requirements on entities that advertise and promote
pharmaceuticals including, but not limited to, standards and regulations for direct-to-consumer advertising, off-label promotion,
industry-sponsored scientific and educational activities, and promotional activities involving the Internet.

Many of our and our partners’ products and product candidates are considered to be drug/device combination products by
the FDA, consisting of a drug product and a drug delivery device. If marketed individually, each component would be subject
to different regulatory pathways and reviewed by different centers within the FDA. A combination product, however, is
assigned to a center that will have primary jurisdiction over its pre-market review and regulation based on a determination of
the product’s primary mode of action, which is the single mode of action that provides the most important therapeutic action. In
the case of our and our partners’ products and product candidates, the primary mode of action is typically attributable to the
drug component of the products, which means that the Center of Drug Evaluation and Research has primary jurisdiction over
the products’ premarket development and review. These products and product candidates will be and have been subject to the
FDA drug approval process and will not require a separate FDA clearance or approval for the device component. Even though
these products and product candidates will not require a separate FDA clearance or approval, both the drug and device centers
within the FDA will review the marketing application for safety, the efficacy of both the drug and device component, including
the design and reliability of the injector, and a number of other different areas, such as to ensure that the drug labeling
adequately discloses all relevant information and risks, and to confirm that the instructions for use are accurate and easy to use.
These reviews could increase the time needed for review completion of a successful application and may require additional
studies, such as usage studies, to establish the validity of the instructions for use. Such reviews and requirements may extend
the time necessary for the approval of drug-device combinations. In the case of combination product candidates for which we or
our partners are seeking approval via the ANDA pathway, it is also possible that the agency may decide that the unique nature
of combination products leads it to question the claims of bioequivalence and/or same labeling, resulting in the need to refile the
application under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act. This may result in delays in product approval
and may cause us or our partners to incur additional costs associated with testing, including clinical trials. Approval via the
505(b)(2) pathway may also result in additional selling expenses and a decrease in market acceptance due to the lack of
substitutability by pharmacies or formularies. In addition, approval under the 505(b)(2) or ANDA regulatory pathway is not a
guarantee of an exclusive position for the approved product in the marketplace.

Further, although precedent and guidance exist for the approval of such combination products, the FDA could change
what it requires or how it reviews submissions. Changes in review processes or the requirement for the study of combination
products could delay anticipated launch dates or be cost prohibitive. Such delay or failure to launch these products or devices
could adversely affect our revenues and future profitability. If our or our partners’ combination product candidates are
approved, we, our partners, and any of our respective contractors will be required to comply with FDA regulatory requirements
related to both drugs and devices. For instance, drug/device combination products must comply with both the drug cGMPs and
device QSRs. Depending on whether the drug and device components are at the same facility, however, the FDA regulations
provide a streamlined method to comply with both sets of requirements. The FDA has specifically promulgated guidance on
injectors, which discuss the FDA’s requirements with respect to marketing application and post-market injector design controls
and reliability analyses. Additionally, drug/device combination products will be subject to additional FDA and constituent part
reporting requirements. Compliance with these requirements will require additional effort and monetary expenditure.

We may be subject, directly or indirectly, to various broad federal and state healthcare laws. If we are unable to comply, or
have not fully complied, with such laws, we could face civil, criminal and administrative penalties, damages, monetary fines,
disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs,
contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our
operations, any of which could adversely affect our ability to operate.

Our business operations and activities may be directly, or indirectly, subject to various broad federal and state healthcare
laws, including without limitation, anti-kickback laws, the Foreign Corrupt Practices Act (FCPA), false claims laws, civil
monetary penalty laws, data privacy and security laws, tracing and tracking laws, as well as transparency (or “sunshine”) laws
regarding payments or other items of value provided to healthcare providers. These laws may restrict or prohibit a wide range

of business activities, including, but not limited to, research, manufacturing, distribution, pricing, discounting, marketing and
promotion and other business arrangements. These laws may impact, among other things, our current activities with principal
investigators and research subjects, as well as sales, marketing and education programs. Many states have similar healthcare
fraud and abuse laws, some of which may be broader in scope and may not be limited to items or services for which payment is
made by a government health care program.

Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial
costs. While we have adopted a healthcare corporate compliance program, it is possible that governmental and enforcement
authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law
interpreting applicable fraud and abuse or other healthcare laws. If our operations or activities are found to be in violation of
any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without
limitation, civil, criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from
participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished
profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our ability to
operate.

In addition, any sales of products outside the U.S. will also likely subject us to the FCPA and foreign equivalents of the

healthcare laws mentioned above, among other foreign laws.

We may be required to initiate or defend against legal proceedings related to intellectual property rights, which may result in
substantial expense, delay and/or cessation of certain development and commercialization of our products.

We primarily rely on patents to protect our intellectual property rights. The strength of this protection, however, is

uncertain. For example, it is not certain that:

•

we will be able to obtain patent protection for our products and technologies;

the scope of any of our issued patents will be sufficient to provide commercially significant exclusivity for our
products and technologies;

others will not independently develop similar or alternative technologies or duplicate our technologies and obtain
patent protection before we do; and

any of our issued patents, or patent pending applications that result in issued patents, will be held valid,
enforceable and infringed in the event the patents are asserted against others.

We currently own or license several patents and also have pending patent applications applicable to rHuPH20 and other
proprietary materials. There can be no assurance that our existing patents, or any patents issued to us as a result of our pending
patent applications, will provide a basis for commercially viable products, will provide us with any competitive advantages, or
will not face third party challenges or be the subject of further proceedings limiting their scope or enforceability. Any
weaknesses or limitations in our patent portfolio could have a material adverse effect on our business and financial condition. In
addition, if any of our pending patent applications do not result in issued patents, or result in issued patents with narrow or
limited claims, this could result in us having no or limited protection against generic or biosimilar competition against our
product candidates which would have a material adverse effect on our business and financial condition.

We may become involved in interference proceedings in the U.S. Patent and Trademark Office, or other proceedings in
other jurisdictions, to determine the priority, validity or enforceability of our patents. In addition, costly litigation could be
necessary to protect our patent position.

We also rely on trademarks to protect the names of our products (e.g. Hylenex recombinant). We may not be able to
obtain trademark protection for any proposed product names we select. In addition, product names for pharmaceutical products
must be approved by health regulatory authorities such as the FDA in addition to meeting the legal standards required for
trademark protection and product names we propose may not be timely approved by regulatory agencies which may delay
product launch. In addition, our trademarks may be challenged by others. If we enforce our trademarks against third parties,
such enforcement proceedings may be expensive.

We also rely on trade secrets, unpatented proprietary know-how and continuing technological innovation that we seek to
protect with confidentiality agreements with employees, consultants and others with whom we discuss our business. Disputes
may arise concerning the ownership of intellectual property or the applicability or enforceability of these agreements, and we
might not be able to resolve these disputes in our favor.

In addition to protecting our own intellectual property rights, third parties may assert patent, trademark or copyright
infringement or other intellectual property claims against us. If we become involved in any intellectual property litigation, we
may be required to pay substantial damages, including but not limited to treble damages, attorneys’ fees and costs, for past
infringement if it is ultimately determined that our products infringe a third party’s intellectual property rights. Even if
infringement claims against us are without merit, defending a lawsuit takes significant time, may be expensive and may divert
management’s attention from other business concerns. Further, we may be stopped from developing, manufacturing or selling
our products until we obtain a license from the owner of the relevant technology or other intellectual property rights. If such a
license is available at all, it may require us to pay substantial royalties or other fees.

We may incur significant liability if it is determined that we are promoting or have in the past promoted the “off-label” use
of drugs or medical devices, or otherwise promoted or marketed approved products in a manner inconsistent with the FDA’s
requirements.

In the U.S. and certain other jurisdictions, companies may not promote drugs or medical devices for “off-label” uses, that
is, uses that are not described in the product’s labeling and that differ from those that were approved or cleared by the FDA or
other foreign regulatory agencies. However, physicians and other healthcare practitioners may prescribe drug products and use
medical devices for off-label or unapproved uses, and such uses are common across some medical specialties. Although the
FDA does not regulate a physician’s choice of medications, treatments or product uses, the Federal Food, Drug and Cosmetic
Act and FDA regulations significantly restrict permissible communications on the subject of off-label uses of drug products and
medical devices by pharmaceutical and medical device companies. As the sponsors of FDA approved products, we and our
partners will not only be responsible for the actions of the companies but also can be held liable for the actions of employees
and contractors, requiring that all employees and contractors engaging in regulated functions, such as product promotion, be
adequately trained and monitored, which requires time and monetary expenditures.

If the FDA determines that a company has improperly promoted a product “off label” or otherwise not in accordance with
the agency’s promotional requirements, the FDA may issue a warning letter or seek other enforcement action to limit or restrict
certain promotional activities or materials or seek to have product withdrawn from the market or seize product, among other
enforcement requirements. In addition, a company that is found to have improperly promoted off-label uses may be subject to
significant liability, including civil fines, criminal fines and penalties, civil damages and exclusion from federal funded
healthcare programs such as Medicare and Medicaid and/or government contracting, consent decrees and corporate integrity
agreements, as well as potential liability under the federal FCA and applicable state false claims acts. Conduct giving rise to
such liability could also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by
such conduct.

Moreover, in addition to the regulatory restrictions on off-label promotion, there are other FDA restrictions on and
requirements concerning product promotion and advertising, such as requirements that such communications be truthful and
non-misleading and adequately supported. The FDA also has requirements concerning the distribution of drug samples. The
FDA and other authorities may take the position that we are not in compliance with promotional, advertising, and marketing
requirements, and, if such non-compliance is proven, we may be subject to significant liability, including but not limited to
administrative, civil and criminal penalties and fines, in addition to regulatory enforcement actions.

For certain of our products, we and our independent contractors, distributors, prescribers, and dispensers are required to
comply with regulatory requirements related to controlled substances, which will require the expenditure of additional time
and will incur additional expenses to maintain compliance and may subject us to additional penalties for noncompliance,
which could inhibit successful commercialization.

Certain of our products are controlled substances and accordingly, we, and our contractors, distributors, prescribers, and
dispensers must comply with Federal controlled substances laws and regulations, enforced by the U.S. Drug Enforcement
Administration (“DEA”), as well as state-controlled substances laws and regulations enforced by state authorities. These
requirements include, but are not limited to, registration, security, recordkeeping, reporting, storage, distribution, importation,
exportation, inventory, and other requirements. These requirements are enforced by the DEA through periodic inspections. Not
only must continuous controlled substance registration be maintained, but compliance with the applicable controlled substance
requirements will require significant efforts and expenditures, which could also inhibit successful commercialization. These
compliance requirements also add complexity to the distribution, prescribing and dispensing of certain of our products that may
also impact commercialization, including the establishment of anti-diversion procedures. If we and our contractors, distributors,
prescribers, and dispensers do not comply with the applicable controlled substance requirements, we or they may be subject to
administrative, civil or criminal enforcement, including civil penalties, refusals to renew necessary registrations, revocation of
registrations, criminal proceedings, or consent decrees.

Patent protection for biotechnology inventions and for inventions generally is subject to significant scrutiny. if patent laws
or the interpretation of patent laws change, our business may be adversely impacted because we may lose the ability to
enforce our intellectual property rights against competitors develop and commercialize products based on our discoveries.

Patent protection for protein-based therapeutic products is highly uncertain and involves complex legal and factual
questions. In recent years, there have been significant changes in patent law, including the legal standards that govern the scope
of protein and biotechnology patents. Standards for patentability of full-length and partial genes, and their corresponding
proteins, are changing. Recent court decisions have made it more difficult to obtain patents, by making it more difficult to
satisfy the patentable subject matter requirement and the requirement of non-obviousness, have decreased the availability of
injunctions against infringers, and have increased the likelihood of challenging the validity of a patent through a declaratory
judgment action. Taken together, these decisions could make it more difficult and costly for us to obtain, license and enforce
our patents. In addition, the Leahy-Smith America Invents Act (HR 1249) was signed into law in September 2011, which
among other changes to the U.S. patent laws, changes patent priority from “first to invent” to “first to file,” implements a post-
grant opposition system for patents and provides for a prior user defense to infringement. These judicial and legislative changes
have introduced significant uncertainty in the patent law landscape and may potentially negatively impact our ability to procure,
maintain and enforce patents to provide exclusivity for our products.

There also have been, and continue to be, policy discussions concerning the scope of patent protection awarded to
biotechnology inventions. Social and political opposition to biotechnology patents may lead to narrower patent protection
within the biotechnology industry. Social and political opposition to patents on genes and proteins and recent court decisions
concerning patentability of isolated genes may lead to narrower patent protection, or narrower claim interpretation, for isolated
genes, their corresponding proteins and inventions related to their use, formulation and manufacture. Patent protection relating
to biotechnology products is also subject to a great deal of uncertainty outside the U.S., and patent laws are evolving and
undergoing revision in many countries. Changes in, or different interpretations of, patent laws worldwide may result in our
inability to obtain or enforce patents, and may allow others to use our discoveries to develop and commercialize competitive
products, which would impair our business.

If third-party reimbursement and customer contracts are not available, our proprietary and partnered products may not be
accepted in the market resulting in commercial performance below that which was expected or projected.

Our and our partners’ ability to earn sufficient returns on proprietary and partnered products will depend in part on the
extent to which reimbursement for these products and related treatments will be available from government health
administration authorities, private health insurers, managed care organizations and other healthcare providers.

Third-party payers are increasingly attempting to limit both the coverage and the level of reimbursement of new drug
products to contain costs. Consequently, significant uncertainty exists as to the reimbursement status of newly approved
healthcare products. Third-party payers may not establish adequate levels of reimbursement for the products that we and our
partners commercialize, which could limit their market acceptance and result in a material adverse effect on our revenues and
financial condition.

Customer contracts, such as with group purchasing organizations and hospital formularies, will often not offer contract or
formulary status without either the lowest price or substantial proven clinical differentiation. If, for example, Hylenex is
compared to animal-derived hyaluronidases by these entities, it is possible that neither of these conditions will be met, which
could limit market acceptance and result in a material adverse effect on our revenues and financial condition.

The rising cost of healthcare and related pharmaceutical product pricing has led to cost containment pressures from third-
party payers as well as changes in federal coverage and reimbursement policies and practices that could cause us and our
partners to sell our products at lower prices, and impact access to our and our partners’ products, resulting in less revenue
to us.

Any of our proprietary or partnered products that have been, or in the future are, approved by the FDA may be purchased
or reimbursed by state and federal government authorities, private health insurers and other organizations, such as health
maintenance organizations and managed care organizations. Such third-party payers increasingly challenge pharmaceutical
product pricing. The trend toward managed healthcare in the U.S., the growth of such organizations, and various legislative
proposals and enactments to reform healthcare and government insurance programs, including the Medicare Prescription Drug
Modernization Act of 2003 and the Affordable Care Act of 2010 (ACA), could significantly influence the manner in which
pharmaceutical products are prescribed and purchased, resulting in lower prices and/or a reduction in demand. Such cost
containment measures and healthcare reforms could adversely affect our ability to sell our product and our partners’ ability to
sell their products.

In the U.S., our business may be impacted by changes in federal reimbursement policy resulting from executive actions,

federal regulations, or federal demonstration projects.

The federal administration and/or agencies, such as the Centers for Medicare & Medicaid Services, or CMS, have
announced a number of demonstration projects, recommendations and proposals to implement various elements described in the

drug pricing blueprint. CMS, the federal agency responsible for administering Medicare and overseeing state Medicaid
programs and Health Insurance Marketplaces, has substantial power to implement policy changes or demonstration projects that
can quickly and significantly affect how drugs, including our products, are covered and reimbursed. For example, in November
2020, former President Trump announced the interim final rule to implement the Most Favored Nations drug pricing model
seeking to tie Medicare payment rates to an international index price. This final rule was subsequently rescinded by CMS.
Additionally, a number of Congressional committees have also held hearings and evaluated proposed legislation on drug
pricing and payment policy which may affect our business. For example, in July 2019, the Senate Finance Committee advanced
a bill that in part would penalize pharmaceutical manufacturers for increasing drug list prices covered by Medicare Part B and
Part D, faster than the rate of inflation, and cap out-of-pocket expenses for Medicare Part D beneficiaries. Several other
proposals have been introduced that, if enacted and implemented, could affect access to and sales of our and our partners’
products, allow the federal government to engage in price negotiations on certain drugs, and allow importation of prescription
medication from Canada or other countries. For example, in August 2022, “The Inflation Reduction Act of 2022” was enacted
which will, among other things, allow and require the federal government to negotiate prices for some drugs covered under
Medicare Part B and Part D, require drug companies to pay rebates to Medicare if prices rise faster than inflation for drugs used
by Medicare beneficiaries and cap out-of-pocket spending for individuals enrolled in Medicare Part D.

In this dynamic environment, we are unable to predict which or how many federal policy, legislative or regulatory
changes may ultimately be enacted. To the extent federal government initiatives decrease or modify the coverage or
reimbursement available for our or our partners’ products, limit or impact our decisions regarding the pricing of
biopharmaceutical products or otherwise reduce the use of our or our partners’ U.S. products, such actions could have a
material adverse effect on our business and results of operations.

Furthermore, individual states are considering proposed legislation and have become increasingly aggressive in passing
legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access, importation from other countries and bulk
purchasing. Legally mandated price controls on payment amounts by third-party payers or other restrictions could negatively
and materially impact our revenues and financial condition. We anticipate that we will encounter similar regulatory and
legislative issues in most other countries outside the U.S.

In addition, private payers in the US, including insurers, pharmacy benefit managers (PBMs), integrated healthcare
delivery systems, and group purchasing organizations, are continuously seeking ways to reduce drug costs. Many payers have
developed and continue to develop ways to shift a greater portion of drug costs to patients through, for example, limited benefit
plan designs, high deductible plans and higher co-pay or coinsurance obligations. Consolidation in the payer space has also
resulted in a few large PBMs and insurers which place greater pressure on pricing and utilization negotiations for our and our
partners’ products in the U.S., increasing the need for higher discounts and rebates and limiting patient access and utilization.
Ultimately, additional discounts, rebates and other price reductions, fees, coverage and plan changes, or exclusions imposed by
these private payers on our and our partners’ products could have an adverse event on product sales, our business and results of
operations.

To help patients afford certain of our products, we offer discount, rebate, and co-pay coupon programs. CMS recently has
issued a regulation imposing additional obligations on manufacturers in order to continue excluding such programs from
government pricing calculations to avoid payment of increased Medicaid rebates. In recent years, other pharmaceutical
manufacturers have been named in class action lawsuits challenging the legality of their co-pay programs under a variety of
federal and state laws. Our co-pay coupon programs could become the target of similar lawsuits or insurer actions. It is possible
that the outcome of litigation against other manufacturers, changes in insurer policies regarding co-pay coupons, and/or the
introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these programs.

We also face risks relating to the reporting of pricing data that affects the reimbursement of and discounts provided for
our products. Government price reporting regulations are complex and may require a manufacturer to update certain previously
submitted data. If our submitted pricing data are incorrect, we may become subject to substantial fines and penalties or other
government enforcement actions, which could have a material adverse effect on our business and results of operations. In
addition, as a result of restating previously reported price data, we also may be required to pay additional rebates and provide
additional discounts.

We face competition and rapid technological change that could result in the development of products by others that are
competitive with our proprietary and partnered products, including those under development.

Our proprietary and partnered products have numerous competitors in the U.S. and abroad including, among others, major
pharmaceutical and specialized biotechnology firms, universities and other research institutions that have developed competing
products. Many of these competitors have substantially more resources and product development, manufacturing and marketing
experience and capabilities than we do. The competitors for Hylenex recombinant include, but are not limited to, Bausch Health
Companies, Inc.’s FDA-approved product, Vitrase®, an ovine (ram) hyaluronidase, and Amphastar Pharmaceuticals, Inc.’s
product, Amphadase®, a bovine (bull) hyaluronidase. For our ENHANZE technology, such competitors may include major

pharmaceutical and specialized biotechnology firms. These competitors may develop technologies and products that are more
effective, safer, or less costly than our current or future proprietary and partnered products and product candidates or that could
render our and our partners’ products, technologies and product candidates obsolete or noncompetitive.

General Risks

If we are unable to attract, hire and retain key personnel our business could be negatively affected.

Our success depends on the performance of key employees with relevant experience. We depend substantially on our
ability to hire, train, motivate and retain high quality personnel. If we are unable to identify, hire and retain qualified personnel,
our ability to support current and future alliances with strategic partners could be adversely impacted. Our use of domestic and
international third-party contractors, consultants and staffing agencies also subjects us to potential co-employment liability
claims.

Furthermore, if we were to lose key personnel, we may lose some portion of our institutional knowledge and technical
know-how, potentially causing a disruption or delay in one or more of our partnered development programs until adequate
replacement personnel could be hired and trained. In addition, we do not have key person life insurance policies on the lives of
any of our employees which would help cover the cost of associated with the loss of key employees.

Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.

Our operations, including laboratories, offices and other research facilities, are headquartered in San Diego, California.
We have additional facilities in Ewing, New Jersey and Minnetonka, Minnesota. We depend on our facilities and on our
collaborators, contractors and vendors for the continued operation of our business. Natural disasters or other catastrophic
events, pandemics, interruptions in the supply of natural resources, political and governmental changes, wildfires and other
fires, tornadoes, floods, explosions, actions of animal rights activists, earthquakes and civil unrest could disrupt our operations
or those of our partners, contractors and vendors. Even though we believe we carry commercially reasonable business
interruption and liability insurance, and our contractors may carry liability insurance that protect us in certain events, we may
suffer losses as a result of business interruptions that exceed the coverage available under our and our contractors’ insurance
policies or for which we or our contractors do not have coverage. Any natural disaster or catastrophic event could have a
significant negative impact on our operations and financial results. Moreover, any such event could delay our partners’ research
and development programs.

Cyberattacks, security breaches or system breakdowns may disrupt our operations and harm our operating results and
reputation.

We and our partners are subject to increasingly sophisticated attempts to gain unauthorized access to our information
technology storage and access systems and are devoting resources to protect against such intrusion. Cyberattacks could render
us or our partners unable to utilize key systems or access important data needed to operate our business. The wrongful use,
theft, deliberate sabotage or any other type of security breach with respect to any of our or any of our vendors and partners’
information technology storage and access systems could result in the breakdown or other service interruption, or the disruption
of our ability to use such systems or disclosure or dissemination of proprietary and confidential information that is
electronically stored, including intellectual property, trade secrets, financial information, regulatory information, strategic plans,
sales trends and forecasts, litigation materials or personal information belonging to us, our staff, our patients, customers and/or
other business partners which could result in a material adverse impact on our business, operating results and financial
condition. We continue to invest in monitoring, and other security and data recovery measures to protect our critical and
sensitive data and systems. However, these may not be adequate to prevent or fully recover systems or data from all
breakdowns, service interruptions, attacks or breaches of our systems. In addition, our cybersecurity insurance may not be
sufficient to cover us against liability related to any such breaches. Furthermore, any physical break-in or trespass of our
facilities could result in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary
and confidential information, including research or clinical data or damage to our research and development equipment and
assets. Such adverse effects could be material and irrevocable to our business, operating results, financial condition and
reputation.

Item 1B. Unresolved Staff Comments

None.

Item 2. Properties

Our properties consist of leased office, laboratory, warehouse and manufacturing facilities. Our administrative offices and
research facilities are currently located in San Diego, California. In addition, we have an office in Ewing, New Jersey. We also
lease a building in Minnetonka, Minnesota consisting of office, laboratory, manufacturing and warehousing space. As of
December 31, 2022, we leased an aggregate of approximately 194,000 square feet of space. We believe our facilities are
adequate for our current and near-term needs.

Item 3.

Legal Proceedings

From time to time, we may be involved in disputes, including litigation, relating to claims arising out of operations in the
normal course of our business. Any of these claims could subject us to costly legal expenses and, while we generally believe
that we have adequate insurance to cover many different types of liabilities, our insurance carriers may deny coverage or our
policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any
such awards could have a material adverse effect on our consolidated results of operations and financial position. Additionally,
any such claims, whether or not successful, could damage our reputation and business. We currently are not a party to any legal
proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material
adverse effect on our consolidated results of operations or financial position.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity

PART II

Securities

Market Information

Our common stock is listed on the NASDAQ Global Select Market under the symbol “HALO.” As of February 14, 2023,

we had approximately 69,016 stockholders of record and beneficial owners of our common stock.

Dividends

We have never declared or paid any dividends on our common stock. We currently intend to retain available cash for
funding operations, stock repurchases and other capital initiatives; therefore, we do not expect to pay any dividends on our
common stock in the foreseeable future. Any future determination to pay dividends on our common stock will be at the
discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition,
capital requirements, contract restrictions, business prospects and other factors our board of directors may deem relevant.

Purchase of Equity Securities by the Issuer

In November 2019, we announced that the Board of Directors authorized the initiation of a capital return program to
repurchase up to $550.0 million of outstanding common stock over a three-year period. The shares were purchased through
open market transactions and through an Accelerated Share Repurchase (ASR) agreement. During 2021, we repurchased 4.6
million shares of common stock for $200.0 million at an average price of $43.02 under the program. We completed the program
in October 2021 having repurchased a total of 22.3 million shares for $550.0 million at an average price per share of $24.72.
We retired the repurchased shares and they resumed the status of authorized and unissued shares.

In December 2021, the Board of Directors authorized our second share repurchase program, to repurchase up to $750.0
million of our outstanding common stock over a three-year period. In August 2022, we entered into an ASR agreement with
Bank of America to repurchase $109.8 million of our common stock. At inception, pursuant to the agreement, we paid
$109.8 million to Bank of America and took an initial delivery of 2.0 million shares. In December 2022, we finalized the
transaction and received an additional 0.4 million shares. We retired the repurchased shares and they resumed the status of
authorized and unissued shares. Under this program, through December 31, 2022, we repurchased 8.4 million shares of
common stock for $350.0 million at an average price of $41.69.

Stock Performance Graph and Cumulative Total Return

Notwithstanding any statement to the contrary in any of our previous or future filings with the SEC, the following
information relating to the price performance of our common stock shall not be deemed to be “filed” with the SEC or to be
“soliciting material” under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and it shall not be deemed
to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Exchange Act,
except to the extent we specifically incorporate it by reference into such filing.

The graph below compares Halozyme Therapeutics, Inc.’s cumulative five-year total shareholder return on common stock
with the cumulative total returns of the NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph tracks
the performance of a $100 investment in our common stock and in each of the indexes (with the reinvestment of all dividends)
from December 31, 2017 to December 31, 2022. The historical stock price performance included in this graph is not necessarily
indicative of future stock price performance.

Halozyme Therapeutics, Inc. . . . . . . . . . . . . .
NASDAQ Composite . . . . . . . . . . . . . . . . . . .
NASDAQ Biotechnology . . . . . . . . . . . . . . . .

12/31/2017
$100
$100
$100

12/31/2018
$72
$97
$91

12/31/2019
$88
$133
$114

12/31/2020
$211
$192
$144

12/31/2021
$198
$235
$144

12/31/2022
$281
$159
$130

Item 6.

(Reserved)

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

In addition to historical information, the following discussion contains forward-looking statements that are subject to

risks and uncertainties. Actual results may differ substantially from those referred to herein due to a number of factors,
including but not limited to risks described in the Part I, Item 1A, Risks Factors, and elsewhere in this Annual Report.
References to “Notes” are Notes included in our Notes to Consolidated Financial Statements.

Overview

Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive

solutions with the goal of improving the patient experience and potentially outcomes.

Our first commercially approved product Hylenex® recombinant (“Hylenex”), and our ENHANZE partners’ approved
products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is
the active ingredient Hylenex®, that works by breaking down hyaluronan (“HA”), a naturally occurring carbohydrate that is a
major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing
for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and
other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the
delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with
biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of
administration. In the development of proprietary intravenous (“IV”) drugs combined with our ENHANZE technology, data
have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration
of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared
to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already
administered subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more
flexible treatment options such as home administration by a healthcare professional or potentially the patient or caregiver.
Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending the patent
life of the product beyond the patent expiry of the proprietary IV drug.

We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-
La Roche, Inc. (“Roche”), Takeda Pharmaceuticals International AG and Baxalta US Inc. (“Takeda”), Pfizer Inc. (“Pfizer”),
Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company
(“BMS”), Alexion Pharma International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca
PLC)(“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (“Horizon”), ViiV Healthcare (the global specialist HIV
Company majority owned by GlaxoSmithKline) (“ViiV”) and Chugai Pharmaceutical Co., Ltd (“Chugai”). In addition to
receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone
payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-
formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of
one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen
collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved
products will depend on the ability of our partners, in some areas supported by Halozyme, to develop, manufacture, secure and
maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Our 2022 and recent key events are as follows:

Roche

•

In August 2022, Roche announced that the Phase 3 IMscin001 study evaluating a subcutaneous formulation of
Tecentriq® (atezolizumab) with ENHANZE met its co-primary endpoints. The study showed non-inferior levels of
Tecentriq in the blood (pharmacokinetics), when injected subcutaneously, compared with IV infusion, in cancer
immunotherapy-naïve patients with advanced or metastatic non-small cell lung cancer for whom prior platinum
therapy has failed. The safety profile of the SC formulation was consistent with that of IV Tecentriq. In November
2022, Roche submitted a BLA to the FDA and a MAA to the EMA for SC atezolizumab with ENHANZE across all
approved indications of IV Tecentriq. In January 2023, the FDA accepted the BLA with a PDUFA goal date of
September 15, 2023.

In November 2022, Roche submitted an Initial Market Application (IMA) for Mabthera SC to the Center for Drug
Evaluation (CDE) in China.

In October 2022, Roche Pharmaceuticals China announced the approval of Herceptin SC (trastuzumab injection
subcutaneous with ENHANZE) in China for the treatment of patients with early-stage and metastatic HER2-positive
breast cancer.

In July 2022, Roche submitted an IMA for the fixed-dose combination of Perjeta® (pertuzumab) and Herceptin for
subcutaneous injection (Phesgo™) to the CDE in China.

In April 2022, Roche initiated a phase 3 study evaluating OCREVUS (ocrelizumab) with ENHANZE in subjects with
multiple sclerosis.

argenx

•

In November 2022, argenx announced the acceptance of the BLA for SC efgartigimod for the treatment of adults with
generalized myasthenia gravis (gMG). In January 2023, argenx announced that FDA extended the PDUFA date to
June 20, 2023.

•

In November 2022, argenx announced the submission of a Marketing Authorization Application to the EMA for SC
efgartigimod for the treatment of adults with gMG.

In June 2022, argenx initiated a phase 2 study evaluating efgartigimod with ENHANZE in subjects with bullous
pemphigoid.

In March 2022, argenx announced that data from argenx’s phase 3 ADAPT-SC study evaluating SC efgartigimod
(1000mg efgartigimod-PH20) for the treatment of gMG achieved the primary endpoint of total IgG reduction from
baseline at day 29, demonstrating statistical non-inferiority to VYVGART® (efgartigimod alfa-fcab) intravenous IV
formulation in gMG patients.

Chugai

In September 2022, Chugai Pharmaceutical Co., Ltd. (a Member of the Roche Group) announced the submission of a
NDA in Japan for the fixed-dose SC combination of pertuzumab and trastuzumab (same monoclonal antibodies as in
Perjeta and Herceptin) with ENHANZE®.

In May 2022, Chugai initiated a Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of a
targeted antibody administered subcutaneously with ENHANZE.

In March 2022, we entered into a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd.
The license gives Chugai exclusive access to ENHANZE drug delivery technology for an undisclosed target. Under
the terms of the agreement, we received an upfront payment of $25 million and Chugai is obligated to make future
payments of up to $160 million, in the aggregate, subject to achievement of specified development, regulatory and
sales-based milestones. We will also be entitled to receive royalties on sales of commercialized medicines using our
ENHANZE technology.

Janssen

In November 2022, Janssen initiated a Phase 2 study of amivantamab with ENHANZE in multiple regimens in patients
with advanced or metastatic solid tumors including epidermal growth factor receptor (EGFR)-mutated non-small cell
lung cancer (PALOMA-2).

In September 2022, Janssen initiated a Phase 3 study of lazertinib and amivantamab with ENHANZE in patients with
EGFR-mutated advanced or metastatic non-small cell lung cancer (PALOMA-3).

ViiV

In June 2022, ViiV initiated enrollment of a Phase 1 single dose escalation study in subjects with HIV to evaluate
pharmacokinetics, safety and tolerability of long-acting cabotegravir administered subcutaneously with ENHANZE.

In March 2022, ViiV initiated enrollment of a Phase 1 study to evaluate the safety and pharmacokinetics of N6LS, a
broadly neutralizing antibody, administered subcutaneously with ENHANZE.

Takeda

In December 2022, Takeda achieved a sales milestone for HYQVIA, triggering a payment of $10 million.

In July 2022, Takeda filed a sBLA for the potential expanded use of HYQVIA for pediatric indication for primary
immunodeficiency.

In July 2022, Takeda announced positive topline results from pivotal Phase 3 trial evaluating HYQVIA®
(Immunoglobulin infusion 10% (Human) with rHuPH20), for maintenance treatment of chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP), and Takeda confirmed its intention to submit regulatory applications in
the United States and European Union in its fiscal year 2022.

BMS

BMS plans to initiate a Phase 3 trial in early 2023 to demonstrate the drug exposure level of nivolumab and relatlimab
fixed-dose combination with ENHANZE is not inferior to IV administration in participants with previously untreated
metastatic or unresectable melanoma (Relativity-127).

In August 2022, BMS initiated a Phase 3 trial to compare the drug levels of nivolumab with ENHANZE administered
subcutaneously versus
resection
(CheckMate-6GE).

in participants with melanoma

following complete

IV administration

In June 2022, BMS nominated an undisclosed target resulting in a $5 million payment.

•

Corporate

•

In January 2023, we elected to redeem on March 17, 2023 all of our remaining outstanding 1.25% convertible senior
notes due 2024.

In August 2022, we completed the sale of $720.0 million aggregate principal amount of the 2028 Convertible Senior
Note. We used a portion of the net proceeds to facilitate an induced conversion of a portion of the 2024 Convertible
Senior Notes. In connection with the induced conversion, we paid the holders $77.6 million in cash and issued 1.51
million shares. We also used a portion of the net proceeds to repay the $250.0 million term loan facility due 2026 and
the $120.0 million revolving credit facility.

In August 2022, we entered into an amendment to our credit agreement that increased the size of our revolving credit
facility from $350 million to $575 million.

In the third quarter of 2022, we accelerated $100 million share repurchase from 2023 into 2022. We repurchased 2.1
million shares of common stock in open market purchases for $90.2 million at an average price per share of $43.09
and entered into an ASR agreement to repurchase $109.8 million of our common stock for which we took an initial
delivery 2.0 million shares. In December 2022, we finalized the ASR transaction and received an additional 0.4 million
shares for a total of 2.4 million shares at an average price per share of $45.62. During 2022, we repurchased a total of
4.5 million shares for $200.0 million at an average price per share of $44.44. As of December 31, 2022, we
repurchased a total of 8.4 million shares for $350.0 million at an average price per share of $41.69 under our $750
million 3-year share repurchase plan.

In June 2022, we completed an $150 million ASR that was initiated in December of 2021, resulting in the total
repurchase of 3.9 million shares at a price of $38.51 per share.

In June 2022, we announced the commercial launch of TLANDO® (testosterone undecanoate), an oral treatment
indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of
endogenous testosterone (primary or hypogonadotropic hypogonadism). TLANDO® was approved by the U.S. Food
and Drug Administration (FDA) on March 28, 2022.

•

In May 2022, we completed the acquisition of Antares resulting in an expansion of our commercial portfolio of
proprietary and partnered products and the potential for future growth through new agreements.

In May 2022, in connection with the closing of Antares acquisition, we entered into a credit agreement that provided
for a $350 million revolving credit facility and a $250 million term loan facility. The proceeds from a $120 million
draw on the revolving credit facility and the $250 million term facility were used to fund a portion of the Antares
acquisition, refinance Antares’ existing debt and pay fees and expenses in connection with the acquisition.

In March 2022, we entered into an agreement for assignment and assumption of a lease with Seismic Software, Inc.
pursuant to which effective January 1, 2023 we assumed Seismic’s office lease, as amended with Kilroy Realty L.P.
for approximately 73,238 square feet of space in office and research facilities. The premises are intended to serve as
our new headquarters which we occupied on January 1, 2023.

Results of Operations

Comparison of Years Ended December 31, 2022 and 2021

Royalties – Royalty revenue was $360.5 million in 2022 compared to $203.9 million in 2021. The increase was mainly
driven by continued sales uptake of DARZALEX FASPRO by Janssen and Phesgo by Roche in all geographies and
contribution from new device royalty revenue as a result of the Antares acquisition, partially offset by slightly lower sales of
Herceptin SC and MabThera SC by Roche. We expect royalty revenue to continue to grow as a result of our 2020 ENHANZE
partner product launches, offsetting the ongoing impact from biosimilars related to our mature ENHANZE partner products.

Product Sales, Net – Product sales, net were as follows (in thousands):

Sales of bulk rHuPH20 . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sales of proprietary products . . . . . . . . . . . . . . . . . . . . . . . .
Sales of device partnered products . . . . . . . . . . . . . . . . . . . .
Total product sales, net . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2022
82,084 $
72,849
36,097
191,030 $

2021
80,961
23,263
—
104,224

Dollar Change
1,123
$
49,586
36,097
86,806

Percentage
Change

1 %
213 %
100 %
83 %

Total product sales, net increased by $86.8 million in 2022 compared to 2021, primarily due to contribution from our
proprietary and device partnered products as the result of the Antares acquisition. We expect that sales of proprietary products
will grow in future years as we work to expand market share in the TRT market. We expect that product sales of bulk rHuPH20
and device partnered products will fluctuate in future periods based on the needs of our partners.

Revenues Under Collaborative Agreements – Revenues under collaborative agreements were as follows (in thousands):

Year Ended December 31,

2022

2021

Dollar Change

Percentage
Change

Upfront license fees, license fees for the election of additional
targets, event-based payments, license maintenance fees and
amortization of deferred upfront and other license fees:

BMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Chugai . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Roche . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Janssen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Takeda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ViiV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Subtotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Device licensing and development revenue . . . . . . . . . . . . .
Total revenues under collaborative agreements . . . . .

30,000 $
25,000
19,000

15,000
10,000
—
99,000 $
9,611
108,611 $

25,000
—
5,000

59,000
—
45,000
134,000
1,186
135,186

5,000
25,000
14,000

(44,000)
10,000
(45,000)
(35,000)
8,425
(26,575)

20 %
100 %
280 %

(75) %
100 %
(100) %
(26) %
710 %
(20) %

Revenue from license fees decreased by $35.0 million in 2022, compared to 2021 primarily due to the timing of
milestones driven by partner activities. Revenue from upfront licenses fees, license fees for the election of additional targets,
license maintenance fees and other license fees and event-based payments vary from period to period based on our ENHANZE
collaboration activity. We expect these revenues to continue to fluctuate in future periods based on our partners’ ability to meet
various clinical and regulatory milestones set forth in such agreements and our ability to obtain new collaborative agreements.

Cost of Sales – Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs,
freight costs, internal costs and manufacturing overhead associated with the production of our proprietary and device partnered
products and bulk rHuPH20. Cost of product sales were $139.3 million in 2022 compared to $81.4 million in 2021. The
increase of $57.9 million in cost of product sales was mainly due to an increase in sales in our proprietary, partnered products as
a result of the Antares acquisition and amortization of inventory step-up associated with purchase accounting for the Antares
acquisition.

Amortization of intangibles – Amortization of intangibles expense was $43.1 million for 2022. The amortization of
intangibles expense is due to the acquisition of Antares in May 2022, in which we acquired intangible assets that are amortized
over their useful lives.

Research and Development – Research and development expenses consist of external costs, salaries and benefits and
allocation of facilities and other overhead expenses related to research manufacturing, preclinical and regulatory activities
related to our ENHANZE collaborations and our development platform. Research and development expenses were $66.6
million in 2022 compared to $35.7 million in 2021. The increase of $30.9 million is primarily due to planned investments in
ENHANZE and an increase in compensation expense related to the ongoing combined larger workforce as a result of the
Antares acquisition.

Selling, General and Administrative – Selling, general and administrative (SG&A) expenses consist primarily of salaries
and related costs for personnel in executive, selling and administrative functions as well as professional fees for legal and
accounting, business development, commercial operations support for proprietary products and alliance management and
marketing support for our collaborations. SG&A expenses were $143.5 million in 2022 compared to $50.3 million in 2021. The
increase of $93.2 million, was primarily due to one-time Antares Pharma acquisition costs and an increase in compensation
expense related to the ongoing combined larger workforce.

Interest Expense – Interest expense was $16.9 million in 2022 compared to $7.5 million in 2021. The increase of $9.4
million was primarily due an increase in interest expense related to the 2022 term loans, the revolving credit facility and the
2028 Convertible Notes.

Income Taxes – Income tax expense was $46.8 million in 2022 compared to income tax benefit of $154.2 million in 2021.
The increase in income tax expense is due to the recording of our first year of income tax expense in the current year whereas in
the prior year period there was an income tax benefit due to the release of the valuation allowance.

Comparison of Years Ended December 31, 2021 and 2020

For discussion related to changes in financial condition and the results of operations for fiscal year 2021 compared to
fiscal year 2020, refer to Part II - Item 7. Management’s Discussion and Analysis of Financial Condition and Results of
Operations included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was
filed with the SEC on February 22, 2022.

Liquidity and Capital Resources

Our principal sources of liquidity are our existing cash, cash equivalents and available-for-sale marketable securities. As
of December 31, 2022, we had cash, cash equivalents and marketable securities of $362.8 million. We believe that our current
cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months. We
expect to fund our operations going forward with existing cash resources, anticipated revenues from our existing collaborations
and cash that we may raise through future transactions. We may raise cash through any one of the following financing vehicles:
(i) new collaborative agreements; (ii) expansions or revisions to existing collaborative relationships; (iii) private financings;
(iv) other equity or debt financings; (v) monetizing assets; and/or (vi) the public offering of securities.

We may, in the future, draw on our existing line of credit, offer and sell additional equity, debt securities and warrants to
purchase any of such securities, either individually or in units to raise capital to raise funds for additional working capital,
capital expenditures, share repurchases, acquisitions or for other general corporate purposes. Our material cash requirements
include the following contractual and other obligations.

Long-term debt

Our long-term debt consists of convertible notes. The aggregate principal amount of our convertible notes is $1,538.5
million, with $13.5 million classified as short term. Future interest payments associated with our convertible notes total $48.9
million, with $9.3 million payable within 12 months.

Leases

We have lease arrangements related to our office and research facilities and certain autos under non-cancelable operating

leases. As of December 31, 2022, we have lease payment obligations of $47.0 million, with $7.8 million payable within 12
months.

Third-party manufacturing obligations

We have contracted with third-party manufacturers for the supply of bulk rHuPH20, fill/finish of Hylenex recombinant,
other proprietary products and partnered products. Under these agreements, we are required to purchase certain quantities each
year during the terms of the agreements. Contractual obligations for purchases of goods or services include agreements that are
enforceable and legally binding to us and that specify all significant terms, including fixed or minimum quantities to be
purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. For obligations with
cancellation provisions, the amounts disclosed here were limited to the non-cancelable portion of the agreement terms or the
minimum cancellation fee. As of December 31, 2022, we had third-party manufacturing obligations of $97.8 million, payable
within 12 months.

Other purchase obligations and commitments

Purchase obligations represent an estimate of all open purchase orders and contractual obligations in the ordinary course
of business for which we have not received the goods or services. We also have commitments which represents minimum
royalty payments to be paid in accordance with the TLANDO exclusive license agreement with Lipocine. As of December 31,
2022, we had other purchase obligations and other commitments of $48.7 million, with $44.2 million payable within 12
months.

The expected timing of payments of the obligations above is estimated based on information we have as of December 31,
2022. Timing of payments and actual amounts paid may be different, depending on the time of receipt of goods or services, or
changes to agreed-upon amounts for some obligations.

Our future capital uses and requirements and anticipated sources of funds to satisfy these requirements depend on

numerous forward-looking factors. These factors may include, but are not limited to, the following:

•

the costs of investments in our ENHANZE platform and auto-injector technology including development of new versions
of rHuPH20 and auto-injector devices;

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

the costs to develop and validate additional manufacturing processes of rHuPH20, auto-injectors, and testosterone
replacement therapies;

the costs to expand the number of collaboration partner products developed and launched by partners including costs to
scale-up manufacturing;

the amount of royalties and milestones from our partners;

the effect of competing technological and market developments;

the terms and timing of any collaborative, licensing and other arrangements that we may establish; and

the extent to which we acquire or in-license new products, technologies or businesses and invest in development.

Cash Flows

Operating Activities

Net cash provided by operations was $240.1 million in 2022 compared to $299.4 million in 2021. The $59.3 million
decrease in cash provided by operations was mainly due to an increase in transaction expenses associated with the Antares
acquisition and an increase in working capital spend, partially offset by an increase in royalties revenue for 2022 compared to
the prior year.

Investing Activities

Net cash used in investing activities was $487.0 million in 2022 compared to net cash used in investing activities of
$406.3 million in 2021. The increase in cash used in investing activities was primarily due to the acquisition of Antares,
partially offset by an increase in cash from the sale of marketable securities and the sale of assets in 2022.

Financing Activities

Net cash provided by financing activities was $362.4 million in 2022, compared to net cash provided by financing
activities of $77.9 million in 2021, mainly due to $702.0 million cash received from the 2028 Convertible Notes offering and
$291.6 million decrease related to the 2024 Convertible Notes induced conversion, a $150.1 million decrease in repurchase of
common stock and a $1.5 million increase in net proceeds from the issuance of common stock under equity incentive plans,
partially offset by, $784.9 million cash received from the 2027 Convertible Notes offering in the prior year and a $69.1 million
payment for the Capped Call Transactions during the current year.

Share Repurchases

In November 2019, our Board of Directors approved a $550 million share repurchase program, pursuant to which we
could repurchase our issued and outstanding shares of common stock from time to time. We completed the share repurchase
program in October 2021 and retired the repurchased shares. In December 2021, we announced our second share repurchase
program, to repurchase up to $750.0 million of our outstanding common stock over a three-year period. See Note 10.
Stockholders’ Equity, within the notes to the consolidated financial statements for additional information regarding our share
repurchases.

Long-Term Debt

1.00% Convertible Notes due 2028

In August 2022, we completed the sale of $720.0 million in aggregate principal amount of 1.00% Convertible Senior
Notes due 2028 (the “2028 Convertible Notes” and collectively with the 2024 and the 2027 Convertible Notes the “Convertible
Notes”). The net proceeds in connection with the issuance of the 2028 Convertible Notes, after deducting the initial purchasers’
fee of $18.0 million, was approximately $702.0 million. We also incurred additional debt issuance costs totaling $1.0 million.
Debt issuance costs and the initial purchasers’ fee are presented as a debt discount.

The 2028 Convertible Notes pay interest semi-annually in arrears on February 15th and August 15th of each year at an
annual rate of 1.00%. The 2028 Convertible Notes are general unsecured obligations and rank senior in right of payment to all
indebtedness that is expressly subordinated in right of payment to the 2028 Convertible Notes, rank equally in right of payment
with all existing and future liabilities that are not so subordinated, are effectively junior to any secured indebtedness to the
extent of the value of the assets securing such indebtedness, and are structurally subordinated to all indebtedness and other
liabilities (including trade payables) of our current or future subsidiaries. The 2028 Convertible Notes have a maturity date of
August 15, 2028.

Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any
calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of
common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days
ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the 5 consecutive
business days immediately after any 5 consecutive trading day period (such 5 consecutive trading day period, the “measurement
period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was
less than 98% of the product of the last reported sale price per share of our common stock on such trading day and the
conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common stock,
as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and (5) at
any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day immediately
before the maturity date. As of December 31, 2022, the 2028 Convertible Notes are not convertible.

Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash,
deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion
rate for the 2028 Convertible Notes is 17.8517 shares of common stock per $1,000 in principal amount of 2028 Convertible
Notes, equivalent to a conversion price of approximately $56.02 per share of our common stock. The conversion rate is subject
to adjustment in some events but will not be adjusted for any accrued or unpaid interest.

0.25% Convertible Notes due 2027

In March 2021, we completed the sale of $805.0 million in aggregate principal amount of 0.25% Convertible Senior Notes
due 2027 (the “2027 Convertible Notes” and collectively with the 2024 Convertible Notes the “Convertible Notes”). The net
proceeds in connection with the 2027 Convertible Notes, after deducting the initial purchasers’ fee of $20.1 million, was
approximately $784.9 million. We also incurred additional debt issuance costs totaling $0.4 million. Debt issuance costs and the
initial purchasers’ fee are presented as a debt discount.

The 2027 Convertible Notes pay interest semi-annually in arrears on March 1st and September 1st of each year at an
annual rate of 0.25%. The 2027 Convertible Notes are general unsecured obligations and will rank senior in right of payment to
all indebtedness that is expressly subordinated in right of payment to the 2027 Convertible Notes, will rank equally in right of
payment with all existing and future liabilities that are not so subordinated, will be effectively junior to any secured
indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally subordinated to all
indebtedness and other liabilities (including trade payables) of our current or future subsidiaries. The 2027 Convertible Notes
have a maturity date of March 1, 2027.

Holders may convert their 2027 Convertible Notes at their option only in the following circumstances: (1) during any
calendar quarter commencing after the calendar quarter ending on June 30, 2021, if the last reported sale price per share of
common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days
ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive
business days immediately after any five consecutive trading day period (such five consecutive trading day period, the
“measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement
period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and
the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common
stock, as described in the offering memorandum for the 2027 Convertible Notes; (4) if we call such notes for redemption; and
(5) at any time from, and including, September 1, 2026 until the close of business on the scheduled trading day immediately
before the maturity date. The Notes will be convertible, regardless of the foregoing circumstances, at any time from, and

including, September 1, 2026 until the close of business on the scheduled trading day immediately preceding the maturity date.
As of December 31, 2022, the 2027 Convertible Notes are not convertible.

Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash,
deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion
rate for the 2027 Convertible Notes is 12.9576 shares of common stock per $1,000 in principal amount of 2027 Convertible
Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion rate is subject
to adjustment.

1.25% Convertible Notes due 2024

In November 2019, we completed the sale of $460.0 million in aggregate principal amount of 1.25% Convertible Senior
Notes due 2024 (“2024 Convertible Notes”). The net proceeds in connection with 2024 Convertible Notes, after deducting the
initial purchases’ fee of $12.7 million, was approximately $447.3 million. We also incurred debt issuance cost totaling $0.3
million. Debt issuance costs and the initial purchasers’ fee are presented as a debt discount.

The 2024 Convertible Notes pay interest semi-annually in arrears on June 1st and December 1st of each year, beginning
on June 1, 2020, at an annual rate of 1.25%. The 2024 Convertible Notes are general unsecured obligations and will rank senior
in right of payment to all indebtedness that is expressly subordinated in right of payment to the 2024 Convertible Notes, will
rank equally in right of payment with all existing and future liabilities that are not so subordinated, will be effectively junior to
any secured indebtedness to the extent of the value of the assets securing such indebtedness and will be structurally
subordinated to all indebtedness and other liabilities (including trade payables) of the our current or future subsidiaries. The
2024 Convertible Notes have a maturity date of December 1, 2024.

Holders may convert their 2024 Convertible Notes at their option only in the following circumstances: (1) during any
calendar quarter commencing after the calendar quarter ending on March 31, 2020, if the last reported sale price per share of
common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days
ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive
business days immediately after any five consecutive trading day period (such five consecutive trading day period, the
“measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement
period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and
the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common
stock, as described in the offering memorandum for the 2024 Convertible Notes; (4) if we call such notes for redemption; and
(5) at any time from, and including, June 1, 2024 until the close of business on the scheduled trading day immediately before
the maturity date. As of December 31, 2022, the 2024 Convertible Notes are convertible and are classified as a current liability

In January 2021, we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible
Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024
Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes,
equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to
adjustment.

In March 2021, we completed a privately negotiated induced conversion of $369.1 million principal amount of the 2024
Convertible Notes (“2021 Note Repurchases” or the “2021 Induced Conversion”). In connection with the 2021 Induced
Conversion, we paid approximately $370.2 million in cash, which includes principal and accrued interest, and issued
approximately 9.08 million shares of our common stock representing the intrinsic value based on the contractual conversion
rate and incremental shares as an inducement for conversion. As a result of the 2021 Induced Conversion, we recorded $21.0
million in induced conversion expense which is included in Other income (expense) of the Condensed Consolidated Statements
of Operations for the twelve months ended December 31, 2022. The induced conversion expense represents the fair value of the
common stock issued upon conversion in excess of the common stock issuable under the original terms of the 2024 Convertible
Notes.

In August 2022, we completed a privately negotiated induced conversion of $77.4 million principal amount of the 2024
Convertible Notes (“2022 Note Repurchases” or the “2022 Induced Conversion”). In connection with the 2022 Induced
Conversion, we paid approximately $77.6 million in cash, which includes principal and accrued interest, and issued
approximately 1.51 million shares of our common stock representing the intrinsic value based on the contractual conversion
rate and incremental shares as an inducement for conversion. As a result of the 2022 Induced Conversion, we recorded
$2.7 million in induced conversion expense which is included in other income (expense) of the consolidated statements of
income. The induced conversion expense represents the fair value of the common stock issued upon conversion in excess of the
common stock issuable under the original terms of the 2024 Convertible Notes.

In January 2023, we issued a notice for the redemption of 2024 Convertible Notes, and we expect to make cash payment

of $13.5 million to effect the redemption in March 2023.

Revolving Credit and Term Loan Facilities (May 2022)

In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement with Bank of
America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the other lenders and L/C Issuers party
thereto (the “2022 Credit Agreement), evidencing a credit facility (the “2022 Facility”) that provides for (i) a $350 million
revolving credit facility (the “Revolving Credit Facility”) and (ii) a $250 million term loan facility (the “Term Facility”). The
proceeds from a $120 million draw on the Revolving Credit Facility and the $250 million Term Facility were used to fund a
portion of the Antares acquisition, refinance Antares’ existing debt and pay fees and expenses in connection with the
acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain conditions, to
increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying financial
covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage ratio
covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the
Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.

The Term Facility requires quarterly scheduled repayments of the term loans in each of the first, second, third and fourth
years following the Closing in annual amounts equal to 2.50%, 5.00%, 7.50% and 10.00% of the initial principal amount of the
term loans, respectively. The term loans are also subject to mandatory prepayments from the proceeds of certain asset sales,
subject to our right to reinvest the proceeds thereof.

Borrowings under the 2022 Facility bear interest, at our option, at a rate equal to an applicable margin plus: (a) the
applicable Term Secured Overnight Financing Rate (SOFR) (which includes a SOFR adjustment of 0.10%), or (b) a base rate
determined by reference to the highest of (1) the federal funds effective rate plus 0.50%, (2) the Bank of America prime rate, (3)
the Term SOFR rate for an interest period of one month plus 1.10%, and (4) 1.00%. The margin for the 2022 Facility ranges,
based on our consolidated total net leverage ratio, from 0.25% to 1.25% in the case of base rate loans and from 1.25% to 2.25%
in the case of Term SOFR rate loans. In addition to paying interest on the outstanding principal under the Facility, we will pay
(i) a commitment fee in respect of the unutilized commitments thereunder and (ii) customary letter of credit fees and agency
fees. The commitment fees range from 0.15% to 0.35% per annum based on our consolidated net leverage ratio.

In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the “Amendment”) among the Company,
the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A.,
as Administrative Agent (in such capacity, the “Administrative Agent”) and swing line lender (in such capacity, the “Swing
Line Lender”), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the “Credit
Agreement”) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C
Issuers. The Amendment, among other things, increases the size of the revolving credit facility from $350 million to
$575 million. The terms of the revolving credit facility are otherwise unchanged. Concurrently with the entry into the
Amendment, the Company repaid the entire outstanding term loan facility and repaid all outstanding loans under the revolving
credit facility under the Credit Agreement.

As of December 31, 2022, the revolving credit facility was undrawn.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The
preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We review our
estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe
to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Our significant
accounting policies are outlined in Note 2 to the Consolidated Financial Statements included in the Form 10-K. We believe the
following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial
statements.

Revenue Recognition

Methodology

Judgment and Uncertainties

Revenue is recognized when we
determine it is probable a milestone
will be achieved. This assessment is
based on our past experience with
our collaboration partners, market
insight and partner communication.

Effect if Actual Results Differ From
Assumptions

A revenue reversal will be required in
the event it is determined that
achievement of a milestone, previously
deemed probable, will not occur. This
reversal may be material.

For collaborative agreements, we are entitled
to receive event-based payments subject to
the collaboration partner's achievement of
specified development and regulatory
milestones. We recognize revenue when it is
deemed probable that these milestones will
be achieved, which could be in a period prior
to its actual occurrence. At the end of each
reporting period, we re-evaluate the
probability of achievement of such
milestones, and if necessary, adjust our
estimate of the overall transaction price.

For collaborative agreements, royalty
revenue is recognized in the period the
underlying sales occur, but we do not receive
final royalty reports from our collaboration
partners until after we complete our financial
statements for a prior quarter. Therefore, we
recognize revenue based on estimates of the
royalty earned, which are based on
preliminary reports provided by our
collaboration partners.

For collaborative arrangements, when
necessary, we perform an allocation of the
upfront amount based on relative stand-alone
selling prices (SSP) of licenses for individual
targets. We determine
license SSP using an income-based valuation
approach utilizing risk-adjusted discounted
cash flow projections.

The amount of royalty revenue
recognized for the quarter is
estimated using our knowledge of
past royalty payments, market
insight and an estimate made by our
collaboration partners provided in a
preliminary report.

A final royalty report and associated
royalty payment is received
approximately 60 days after quarter-
end. If necessary, a true-up is recorded
at that time if there is a difference from
the initial estimated royalty revenue
recorded. To date, the true-up entries
have not been material.

The inputs used in the valuation
model to determine SSP are based
on estimates utilizing market data
and information provided by our
collaboration partners.

Differences in the allocation of the
transaction price between delivered and
undelivered performance obligations
can impact the timing of revenue
recognition but do not change the total
revenue recognized under any
agreement.

Effect if Actual Results Differ From
Assumptions

We do not currently believe there is a
reasonable likelihood that there will be
a material change in estimates or
assumptions we use to determine stock-
based compensation expense. However,
if actual results are not consistent with
our estimates or assumptions, we may
be exposed to changes in share-based
compensation expense that could be
material.

If actual results are not consistent with
the assumptions used, the share-based
compensation expense reported in our
financial statements may not be
representative of the actual economic
cost of the share-based compensation.
A 10% change in our share-based
compensation expense for the year
ended December 31, 2022 would have
affected pre-tax earnings by
approximately $2.4 million in 2022.

If the subsequent actual results and
updated projections of the underlying
business activity change compared with
the assumptions and projections used to
develop these values, we could record
impairment charges. In addition, we
have estimated the economic lives of
certain acquired assets and these lives
to calculate amortization
are used
expense.
the
If our estimates of
economic lives change, amortization
expenses could be accelerated or
slowed.

If there is a change in the inputs and
assumptions used to fair value the
contingent liability, that could have a
material impact on our consolidated
statements of
balance
income.

sheet and

Share-Based Payments

Methodology

Judgment and Uncertainties

We maintain a Stock Incentive Plan, which
provides for share-based payment awards,
including stock options, restricted stock and
performance awards. We determine the fair
value of our stock option awards at the date
of grant using a Black-Scholes model. We
determine the fair value of our restricted
stock awards at the date of grant using the
closing market value of our common stock
on the date of grant.

Business Combinations
In connection with the Antares acquisition,
as disclosed in Note 3, the acquisition of
Antares has been accounted for using the
in
acquisition method of
accounting
accordance with ASC 805, under
the
acquisition method of accounting we
recognized the identifiable assets acquired
and the liabilities assumed at their fair values
as of the date of acquisition. We measured
the goodwill as the excess of consideration
transferred, which we also measure at fair
value, over the net of the acquisition date fair
values of the identifiable assets acquired and
liabilities assumed.

Contingent Liability
liability with a value of
A contingent
$15.7 million was assumed related
to
TLANDO. The fair value was measured
using the income approach, specifically the
probability weighted expected return method
for the development milestone payments and
the option pricing methodology using the
Monte Carlo simulation for commercial
milestone payments and royalty payments.
the
fair value of
the
We
contingent liability on a quarterly basis.

remeasure

Option-pricing models and generally
accepted valuation techniques
require management to make
assumptions and to apply judgment
to determine the fair value of our
awards. These assumptions and
judgments include estimating the
future volatility of our stock price,
expected dividend yield and future
employee stock option exercise
behaviors. Changes in these
assumptions can materially affect
the fair value estimate.

Our performance awards require
management to make assumptions
regarding the likelihood of
achieving long-term Company
goals.

estimates

and
Significant
assumptions used in estimating the
fair value of acquired technology
and other
intangible
identifiable
assets include future cash flows that
we expect to generate from the
acquired assets.

risk

free

The inputs used in the Monte Carlo
simulation
significant
include
estimates and assumptions which
include forecasted revenues, cost of
rate, weighted
debt,
average cost of capital, revenue
revenue
market price
volatility.
and
assumptions used in the income
approach include the probability of
achieving certain milestones and a
discount rate.

risk and
Estimates

Goodwill and Intangibles
We estimate the fair value of acquired
intangible assets that have finite useful lives
whenever
in
event
circumstances indicates that the carrying
value of the asset may not be recoverable.
We test for potential impairment of goodwill
that have
intangible assets
and other
indefinite useful lives annually in the second
fiscal quarter or whenever indicators of
impairment arise.

change

Significant
and
assumptions used in estimating the
fair value of the intangible assets.

estimates

A change in any of the estimates and
result an
assumptions used may
impairment charge in our consolidated
statement of income.

Recent Accounting Pronouncements

Refer to Note 2, Summary of Significant Accounting Policies, of our consolidated financial statements for a discussion of

recent accounting pronouncements and their effect, if any, on us.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

As of December 31, 2022, our cash equivalents and marketable securities consisted of investments in money market
funds, asset-backed securities, U.S. Treasury securities, corporate debt securities, agency bonds and commercial paper. These
investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of
securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at
the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments that
we invest in could be subject to market risk. This means that a change in prevailing interest rates may cause the value of the
instruments to fluctuate. For example, if we purchase a security that was issued with a fixed interest rate and the prevailing
interest rate later rises, the value of that security will probably decline. Based on our current investment portfolio as of
December 31, 2022, we do not believe that our results of operations would be materially impacted by an immediate change of
10% in interest rates.

We do not hold or issue derivatives, derivative commodity instruments or other financial instruments for speculative
trading purposes. Further, we do not believe our cash, cash equivalents and marketable securities have significant risk of default
or illiquidity. We made this determination based on discussions with our investment advisors and a review of our holdings.
While we believe our cash, cash equivalents and marketable securities do not contain excessive risk, we cannot provide
absolute assurance that in the future our investments will not be subject to adverse changes in market value. All of our cash
equivalents and marketable securities are recorded at fair market value.

Item 8. Financial Statements and Supplementary Data

Our financial statements are annexed to this report beginning on page F-1.

Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in
our Exchange Act reports is recorded, processed, summarized and reported within the timelines specified in the Securities and
Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management,
including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decision regarding required
disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and
procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control
objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in
evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision and with the participation of our management, including our principal executive officer and
principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under
Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended. Based on this evaluation, our principal
executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as of
the end of the period covered by this Annual Report on Form 10-K.

Changes in Internal Control Over Financial Reporting

On May 24, 2022, we completed the acquisition of Antares. Under guidelines established by the SEC, companies are
permitted to exclude acquisitions from their assessment of internal control over financial reporting during the first year of an
acquisition while integrating the acquired company. In conducting our evaluation of the effectiveness of our internal control
over financial reporting, we excluded the internal control activities of Antares from our evaluation for the period ended
December 31, 2022. We are in the process of integrating Antares into our system of internal control over financial reporting.

Except as noted above, there have been no significant changes in our internal control over financial reporting that
occurred during the period ended December 31, 2022 that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting.
Internal control over financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) promulgated under the Exchange Act
as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by
our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles and includes those policies and procedures that:

•

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and
dispositions of our assets;

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in
accordance with authorizations of our management and directors; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of
our assets that could have a material effect on our financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

We have included the financial results of Antares in the consolidated financial statements from the date of acquisition.
Antares represented approximately 9% of total assets as of December 31, 2022 and 17% of total revenues, for the year ended
December 31, 2022.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2022. In
conducting its assessment of the effectiveness of our internal control over financial reporting, our management excluded the
internal control activities of Antares from its evaluation for the period ended December 31, 2022. In making this assessment,
our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO) in Internal Control-Integrated Framework (2013 framework) (the COSO criteria). Based on our assessment,
management concluded that, as of December 31, 2022, our internal control over financial reporting is effective based on the
COSO criteria. The independent registered public accounting firm that audited the consolidated financial statements that are
included in this Annual Report on Form 10-K has issued an audit report on the effectiveness of our internal control over
financial reporting as of December 31, 2022. The report appears below.

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders
Halozyme Therapeutics, Inc.

Opinion on Internal Control over Financial Reporting

We have audited Halozyme Therapeutics, Inc.’s internal control over financial reporting as of December 31, 2022, based
on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Halozyme Therapeutics, Inc. (the Company)
maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the
COSO criteria.

As indicated in the accompanying Management’s Report On Internal Control Over Financial Reporting, management’s
assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal
controls of Antares Pharma, Inc., which is included in the 2022 consolidated financial statements of the Company and
constituted 9% of total assets as of December 31, 2022 and 17% of total revenues, for the year then ended. Our audit of internal
control over financial reporting of the Company also did not include an evaluation of the internal control over financial
reporting of Antares Pharma, Inc.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated
statements of income, comprehensive income, cash flows, and stockholders’ equity for each of the three years in the period
ended December 31, 2022, and the related notes and the financial statement schedule listed in the Index at Item 15(a) and our
report dated February 21, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report
on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control
over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be
independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a
material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed
risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides
a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

San Diego, California
February 21, 2023

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

None

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The information required by this item regarding directors is incorporated by reference to our definitive Proxy Statement
(the Proxy Statement) to be filed with the Securities and Exchange Commission in connection with our 2023 Annual Meeting
of Stockholders under the heading “Election of Directors.” The information required by this item regarding our code of ethics is
incorporated by reference to the information under the caption “Code of Conduct and Ethics and Corporate Governance
Guidelines” to be contained in the Proxy Statement. The information required by this item regarding our audit committee is
incorporated by reference to the information under the caption “Board Meetings and Committees—Audit Committee” to be
contained in the Proxy Statement. The information required by this item regarding material changes, if any, to the process by
which stockholders may recommend nominees to our board of directors is incorporated by reference to the information under
the caption “Board Meetings and Committees—Nominating and Governance Committee” to be contained in the Proxy
Statement.

Executive Officers

Helen I. Torley, M.B. Ch. B., M.R.C.P. (60), President, Chief Executive Officer and Director. Dr. Torley joined
Halozyme in January 2014 as President and Chief Executive Officer and as a member of Halozyme’s Board of Directors.
Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and
Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx
Pharmaceuticals (Onyx) from August 2011 to December 2013 overseeing the collaboration with Bayer on Nexavar® and
Stivarga® and the U.S. launch of Kyprolis. She was responsible for the development of Onyx's commercial capabilities in ex-
US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most
recently serving as Vice President and General Manager of the US Nephrology Business Unit from 2003 to 2009 and the U.S.
Bone Health Business Unit from 2009 to 2011. From 1997 to 2002, she held various senior management positions at Bristol-
Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global
Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs,
developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Within the past five
years, Dr. Torley served on the board of directors of Quest Diagnostics Incorporated, a diagnostic information services
company. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal
Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.)
from the University of Glasgow and is a Member of the Royal College of Physicians (M.R.C.P).

Nicole LaBrosse (40), Senior Vice President, Chief Financial Officer. Ms. LaBrosse has served as the Senior Vice
President, Chief Financial Officer since February 2022 and has over 19 years of public accounting and corporate finance
experience. She previously served as the Company’s Vice President, Finance and Accounting from January 2020 to February
2022 and as the Company’s Executive Director, Controller from July 2017 to December 2019. From June 2015 to June 2017,
she was the Company’s Senior Director, Financial Reporting. Prior to joining the Company, Ms. LaBrosse was an auditor with
PricewaterhouseCoopers, LLP from 2004 to 2015. She received a certified public accounting license after receiving a B.S.
degree in corporate finance and accounting and her M.S. degree in accounting from Bentley College.

Mark Snyder (56), Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder joined

Halozyme in January 2022 as Senior Vice President, General Counsel, Chief Compliance Officer and Secretary. Mr. Snyder
has over 30 years of experience in legal and business management roles. Prior to joining Halozyme, from January 2008 to
December 2021, Mr. Snyder served in various senior positions in the legal department at Qualcomm Incorporated, a wireless
communications company, including his most recent positions as Senior Vice President & Deputy General Counsel, Litigation,
from April 2016 to December 2021 and Vice President, Patent Counsel, from October 2010 to April 2016. Before Qualcomm,

Mr. Snyder served as Lead Intellectual Property Counsel at Kyocera Wireless Corp., a wireless communications company, and
has held legal and business management roles in two smaller companies. Mr. Snyder began his legal career as a patent attorney
at the law firm of Sheridan Ross & McIntosh. Mr. Snyder received his B.S. degree in chemical engineering at the University of
Rochester and his M.B.A. degree from Boston College Carroll School of Business. He received his J.D. from Boston College
Law School.

Michael J. LaBarre (59), Senior Vice President, Chief Technical Officer. Dr. LaBarre joined Halozyme in June 2008 as
Vice President, Product Development and has served in various officer positions most recently as Senior Vice President, Chief
Technical Officer since January 2020. Prior to joining Halozyme, Dr. LaBarre served as Vice President, Product Development
at Paramount BioSciences, a pharmaceutical company, from April 2006 to June 2008. Prior to that he served as Director,
Analytical and Protein Biochemistry, Discovery Research at Biogen Idec, a pharmaceutical company, from December 2003 to
April 2006. He also served in various research and development roles at IDEC Pharmaceuticals Corporation, a pharmaceutical
company, from November 1995 to December 2003 most recently as Director, Analytical and Formulation Sciences, R&D.
Prior to joining IDEC, Dr. LaBarre held research and development positions at various pharmaceutical companies from July
1992 to November 1995. Dr. LaBarre received his Ph.D. in Chemistry from the University of Arizona and his B.S. in Chemistry
from Southampton College of Long Island University.

Item 11. Executive Compensation

The information required by this item is incorporated by reference to the information under the captions “Executive
Compensation and Related Information” and “Compensation Committee Interlocks and Insider Participation” to be contained
in the Proxy Statement.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Other than as set forth below, the information required by this item is incorporated by reference to the information under
the caption “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” to be
contained in the Proxy Statement.

Equity Compensation Plan Information

The following table summarizes our compensation plans under which our equity securities are authorized for issuance as

of December 31, 2022:

Plan Category
Equity compensation plans approved by stockholders (1) . . . .
Equity compensation plans not approved by stockholders . . .

Number of Shares
to be Issued upon
Exercise of
Outstanding Options,
Restricted Stock
Units and
Performance Stock
Units
(a)

Weighted
Average
Exercise Price
of Outstanding
Options
(b)

(2)

6,550,450

—
6,550,450

$24.99

—
$24.99

Number of Shares
Remaining Available
for Future Issuance
under Equity
Compensation
Plans (Excluding
Shares Reflected
in Column (a))
(c)

17,413,834

—
17,413,834

_____________________
(1) Represents stock options, restricted stock units, and performance stock units under the Amended and Restated 2021

Stock Plan. This includes 2,650,103 shares available for future purchase under our ESPP plan.

(2) This amount does not include performance stock units as there is no exercise price for such units.

Item 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this item is incorporated by reference to the information under the caption “Certain
Relationships and Related Transactions” and “Corporate Governance - Director Independence” to be contained in the Proxy
Statement.

Item 14. Principal Accounting Fees and Services

The information required by this item is incorporated by reference to the information under the caption “Principal

Accounting Fees and Services” to be contained in the Proxy Statement.

PART IV

Item 15. Exhibits and Financial Statement Schedules

(a)

Documents filed as part of this report.

1. Financial Statements

Report of Independent Registered Public Accounting Firm ID 42 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Consolidated Balance Sheets at December 31, 2022 and 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Consolidated Statements of Income for Each of the Years Ended December 31, 2022, 2021 and 2020 . . . . . . . . .
Consolidated Statements of Comprehensive Income for Each of the Years Ended December 31, 2022,
2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Cash Flows for Each of the Years Ended December 31, 2022, 2021 and 2020 . . . . . .
Consolidated Statements of Stockholders’ Equity for Each of the Years Ended December 31, 2022,
2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Notes to the Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Page

F-1

F-4
F-5

F-6
F-7

F-9

F-10

2. List of all Financial Statement schedules.

The following financial statement schedule of Halozyme Therapeutics, Inc. is filed as part of this Annual Report on
Form 10-K and should be read in conjunction with the consolidated financial statements of Halozyme Therapeutics,
Inc.

Schedule II: Valuation and Qualifying Accounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Page

F-45

All other schedules are omitted because they are not applicable or the required information is shown in the Financial
Statements or notes thereto.

3. List of Exhibits required by Item 601 of Regulation S-K. See part (b) below.

(b)

Exhibits.

Exhibit

Number

Exhibit Title

Herewith

Form

Date Filed

Incorporated by Reference

Filed

3.1

3.2

4.1

4.2

4.3

4.4

4.5

4.6

4.7

10.1

10.2

10.3

10.4

10.5

10.6

Amended and Restated Certification of Incorporation

Bylaws, as amended

Indenture, dated November 18, 2019, between The Bank of New
York Mellon Trust Company, N.A., as trustee, and the Registrant

Form of Note, dated November 18, 2019, between the Bank of New
York Mellon Trust Company, N.A., as trustee, and the Registrant

Indenture, dated March 1, 2021, between Halozyme Therapeutics,
Inc. and The Bank of New York Mellon Trust Company, N.A., as
trustee, and the Registrant

Form of Note, dated March 1, 2021, between Halozyme
Therapeutics, Inc. and The Bank of New York Mellon Trust
Company, N.A., as trustee, and the Registrant

Indenture, dated August 18, 2022, between Halozyme Therapeutics,
Inc. and The Bank of New York Mellon Trust Company, N.A., as
trustee and registrant.

Form of Note, dated August 18, 2022, between Halozyme
Therapeutics, Inc. and The Bank of New York Mellon Trust
Company, N.A., as trustee, and the Registrant (included within
Exhibit 4.5)

Description of Securities

Form of Capped Call Confirmation

Credit Agreement, dated as of May 24, 2022, by and among
Halozyme Therapeutics, Inc., the Guarantors, Bank of America
N.A. and each of those additional Lenders that are a party to such
agreement.

Security Agreement, dated as of May 24, 2022, by and among
Halozyme Therapeutics, Inc., the Guarantors and Bank of America
N.A

Amendment No. 1 to the Credit Agreement

Agreement for Assignment and Assumption of Lease, Del Mar
Corporate Centre I Office Lease and First Amendment to Office
Lease

8-K

5/3/2019

12/10/2021

11/18/2019

8-K

11/18/2019

8-K

3/1/2021

8-K

3/1/2021

8-K

8/18/2022

8-K

8/18/2022

10-K

2/22/2022

8-K

8/18/2022

5/24/2022

8-K

5/24/2022

8-K

8/19/2022

10-Q

5/10/2022

Lease Agreement, dated July 1, 2019, by and between Antares
Pharma, Inc. and Whitewater Properties I, LLC.

8-K

7/5/2019

10.7#

Halozyme Therapeutics, Inc. 2021 Employee Stock Purchase Plan

10-Q

11/8/2022

10.8#

10.9#

Halozyme Therapeutics, Inc. 2021 Stock Plan

Form of Stock Option Agreement (2021 Stock Plan)

8-K

5/5/2021

Exhibit

Number

10.10#

Exhibit Title

Herewith

Form

Date Filed

Form of Restricted Stock Units Agreement for Officers (2021 Stock
Plan)

8-K

5/5/2021

Incorporated by Reference

Filed

10.11#

Form of Restricted Stock Units Agreement (2021 Stock Plan)

10.12#

Form of Restricted Stock Award Agreement (2021 Stock Plan)

10.13#

Form of Performance Stock Units (2021 Stock Plan)

10.14#

10.15#

10.16#

10.17#

10.18#

10.19#

10.20#

10.21#

10.22#

Form of Directors Restricted Stock Units Agreement (2021 Stock
Plan)
Halozyme Therapeutics, Inc. 2011 Stock Plan (as amended through
May 2, 2018)

Form of Stock Option Agreement (2011 Stock Plan)

Form of Stock Option Agreement for Executive Officers (2011
Stock Plan)

Form of Restricted Stock Units Agreement for Officers (2011 Stock
Plan)

Form of Restricted Stock Award Agreement for Officers (2011
Stock Plan)

Form of Stock Option Agreement (2011 Stock Plan -grants made on
or after 11/4/2015)
Form of Restricted Stock Units Agreement (2011 Stock Plan -
grants made on or after 11/4/2015)

Form of Restricted Stock Units Agreement (2011 Plan - grants
made on or after 2/22/2017)

8-K

5/5/2021

4/6/2018

5/6/2011

10-Q

8/10/2015

10-Q

8/10/2015

10-Q

11/9/2015

10-Q

11/9/2015

10-K

2/28/2017

10.23#

Form of Indemnity Agreement for Directors and Executive Officers

8-K

12/20/2007

10.24#

Form of PSU Agreement (2011 Stock Plan)

10.25#

Form of PSU Agreement (2011 Stock Plan)

10.26#

Severance Policy

10.27#

Form of Amended and Restated Change In Control Agreement with
Officer

10-Q

8/10/2020

10-K

10-Q

2/23/2021

11/8/2022

11/9/2015

Incorporated by Reference

Filed

Herewith

Form

Date Filed
DEF-14A 3/23/2016

10-K

2/22/2022

X
X

X
X
X
X

Exhibit

Number
10.28#

10.29#

10.30#

21.1
23.1

31.1

31.2

Halozyme Therapeutics, Inc. Executive Incentive Plan

Exhibit Title

Halozyme Therapeutics, Inc. Non Qualified Deferred Compensation
Plan Adoption Agreement

Halozyme Therapeutics, Inc Directors Deferred Equity
Compensation Plan
Subsidiaries of Registrant
Consent of Independent Registered Public Accounting Firm

Certification of Chief Executive Officer pursuant to Rule 13a-14(a)
and 15d-14(a) of the Securities Exchange Act of 1934, as amended

Certification of Chief Financial Officer pursuant to Rule 13a-14(a)
and 15d-14(a) of the Securities Exchange Act of 1934, as amended

Certification of Chief Executive Officer and Chief Financial Officer
pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002

101.INS XBRL Instance Document - the instance document does not appear

in the interactive Data File because its XBRL tags are embedded
within the Inline XBRL document.

101.SCH XBRL Taxonomy Extension Schema
101.CAL XBRL Taxonomy Extension Calculation Linkbase
101.DEF XBRL Taxonomy Extension Definition Linkbase
101.LAB XBRL Taxonomy Extension Label Linkbase

101.PRE XBRL Taxonomy Presentation Linkbase

104

Cover Page Interactive Data File (formatted as inline XBRL and
contained in Exhibit 101)

_______________

Indicates management contract or compensatory plan or arrangement.

(c)

Financial Statement Schedules. See Item 15(a) 2 above.

Item 16. Form 10-K Summary

None.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly

caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGNATURES

Date:

February 21, 2023

Halozyme Therapeutics, Inc.,
a Delaware corporation

By:

/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
Helen I. Torley, M.B. Ch.B., M.R.C.P.
President and Chief Executive Officer

POWER OF ATTORNEY

Know all persons by these presents, that each person whose signature appears below constitutes and appoints Helen I.
Torley and Nicole LaBrosse, and each of them, as his/her true and lawful attorneys-in-fact and agents, with full power of
substitution and resubstitution, for him/her and in his/her name, place, and stead, in any and all capacities, to sign any and all
amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith,
with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power
and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as
fully to all intents and purposes as he/she might or could do in person, hereby ratifying and confirming that all said attorneys-in-
fact and agents, or any of them or their or his/her substitute or substituted, may lawfully do or cause to be done by virtue
thereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the

following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

Title

Date

/s/ Helen I. Torley, M.B. Ch.B., M.R.C.P.
Helen I. Torley, M.B. Ch.B., M.R.C.P.

President and Chief Executive Officer
(Principal Executive Officer), Director

February 21, 2023

/s/ Nicole LaBrosse

Nicole LaBrosse

/s/ Jeffrey W. Henderson

Jeffrey W. Henderson

/s/ Connie L. Matsui

Connie L. Matsui

/s/ Jean-Pierre Bizzari

Jean-Pierre Bizzari

/s/ Bernadette Connaughton

Bernadette Connaughton

/s/ James M. Daly

James M. Daly

/s/ Barbara Duncan
Barbara Duncan

/s/ Matthew L. Posard
Matthew L. Posard

/s/ Moni Miyashita

Moni Miyashita

Senior Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer)

February 21, 2023

Chair of the Board of Directors

February 21, 2023

Director

February 21, 2023

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders
Halozyme Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Halozyme Therapeutics, Inc. (the Company) as of
December 31, 2022 and 2021, the related consolidated statements of income, comprehensive income, cash flows and
stockholders’ equity for each of the three years in the period ended December 31, 2022, and the related notes and the financial
statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at
December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended
December 31, 2022, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2022, based on criteria
established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (2013 framework) and our report dated February 21, 2023 expressed an unqualified opinion thereon.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the
PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement,
whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the
financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the
overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements
that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures
that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The
communication of these critical audit matters do not alter in any way our opinion on the consolidated financial statements, taken
as a whole, and we are not, by communicating these critical audit matters below, providing separate opinions on the critical
audit matters or on the accounts or disclosures to which they relate.

F-1

Determination of Overall Transaction Price for Collaboration Agreements

Description of the Matter

How We Addressed the Matter in Our
Audit

At December 31, 2022 the Company has eleven collaboration agreements.
As discussed in Notes 2 and 5 of the financial statements, amounts are
included in the transaction price when management determines that it is
probable that the amount will not result in a significant reversal of revenue
in the future. During 2022, the Company recognized $59.0 million of
variable consideration in the transaction price under their collaboration
arrangements.

Auditing management’s conclusions related to determining the probability
of achievement of milestones is complex and highly judgmental as a result
of
the progression of developing and
commercializing the combined targets is completed by the collaboration
partners.

the uncertainties given

We obtained an understanding and evaluated the design and tested the
operating effectiveness of controls over the Company’s process to
routinely evaluate the probability of achievement of milestones and any
related constraint for each collaboration, in addition to the controls over the
completeness and accuracy of determining the population of agreements
and potential milestone payments.

To test the milestone amounts included, or excluded, from the transaction
price, we performed audit procedures that included, among others,
observing the meetings of the Company’s accounting and alliance
managers discussing the status of each collaboration agreement. For each
milestone, we examined evidence including correspondence with the
collaboration partner and evaluated management’s conclusions on the
probabilities of achievement. We reviewed supporting documentation to
corroborate that milestones were included in the transaction price when
determined to be probable of achievement. We reviewed the collaboration
agreements and related amendments to validate the completeness of the list
of targets and potential milestone payments that management considered in
their analysis. We performed a lookback analysis to validate the company’s
accuracy of determining the probability of achieving these milestones.

Valuation of intangible assets acquired in connection with the Antares Pharma, Inc. acquisition

Description of the Matter

As disclosed in Note 3 of the consolidated financial statements, the
Company completed the acquisition of Antares Pharma, Inc. (“Antares”)
on May 24, 2022 for total consideration of approximately $1,045.7 million.
The transaction was accounted for as a business combination. The
Company recorded intangible assets of $589.8 million, which includes in-
process research and development (“IPR&D”) of $48.7 million.

Auditing the Company’s accounting for its acquisition of Antares was
complex due to the significant estimation uncertainty in determining the
fair value of the intangible assets. A significant emphasis is placed on the
appropriateness of the estimate considerations used by management to
determine the fair value of the acquired intangible assets due to sensitivity
of the respective fair values to the underlying assumptions. The Company
used an income approach to measure the intangible assets. The significant
assumptions used to estimate the value of the intangible assets included
discount rates and revenue growth rates. These significant assumptions
related to the intangible assets are forward looking and could be affected
by future economic and market conditions.

F-2

How We Addressed the Matter in Our
Audit

We obtained an understanding, evaluated the design and tested the
operating effectiveness of internal controls over the Company's process for
determining the fair value of intangible assets acquired in connection with
the Antares acquisition. This included controls over management’s
development of the above-described assumptions used in the valuation
models applied.

To test the estimated fair value of the intangible assets, we performed audit
procedures that included, among others, evaluating the Company’s use of
the income approach and testing the significant assumptions used in the
valuation model, as described above. We evaluated the completeness and
accuracy of underlying data used in supporting the assumptions and
estimates. We evaluated the reasonableness of projected revenue growth
used within the valuations against analyst expectations, industry trends,
and other market information. In addition, we involved valuation
specialists
the significant assumptions and
in assessing
methodologies used by the Company.

to assist

We have served as the Company’s auditor since 2006.

/s/ Ernst & Young LLP

San Diego, California
February 21, 2023

F-3

HALOZYME THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)

December 31,
2022

December 31,
2021

Current assets:

ASSETS

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Marketable securities, available-for-sale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, net and other contract assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax assets, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Current liabilities:

LIABILITIES AND STOCKHOLDERS’ EQUITY

Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue, current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of long-term debt, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue, net of current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contingent liability
Commitments and contingencies (Note 12)
Stockholders’ equity:

234,195
128,599
231,072
100,123
45,024
739,013
75,570
26,301
409,049
546,652
44,426
500
1,841,511

17,693
96,516
3,246
13,334
130,789
2,253
1,492,766
30,433
15,472

118,719
622,203
90,975
53,908
40,482
926,287
8,794
13,414
—
—
155,434
500
1,104,429

1,541
24,441
1,746
89,419
117,147
2,530
787,255
544
—

Preferred stock - $0.001 par value; 20,000 shares authorized; no shares
issued and outstanding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Common stock - $0.001 par value; 300,000 shares authorized; 135,154 and
137,498 shares issued and outstanding at December 31, 2022 and 2021,
respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Retained earnings (Accumulated deficit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total stockholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total liabilities and stockholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

—

135
27,368
(922)
143,217
169,798
1,841,511

138
256,347
(620)
(58,912)
196,953
1,104,429

See accompanying notes to consolidated financial statements.

F-4

HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share amounts)

Revenues:

Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Product sales, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Revenues under collaborative agreements . . . . . . . . . . . . . . . . . . . . . . .

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Operating expenses:

Cost of sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Amortization of intangibles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other income (expense):

Investment and other income, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Inducement expense related to convertible notes . . . . . . . . . . . . . . . . . .

Interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net income before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income tax expense (benefit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Year Ended December 31,

2022

2021

2020

360,475

203,900

191,030

108,611

660,116

139,304

43,148

66,607

143,526

392,585

267,531

1,046

(2,712)

(16,947)

248,918

46,789

104,224

135,186

443,310

81,413

—

35,672

50,323

167,408

275,902

1,102

(20,960)

(7,526)

248,518

(154,192)

88,596

55,987

123,011

267,594

43,367

—

34,236

45,736

123,339

144,255

5,425

—

(20,378)

129,302

217

202,129

402,710

129,085

Net income per share: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

1.48
1.44

$
$

2.86
2.74

$
$

0.95
0.91

Shares used in computing net income per share: . . . . . . . . . . . . . . . . . . . . . .
Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

136,844
140,608

140,646
146,796

136,206
141,463

See accompanying notes to consolidated financial statements.

F-5

HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)

Year Ended December 31,

2022

2021

2020

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

202,129

402,710

129,085

Other comprehensive income:

Unrealized loss on marketable securities . . . . . . . . . . . . . . . . . . . . . . .

Foreign currency translation adjustment . . . . . . . . . . . . . . . . . . . . . . .

Unrealized gain (loss) on foreign currency . . . . . . . . . . . . . . . . . . . . .

(349)

(683)

(164)

(32)

(22)

Total comprehensive income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

201,827

402,068

128,867

See accompanying notes to consolidated financial statements.

F-6

HALOZYME THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

Operating activities:

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Adjustments to reconcile net income to net cash provided by operating
activities:

Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of (accretion of discounts) premiums on marketable
securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Realized loss on marketable securities . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss (gain) on disposal of equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferral of unearned revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Recognition of deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lease payments deferred . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss on impairment of right-of-use asset . . . . . . . . . . . . . . . . . . . . . . . . .
Induced conversion expense related to convertible notes . . . . . . . . . . . . .
Deferred income taxes (including benefit from valuation allowance
release) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Changes in operating assets and liabilities:

Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other assets . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable and accrued expenses . . . . . . . . . . . . . . . . . . . . . .
Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Investing activities:

Purchases of marketable securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from maturities of marketable securities . . . . . . . . . . . . . . . . . . . . . .
Acquisitions of business, net of cash acquired . . . . . . . . . . . . . . . . . . . . . . . . .
Purchases of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash (used in) provided by investing activities . . . . . . . . . . . . . . . . . . . . . . . . .
Financing activities:

Proceeds from term loan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayment of term loan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from revolving credit facilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayment of revolving credit facilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from issuance of 2027 Convertible Notes, net . . . . . . . . . . . . . . . . . .
Repayment of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from issuance of 2028 Convertible Notes . . . . . . . . . . . . . . . . . . . . .
Purchase of capped call . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payment of debt issuance cost . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repurchase of common stock . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from issuance of common stock under equity incentive plans, net of
taxes paid related to net share settlement . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net cash provided by (used in) financing activities . . . . . . . . . . . . . . . . . . . . . . . . .
Net increase (decrease) in cash, cash equivalents and restricted cash . . . . . . . . . . .
Cash, cash equivalents and restricted cash at beginning of period . . . . . . . . . . . . . .
Cash, cash equivalents and restricted cash at end of period . . . . . . . . . . . . . . . . . . . $

Year Ended December 31,
2021

2020

2022

202,129

402,710

129,085

24,397
6,493
43,148
7,839

1,106
1,727
129
—
(2,494)
(903)
—
2,712

40,005
(227)

(83,941)
(17,481)
(9,064)
24,535
240,110

(255,208)
746,127
(999,120)
(4,810)
26,006
(487,005)

250,000
(250,000)
120,000
(120,000)
—
(77,453)
702,000
(69,120)
(7,104)
(200,002)

14,050
362,371
115,476
119,219
234,695

20,820
2,997
—
3,642

2,257
—
—
—
(1,496)
(751)
—
20,960

(155,434)
(3)

6,755
7,371
(11,555)
1,167
299,440

(652,515)
247,683
—
(1,457)
—
(406,289)

—
—
—
—
784,875
(369,064)
—
—
(424)
(350,058)

12,536
77,865
(28,984)
148,203
119,219

17,204
3,284
—
14,136

839
—
(772)
4,632
(4,119)
(1,033)
577
—

—
(13)

(38,288)
(31,388)
2,518
(41,208)
55,454

(226,185)
305,967
—
(2,504)
1,076
78,354

—
—
—
—
—
(19,560)
—
—
—
(150,117)

63,393
(106,284)
27,524
120,679
148,203

F-7

Year Ended December 31,
2021

2020

2022

Supplemental disclosure of cash flow information:

Interest paid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Income taxes paid (received), net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Supplemental disclosure of non-cash investing and financing activities:

Amounts accrued for purchases of property and equipment . . . . . . . . . . . . . . . . . $
Right-of-use assets obtained in exchange for lease obligation . . . . . . . . . . . . . . . . $
$
Common stock issued for induced conversion related to convertible notes . . . . .

6,107
16,224

6,229
34,435
1,018

$
$

$
$
$

$
3,296
(375) $

72
318
7,865

$
$
$

6,534
180

117
1,746
—

See accompanying notes to consolidated financial statements.

F-8

HALOZYME THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)

Common Stock

Amount

Additional
Paid-In
Capital

Accumulated
Other
Comprehensive
Income (Loss)

Retained
Earnings
(Accumulated
Deficit)

Total
Stockholders’
Equity

BALANCE AT DECEMBER 31, 2019 . . . . . . . .

136,713

137

$ 695,066 $

240

(603,678) $

91,765

Share-based compensation expense . . . . . . . . . . .

—

17,204

Issuance of common stock pursuant to exercise of
stock options and vesting of restricted stock
units, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5,278

63,388

Issuance of restricted stock awards, net . . . . . . . .

Repurchase of common stock . . . . . . . . . . . . . . . .

(7,022)

Equity component of convertible notes . . . . . . . .

Other comprehensive loss . . . . . . . . . . . . . . . . . . .

Net lncome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

(7)

—

(150,110)

(65)

—

BALANCE AT DECEMBER 31, 2020 . . . . . . . .

135,030

135

$ 625,483 $

Cumulative adjustment from adoption of ASU
2020-06 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Share-based compensation expense . . . . . . . . . . .
Issuance of common stock for the induced
conversion related to convertible notes . . . . . . . .

—

9,083

Issuance of common stock pursuant to exercise of
stock options and vesting of restricted stock units
and performance stock units, net and shares
issued under ESPP plan . . . . . . . . . . . . . . . . . . . .

Repurchase of common stock . . . . . . . . . . . . . . . .

Other comprehensive loss . . . . . . . . . . . . . . . . . . .

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,497

(8,112)

—

(65,535)

20,820

13,095

12,534

(350,050)

—

(8)

—

(218)

—

(642)

—

17,204

63,393

—

(150,117)

(65)

(218)

129,085

(474,593) $

151,047

12,971

—

(52,564)

20,820

13,104

—

12,536

(350,058)

(642)

402,710

BALANCE AT DECEMBER 31, 2021 . . . . . . . .

137,498

138

$ 256,347 $

(620) $

(58,912) $

196,953

Share-based compensation expense . . . . . . . . . . .
Issuance of common stock for the induced
conversion related to convertible notes . . . . . . . .

Issuance of common stock pursuant to exercise of
stock options and vesting of restricted stock units
and performance stock units, net and shares
issued under the ESPP plan . . . . . . . . . . . . . . . . .

—

1,512

—

24,397

1,692

—

24,397

1,693

1,077

14,049

—

14,050

Capped call transaction . . . . . . . . . . . . . . . . . . . . .

(69,120)

Repurchase of common stock . . . . . . . . . . . . . . . .

(4,933)

(5)

(199,997)

Other comprehensive loss . . . . . . . . . . . . . . . . . . .

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

(302)

—

(69,120)

(200,002)

(302)

202,129

BALANCE AT DECEMBER 31, 2022 . . . . . . . .

135,154

135

27,368 $

(922) $

143,217

169,798

See accompanying notes to consolidated financial statements.

F-9

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements

1. Organization and Business

Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive

solutions with the goal of improving the patient experience and potentially outcomes.

Our first commercially approved product Hylenex® recombinant (“Hylenex”), and our ENHANZE partners’ approved
products and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 is
the active ingredient in Hylenex, that works by breaking down hyaluronan (“HA”), a naturally occurring carbohydrate that is a
major component of the extracellular matrix of the SC space. This temporarily reduces the barrier to bulk fluid flow allowing
for improved and more rapid SC delivery of high dose, high volume injectable biologics, such as monoclonal antibodies and
other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the
delivery of other drugs or fluids as ENHANZE. We license the ENHANZE technology to form collaborations with
biopharmaceutical companies that develop or market drugs requiring or benefiting from injection via the SC route of
administration. In the development of proprietary intravenous (“IV”) drugs combined with our ENHANZE technology, data
have been generated supporting the potential for ENHANZE to reduce patient treatment burden, as a result of shorter duration
of SC administration with ENHANZE compared to IV administration. ENHANZE may enable fixed-dose SC dosing compared
to weight-based dosing typically required for IV administration, extend the dosing interval for drugs that are already
administered subcutaneously and potentially allow for lower rates of infusion related reactions. ENHANZE may enable more
flexible treatment options such as home administration by a healthcare professional or potentially the patient or
caregiver. Lastly, certain proprietary drugs co-formulated with ENHANZE have been granted additional exclusivity, extending
the patent life of the product beyond the patent expiry of the proprietary IV drug.

We currently have ENHANZE collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-
La Roche, Inc. (“Roche”), Takeda Pharmaceuticals International AG and Baxalta US Inc. (“Takeda”), Pfizer Inc. (“Pfizer”),
Janssen Biotech, Inc. (“Janssen”), AbbVie, Inc. (“AbbVie”), Eli Lilly and Company (“Lilly”), Bristol-Myers Squibb Company
(“BMS”), Alexion Pharma (International Operations Unlimited Company (an indirect wholly owned subsidiary of AstraZeneca
PLC)(“Alexion”), argenx BVBA (“argenx”), Horizon Therapeutics plc. (“Horizon”), ViiV Healthcare (the global specialist HIV
Company majority owned by GlaxoSmithKline) (“ViiV”) and Chugai Pharmaceutical Co., Ltd (“Chugai”). In addition to
receiving upfront licensing fees from our ENHANZE collaborations, we are entitled to receive event and sales-based milestone
payments, revenues from the sale of bulk rHuPH20 and royalties from commercial sales of approved partner products co-
formulated with ENHANZE. We currently receive royalties from three of these collaborations, including royalties from sales of
one product from the Takeda collaboration, three products from the Roche collaboration and one product from the Janssen
collaboration. Future potential revenues from ENHANZE collaborations and from the sales and/or royalties of our approved
products will depend on the ability of our partners, in some areas supported by Halozyme to develop, manufacture, secure and
maintain regulatory approvals for approved products and product candidates and commercialize product candidates.

Through our recent acquisition of Antares Pharma, Inc. (“Antares”), we also develop, manufacture and commercialize, for
ourselves or with our partners, drug-device combination products using our advanced auto-injector technologies. Also as a
result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED®, TLANDO® and
NOCDURNA®
. We have commercialized auto-injector products with several pharmaceutical companies including Teva
Pharmaceutical Industries, Ltd. (“Teva”), Covis Group S.a.r.l. (“Covis”) and Otter Pharmaceuticals, LLC (“Otter”). We have
development programs including auto-injectors with Idorsia Pharmaceuticals Ltd. (“Idorsia”) and Pfizer.

Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,”
“our,” and “us” in these notes to consolidated financial statements refer to Halozyme Therapeutics, Inc. and each of its directly
and indirectly wholly owned subsidiaries disclosed in Note 2.

F-10

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of Halozyme Therapeutics, Inc. and our wholly owned
subsidiaries, Halozyme, Inc. and Antares Pharma, Inc., and Antares Pharma, Inc.’s wholly owned Swiss subsidiaries, Antares
Pharma IPL AG and Antares Pharma AG. All intercompany accounts and transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles
(“U.S. GAAP”) requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial
statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on
historical and anticipated results and trends and on various other assumptions that we believe to be reasonable under the
circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ
from our estimates.

Cash Equivalents and Marketable Securities

Cash equivalents consist of highly liquid investments, readily convertible to cash, that mature within 90 days or less from
the date of purchase. As of December 31, 2022, our cash and cash equivalents consisted of money market funds, bank
certificate of deposits and demand deposits at commercial banks.

Marketable securities are investments with original maturities of more than 90 days from the date of purchase that are
specifically identified to fund current operations. Marketable securities are considered available-for-sale. These investments are
classified as current assets, even though the stated maturity date may be one year or more beyond the current balance sheet date
which reflects management’s intention to use the proceeds from the sale of these investments to fund our operations, as
necessary. Such available-for-sale investments are carried at fair value with unrealized gains and losses recorded in other
comprehensive income (loss) and included as a separate component of stockholders’ equity. The cost of marketable securities is
adjusted for amortization of premiums or accretion of discounts to maturity, and such amortization or accretion is included in
investment and other income, net in the consolidated statements of income. We use the specific identification method for
calculating realized gains and losses on marketable securities sold. None of the realized gains and losses and declines in value
that were judged to be as a result of credit loss on marketable securities, if any, are included in investment and other income, net
in the consolidated statements of operations.

Restricted Cash

Under the terms of the leases of our facilities, we are required to maintain letters of credit as security deposits during the
terms of such leases. At December 31, 2022 and 2021, restricted cash of $0.5 million was pledged as collateral for the letters of
credit.

Fair Value of Financial Instruments

The authoritative guidance for fair value measurements establishes a three tier fair value hierarchy, which prioritizes the
inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active
markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable;
and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its
own assumptions.

Our financial instruments include cash equivalents, available-for-sale marketable securities, accounts receivable, prepaid
expenses and other assets, accounts payable, accrued expenses, long-term debt and contingent liability. Fair value estimates of
these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective
in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The
carrying amount of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued
expenses are generally considered to be representative of their respective fair values because of the short-term nature of those
instruments.

Available-for-sale marketable securities consist of asset-backed securities, corporate debt securities, U.S. Treasury
securities and commercial paper, and are measured at fair value using Level 1 and Level 2 inputs. Level 2 financial instruments
are valued using market prices on less active markets and proprietary pricing valuation models with observable inputs,
including interest rates, yield curves, maturity dates, issue dates, settlement dates, reported trades, broker-dealer quotes, issue
spreads, benchmark securities or other market related data. We obtain the fair value of Level 2 investments from our investment
manager, who obtains these fair values from a third-party pricing source. We validate the fair values of Level 2 financial
instruments provided by our investment manager by comparing these fair values to a third-party pricing source.

F-11

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Concentrations of Credit Risk, Sources of Supply and Significant Customers

We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were
made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may
consider for investment. The primary objective of our investment activities is to preserve principal while at the same time
maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances
with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial
institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by
the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the consolidated
balance sheets.

We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license
and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we
receive payments for royalties, license fees, milestone payments for specific achievements designated in the collaborative
agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we
sell proprietary products in the United States to a limited number of established wholesale distributors in the pharmaceutical
industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required.
Management monitors our exposure to accounts receivable by periodically evaluating the collectability of the accounts
receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the
customer and historical experience. Based upon the review of these factors, we recorded no allowance for doubtful accounts at
December 31, 2022 and 2021. Approximately 52% of the accounts receivable balance at December 31, 2022 represents
amounts due from Janssen and Roche. Approximately 90% of the accounts receivable balance at December 31, 2021 represents
amounts due from Janssen, Roche and Takeda.

The following table indicates the percentage of total revenues in excess of 10% with any single customer:

Partner A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Partner B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Partner C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Partner D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2022
20%
46%
—%
—%

2021
25%
48%
—%
10%

2020
35%
26%
11%
—%

We attribute revenues under collaborative agreements, including royalties, to the individual countries where the customer
is headquartered. We attribute revenues from product sales to the individual countries to which the product is shipped.
Worldwide revenues from external customers are summarized by geographic location in the following table (in thousands):

Year Ended December 31,

2022

2021

2020

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Switzerland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

437,989 $
166,836

293,089 $
134,117

Ireland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Belgium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Japan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

All other foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,088

47,939

5,261

199

11,934

3,957

106,918
95,949

30,552

20,086

10,644

3,445

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

660,116 $

443,310 $

267,594

Accounts Receivable, net

Accounts receivable is recorded at the invoiced amount and is non-interest bearing. Accounts receivable is recorded net
of, cash discounts for prompt payment, distribution fees and chargebacks. We recorded no allowance for doubtful accounts at
December 31, 2022 and 2021 as the collectability of accounts receivable was reasonably assured.

Inventories

Inventories are stated at lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Net realizable
value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal,

F-12

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

and transportation. Inventories are reviewed periodically for potential excess, dated or obsolete status. We evaluate the carrying
value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared to
quantities on hand, the price we expect to obtain for products in their respective markets compared with historical cost and the
remaining shelf life of goods on hand.

Leases

We have entered into operating leases primarily for real estate and automobiles. These leases have contractual terms
which range from 3 years to 12 years. We determine if an arrangement contains a lease at inception. Right of use (“ROU”)
assets and liabilities resulting from operating leases are included in property and equipment, accrued expenses and other long-
term liabilities on our consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the
present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not
provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in
determining the discount rate to calculate the present value of future payments. The operating lease ROU asset also includes
any lease payments made and excludes lease incentives and initial direct costs incurred. Our leases often include options to
extend or terminate the lease. These options are included in the lease term when it is reasonably certain that we will exercise
that option. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense for
minimum lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain

equipment leases, such as automobiles, we account for the lease and non-lease components as a single lease component.

Property and Equipment, Net

Property and equipment, including ROU assets are recorded at cost, less accumulated depreciation and amortization.
Equipment is depreciated using the straight-line method over its estimated useful life ranging from three years to ten years and
leasehold improvements are amortized using the straight-line method over the estimated useful life of the asset or the lease
term, whichever is shorter.

Impairment of Long-Lived Assets

We account for long-lived assets in accordance with authoritative guidance for impairment or disposal of long-lived
assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not
be recoverable.

Comprehensive Income

Comprehensive income is defined as the change in equity during the period from transactions and other events and

circumstances from non-owner sources.

Business Combinations

Under the acquisition method of accounting, we allocate the fair value of the total consideration transferred to the tangible
and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values on the date of acquisition.
These valuations require us to make estimates and assumptions, especially with respect to intangible assets. We record the
excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill. Costs
that we incur to complete the business combination, such as legal and other professional fees, are expensed as incurred.

If the initial accounting for a business combination is incomplete by the end of a reporting period that falls within the
measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the
provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that
existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that
date. We record these adjustments to the provisional amounts with a corresponding offset to goodwill. Any adjustments
identified after the measurement period are recorded in the consolidated statements of income.

Goodwill, Intangible Assets and Other Long-Lived Asset

Assets acquired, including intangible assets and in-process research and development (IPR&D), and liabilities assumed
are measured at fair value as of the acquisition date. Goodwill, which has an indefinite useful life, represents the excess of cost
over fair value of the net assets acquired. Intangible assets acquired in a business combination that are used for IPR&D
activities are considered indefinite lived until the completion or abandonment of the associated research and development
efforts. Upon reaching the end of the relevant research and development project (i.e., upon commercialization), the IPR&D
asset is amortized over its estimated useful life. If the relevant research and development project is abandoned, the IPR&D asset
is expensed in the period of abandonment.

F-13

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Goodwill and IPR&D are not amortized; however, they are reviewed for impairment at least annually during the second
quarter, or more frequently if an event occurs indicating the potential for impairment. Goodwill and IPR&D are considered to
be impaired if the carrying value of the reporting unit or IPR&D asset exceeds its respective fair value.

We perform our goodwill impairment analysis at the reporting unit level, which aligns with our reporting structure and
availability of discrete financial information. During the goodwill impairment review, we assess qualitative factors to determine
whether it is more likely than not that the fair values of our reporting units are less than the carrying amounts, including
goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations,
and our overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more
likely than not that the fair values of our reporting units are less than the carrying amounts, then no additional assessment is
deemed necessary. Otherwise, we proceed to compare the estimated fair values of the reporting units with the carrying values,
including goodwill. If the carrying amounts of the reporting units exceed the fair values, we record an impairment loss based on
the difference. We may elect to bypass the qualitative assessment in a period and proceed to perform the quantitative goodwill
impairment test.

Our identifiable intangible assets with finite useful lives are typically comprised of acquired device technologies and
product rights. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the
assets’ respective estimated useful lives.

We perform regular reviews to determine if any event has occurred that may indicate that intangible assets with finite
useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is
performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds
the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets
and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential
impairment include a significant decline in our stock price and market capitalization compared to the net book value, significant
changes in the ability of a particular asset to generate positive cash flows for our strategic business objectives, and the pattern of
utilization of a particular asset.

Revenue Recognition

We generate revenues from payments received (i) as royalties from licensing our ENHANZE technology and other
royalty arrangements, (ii) under collaborative agreements and (iii) from sales of our proprietary and partnered products. We
recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to
which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with
customers we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) identify the
performance obligations in the contract, including whether they are distinct in the context of the contract; (iii) determine the
transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance
obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance obligations.

ENHANZE and Device Royalties

Under the terms of our ENHANZE collaboration and license agreements, our partners will pay us royalties at an on average
mid-single digit percent rate of their sales if products under the collaboration are commercialized. All amounts owed to us are
noncancelable after the underlying triggering event occurs, and nonrefundable once paid. Unless terminated earlier in
accordance with its terms, collaborations generally continue in effect until the last to expire royalty payment term, as
determined on a product by product and on a country by country basis, with each royalty term starting on the first commercial
sale of that product and ending the later of: (i) a specified period or term set forth in the agreement or (ii) expiration of the last
to expire of the valid claims of our patents covering rHuPH20 or other specified patents developed under the collaboration
which valid claim covers a product developed under the collaboration. When there are no valid claims during the applicable
royalty term in a given country, the royalty rate is reduced for those sales. Partners may terminate the agreement prior to
expiration for any reason in its entirety or on a target-by-target basis generally upon 90 days prior written notice to us. Upon
any such termination, the license granted to partners (in total or with respect to the terminated target, as applicable) will
terminate provided, however, that in the event of expiration of the agreement (as opposed to a termination), the on-going
licenses granted will become perpetual, non-exclusive and fully paid. Sales-based milestones and royalties are recognized in the
period the underlying sales or milestones occur. We do not receive final royalty reports from our ENHANZE partners until after
we complete our financial statements for a prior quarter. Therefore, we recognize revenue based on estimates of the royalty
earned, which are based on internal estimates and available preliminary reports provided by our partners. We will record
adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any
material adjustments.

In addition to the royalties received from licensing our ENHANZE technology, we also earn royalties in connection with
licenses granted under license and development arrangements with our device partners as a result of our acquisition of Antares.

F-14

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

These royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digits
to low double digits and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed
the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’
commercial sales occur. The royalties are generally reported and payable to us within 45 to 60 days of the end of the period in
which the commercial sales are made. We base our estimates of royalties earned on actual sales information from our partners
when available or estimated, prescription sales from external sources and estimated net selling price. We will record
adjustments in the following quarter, if necessary, when final royalty reports are received. To date, we have not recorded any
material adjustments.

Revenue under ENHANZE and Device Collaborative Agreements

ENHANZE Collaboration and License Agreements

Under these agreements, we grant the collaboration partner a worldwide license to develop and commercialize products
using our ENHANZE technology to combine our patented rHuPH20 enzyme with their proprietary biologics directed at up to a
specified number of targets. Targets are usually licensed on an exclusive, global basis. Targets selected subsequent to inception
of the arrangement require payment of an additional license fee. The collaboration partner is responsible for all development,
manufacturing, clinical, regulatory, sales and marketing costs for any products developed under the agreement. We are
responsible for supply of bulk rHuPH20 based on the collaboration partner’s purchase orders, and may also be separately
engaged to perform research and development services. While these collaboration agreements are similar in that they originate
from the same framework, each one is the result of an arms-length negotiation and thus may vary from one to the other.

We generally collect an upfront license payment from collaboration partners, and are also entitled to receive event-based
payments subject to collaboration partners’ achievement of specified development, regulatory and sales-based milestones. In
several agreements, collaboration partners pay us annual fees to maintain their exclusive license rights if they are unable to
advance product development to specified stages. We earn separate fees for bulk rHuPH20 supplies and research and
development services.

Although these agreements are in form identified as collaborative agreements, we concluded for accounting purposes they
represent contracts with customers and are not subject to accounting literature on collaborative arrangements. This is because
we grant to partners licenses to our intellectual property and provide supply of bulk rHuPH20 and research and development
services which are all outputs of our ongoing activities, in exchange for respective consideration. Under these collaborative
agreements, our partners lead development of assets, and we do not share in significant financial risks of their development or
commercialization activities. Accordingly, we concluded our collaborative agreements are appropriately accounted for pursuant
to ASC Topic 606, Revenue from Contracts with Customers.

Under all of our ENHANZE collaborative agreements, we have identified licenses to use functional intellectual property
as the only performance obligation. The intellectual property underlying the license is our proprietary ENHANZE technology
which represents application of rHuPH20 to facilitate delivery of drugs. Each of the licenses grants the partners rights to use our
intellectual property as it exists and is identified on the effective date of the license, because there is no ongoing development of
the ENHANZE technology required. Therefore, we recognize revenue from licenses at the point when the license becomes
effective and the partner has received access to our intellectual property, usually at the inception of the agreement.

When partners can select additional targets to add to the licenses granted, we consider these rights to be options. We
evaluate whether such options contain material rights, i.e. have exercise prices that are discounted compared to what we would
charge for a similar license to a new partner. The exercise price of these options includes a combination of the target selection
fees, event-based milestone payments and royalties. When these amounts in aggregate are not offered at a discount that exceeds
discounts available to other customers, we conclude the option does not contain a material right, and we consider grants of
additional licensing rights upon option exercises to be separate contracts (target selection contracts).

Generally, we provide indemnification and protection of licensed intellectual property for our customers. These provisions
are part of assurance that the licenses meet the agreements’ representations and are not obligations to provide goods or services.

We also fulfill purchase orders for supply of bulk rHuPH20 and perform research and development services pursuant to
projects authorization forms for our partners, which represent separate contracts. In addition to our licenses, we price our supply
of bulk rHuPH20 and research and development services at our regular selling prices, called standalone selling price or
(“SSP”). Therefore, our partners do not have material rights to order these items at prices not reflective of SSP. Refer to the
discussion below regarding recognition of revenue for these separate contracts.

Transaction price for a contract represents the amount to which we are entitled in exchange for providing goods and
services to the customer. Transaction price does not include amounts subject to uncertainties unless it is probable that there will
be no significant reversal of revenue when the uncertainty is resolved. Apart from the upfront license payment (or target
selection fees in the target selection contracts), all other fees we may earn under our collaborative agreements are subject to

F-15

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

significant uncertainties of product development. Achievement of many of the event-based development and regulatory
milestones may not be probable until such milestones are actually achieved. This generally relates to milestones such as
obtaining marketing authorization approvals. With respect to other development milestones, e.g., dosing of a first patient in a
clinical trial, achievement could be considered probable prior to its actual occurrence, based on the progress towards
commencement of the trial. In order to evaluate progress towards commencement of a trial, we assess the status of activities
leading up to our partner’s initiation of a trial such as feedback received from the applicable regulatory authorities, completion
of IND or equivalent filings, readiness and availability of drug, readiness of study sites and our partner’s commitment of
resources to the program. We do not include any amounts subject to uncertainties in the transaction price until it is probable that
the amount will not result in a significant reversal of revenue in the future. At the end of each reporting period, we re-evaluate
the probability of achievement of such milestones and any related constraint, and if necessary, adjust our estimate of the overall
transaction price.

When target exchange rights are held by partners, and the amounts attributed to these rights are not refundable, they are
included in the transaction price. However, they are recorded as deferred revenues because we have a potential performance
obligation to provide a new target upon an exchange right being exercised. These amounts are recognized in revenue when the
right of exchange expires or is exercised.

Because our agreements have one type of performance obligation (licenses) which are typically all transferred at the same
time at agreement inception, allocation of transaction price often is not required. However, allocation is required when licenses
for some of the individual targets are subject to rights of exchange, because revenue associated with these targets cannot be
recognized. When allocation is needed, we perform an allocation of the upfront amount based on relative SSP of licenses for
individual targets. We determine license SSP using an income-based valuation approach utilizing risk-adjusted discounted cash
flow projections of the estimated return a licensor would receive. When amounts subject to uncertainties, such as milestones
and royalties, are included in the transaction price, we attribute them to the specific individual target licenses which generate
such milestone or royalty amounts.

We also estimate SSP of bulk rHuPH20 and research and development services, to determine that our partners do not have
material rights to order them at discounted prices. For supplies of bulk rHuPH20, because we effectively act as a contract
manufacturer to our partners, we estimate and charge SSP based on the typical contract manufacturer margins consistently with
all of our partners. We determine SSP of research and development services based on a fully-burdened labor rate. Our rates are
comparable to those we observe in other collaborative agreements. We also have a history of charging similar rates to all of our
partners.

Upfront amounts allocated to licenses to individual targets are recognized as revenue when the license is transferred to the
partner, as discussed above, if the license is not subject to exchange rights, or when the exchange right expires or is exercised.
Development milestones and other fees are recognized in revenue when they are included in the transaction price, because by
that time we have already transferred the related license to the partner.

In contracts to provide research and development services, such services represent the only performance obligation. The
fees are charged based on hours worked by our employees and the fixed contractual rate per hour, plus third-party pass-through
costs, on a monthly basis. We recognize revenues as the related services are performed based on the amounts billed, as the
partner consumes the benefit of research and development work simultaneously as we perform these services, and the amounts
billed reflect the value of these services to the customer.

Device License, Development and Supply Arrangements

We have several license, development and supply arrangements with pharmaceutical partners as a result of our acquisition
of Antares, under which we grant a license to our device technology and provide research and development services that often
involve multiple performance obligations and highly-customized deliverables. For such arrangements, we identify each of the
promised goods and services within the contract and the distinct performance obligations at inception of the contract and
allocate consideration to each performance obligation based on relative SSP, which is generally determined based on the
expected cost plus mark-up.

If the contract includes an enforceable right to payment for performance completed to date and performance obligations
are satisfied over time, we recognize revenue over the development period using either the input or output method depending on
which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable
right to payment for performance completed to date, revenue is recognized when control of the product is transferred to the
customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of
physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and we have a
present right to payment.

Our typical payment terms for development contracts may include an upfront payment equal to a percentage of the total
contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction

F-16

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

of the individual performance obligations. We record a contract liability for cash received in advance of performance, which is
presented within deferred revenue and deferred revenue, long-term in the condensed consolidated balance sheets and
recognized as revenue in the condensed consolidated statements of income when the associated performance obligations have
been satisfied.

License fees and milestones received in exchange for the grant of a license to our functional intellectual property, such as
patented technology and know-how in connection with a partnered development arrangement, are generally recognized at
inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is
generally not distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are
contingent upon the occurrence of future events are evaluated and recorded at the most likely amount, and to the extent that it is
probable that a significant reversal will not occur when the associated uncertainty is resolved.

Refer to Note 5 Revenue, for further discussion on our collaborative arrangements.

Product Sales, Net

Proprietary Product Sales

Hylenex Recombinant

We sell Hylenex recombinant in the U.S. to wholesale pharmaceutical distributors, who sell the product to hospitals and
other end-user customers. Sales to wholesalers are made pursuant to purchase orders subject to the terms of a master agreement,
and delivery of individual packages of Hylenex recombinant represent performance obligations under each purchase order. We
use a contract manufacturer to produce Hylenex recombinant and a third-party logistics (3PL) vendor to process and fulfill
orders. We concluded we are the principal in the sales to wholesalers because we control access to services rendered by both
vendors and direct their activities. We have no significant obligations to wholesalers to generate pull-through sales.

Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks
when wholesalers sell Hylenex recombinant at negotiated discounted prices to members of certain group purchasing
organizations (“GPOs”) and government programs. We also pay quarterly distribution fees to certain wholesalers for inventory
reporting and chargeback processing, and to GPOs as administrative fees for services and for access to GPO members. We
concluded the benefits received in exchange for these fees are not distinct from our sales of Hylenex recombinant, and
accordingly we apply these amounts to reduce revenues. Wholesalers also have rights to return unsold product nearing or past
the expiration date. Because of the shelf life of Hylenex recombinant and our lengthy return period, there may be a significant
period of time between when the product is shipped and when we issue credits on returned product.

We estimate the transaction price when we receive each purchase order taking into account the expected reductions of the
selling price initially billed to the wholesaler arising from all of the above factors. We have compiled historical experience and
data to estimate future returns and chargebacks of Hylenex recombinant and the impact of the other discounts and fees we pay.
When estimating these adjustments to the transaction price, we reduce it sufficiently to be able to assert that it is probable that
there will be no significant reversal of revenue when the ultimate adjustment amounts are known.

Each purchase order contains only one type of product, and is usually shipped to the wholesaler in a single shipment.

Therefore, allocation of the transaction price to individual packages is not required.

We recognize revenue from Hylenex recombinant product sales and related cost of sales upon product delivery to the
wholesaler location. At that time, the wholesalers take control of the product as they take title, bear the risk of loss of
ownership, and have an enforceable obligation to pay us. They also have the ability to direct sales of product to their customers
on terms and at prices they negotiate. Although wholesalers have product return rights, we do not believe they have a
significant incentive to return the product to us.

Upon recognition of revenue from product sales of Hylenex recombinant, the estimated amounts of credit for product
returns, chargebacks, distribution fees, prompt payment discounts, and GPO fees are included in accrued liabilities and net of
accounts receivable in the consolidated balance sheet. We monitor actual product returns, chargebacks, discounts and fees
subsequent to the sale. If these amounts differ from our estimates, we make adjustments to these allowances, which are applied
to increase or reduce product sales revenue and earnings in the period of adjustment.

In connection with the orders placed by wholesalers, we incur costs such as commissions to our sales representatives.
However, as revenue from product sales is recognized upon delivery to the wholesaler, which occurs shortly after we receive a
purchase order, we do not capitalize these commissions and other costs, based on application of the practical expedient allowed
within the applicable guidance.

Other Proprietary Product Sales

F-17

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

As a result of our acquisition of Antares, our commercial portfolio of proprietary products includes XYOSTED,
TLANDO and NOCDURNA, which we sell primarily to wholesale and specialty distributors. Revenue is recognized when
control has transferred to the customer, which is typically upon delivery, at the net selling price, which reflects the variable
consideration for which reserves and sales allowances are established for estimated returns, wholesale distribution fees, prompt
payment discounts, government rebates and chargebacks, plan rebate arrangements and patient discount and support programs.

The determination of certain reserves and sales allowances requires us to make a number of judgements and estimates to
reflect our best estimate of the transaction price and the amount of consideration to which we believe we would be ultimately
entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party
payers, historical and estimated future percentage of rebates incurred on sales, historical and future insurance plan billings, any
new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing
patterns, product expiration dates and levels of inventory in the distribution channel. The estimated amounts of credit for
product returns, chargebacks, distribution fees, prompt payment discounts, rebates and customer co-pay support programs are
included in accrued liabilities and net of accounts receivable in the condensed consolidated balance sheets.

Partnered Product Sales

Bulk rHuPH20

We sell bulk rHuPH20 to partners for use in research and development and, subsequent to receiving marketing approval,
we sell it for use in collaboration commercial products. Sales are made pursuant to purchase orders subject to the terms of the
collaborative agreement or a supply agreement, and delivery of units of bulk rHuPH20 represent performance obligations under
each purchase order. We provide a standard warranty that the product conforms to specifications. We use contract
manufacturers to produce bulk rHuPH20 and have concluded we are the principal in the sales to partners. The transaction price
for each purchase order of bulk rHuPH20 is fixed based on the cost of production plus a contractual markup, and is not subject
to adjustments. Allocation of the transaction price to individual quantities of the product is usually not required because each
order contains only one type of product.

We recognize revenue from the sale of bulk rHuPH20 as product sales and related cost of sales upon transfer of title to our
partners. At that time, the partners take control of the product, bear the risk of loss of ownership, and have an enforceable
obligation to pay us.

Devices

As a result of our acquisition of Antares, we are party to several license, development, supply and distribution
arrangements with pharmaceutical partners, under which we produce and are the exclusive supplier of certain products, devices
and/or components. Revenue is recognized when or as control of the goods transfers to the customer as discussed below.

We are the exclusive supplier of the Makena® subcutaneous auto-injector product to Covis and the exclusive supplier of
OTREXUP® to Otter Pharmaceuticals, LLC (“Otter”). Because these products are custom manufactured for each customer with
no alternative use and we have a contractual right to payment for performance completed to date, control is continuously
transferred to the customer as the product is produced pursuant to firm purchase orders. Revenue is recognized over time using
the output method based on the contractual selling price and number of units produced. The amount of revenue recognized in
excess of the amount shipped/billed to the customer, if any, is recorded as contract assets in the condensed consolidated balance
sheets due to the short-term nature in which the amount is ultimately expected to be billed and collected from the customer.

All other device partnered product sales are recognized at the point in time in which control is transferred to the customer,
which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements,
and there is generally no right of return. Revenue is recognized at the transaction price, which includes the contractual per unit
selling price and estimated variable consideration, such as volume-based pricing arrangements or profit-sharing arrangements,
if any. We recognize revenue, including the estimated variable consideration we expect to receive for contract margin on future
commercial sales, upon shipment of the goods to our partner. The estimated variable consideration is recognized at an amount
we believe is not subject to significant reversal based on historical experience and is adjusted at each reporting period if the
most likely amount of expected consideration changes or becomes fixed.

Revenue Presentation

In our consolidated statements of income, we report as revenues under collaborative agreements the upfront payments,
event-based development and regulatory milestones and sales milestones. We also include in this category revenues from
separate research and development contracts pursuant to project authorization forms. We report royalties received from partners
as a separate line in our consolidated statements of income.

F-18

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Revenues from sales of our proprietary and partnered products are included in product sales, net in our consolidated

statements of income.

In the footnotes to our consolidated financial statements, we provide disaggregated revenue information by type of
arrangement (product sales, net, collaborative agreements and research and device licensing, and development revenues), and
additionally, by type of payment stream received under collaborative agreements (upfront license and target nomination fees,
event-based development and regulatory milestones and other fees, sales milestones and royalties).

Cost of Sales

Cost of sales consists primarily of raw materials, third-party manufacturing costs, fill and finish costs, freight costs,
internal costs and manufacturing overhead associated with the production of proprietary and partnered products. Cost of sales
also consists of the write-down of excess, dated and obsolete inventories and the write-off of inventories that do not meet
certain product specifications, if any.

Research and Development Expenses

Research and development expenses include salaries and benefits, facilities and other overhead expenses, research related
manufacturing services, contract services and other outside expenses. Research and development expenses are charged to
operating expenses as incurred when these expenditures relate to our research and development efforts and have no alternative
future uses.

We are obligated to make upfront payments upon execution of certain research and development agreements. Advance
payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and
development activities are deferred. Such amounts are recognized as expense as the related goods are delivered or the related
services are performed or such time when we do not expect the goods to be delivered or services to be performed.

Share-Based Compensation

We record compensation expense associated with stock options, restricted stock units (“RSUs”), performance stock units
(“PSUs”) and shares issued under our employee stock purchase plan (“ESPP”) in accordance with the authoritative guidance for
stock-based compensation. The cost of employee services received in exchange for an award of an equity instrument is
measured at the grant date, based on the estimated fair value of the award, and is recognized as expense on a straight-line basis
over the requisite service period of the award. Share-based compensation expense for an award with a performance condition is
recognized when the achievement of such performance condition is determined to be probable. If the outcome of such
performance condition is not determined to be probable or is not met, no compensation expense is recognized and any
previously recognized compensation expense is reversed. Forfeitures are recognized as a reduction of share-based compensation
expense as they occur.

Income Taxes

We provide for income taxes using the liability method. Under this method, deferred income tax assets and liabilities are
determined based on the differences between the financial statement carrying amounts of existing assets and liabilities and their
respective tax bases at each reporting period. We measure deferred tax assets and liabilities using enacted tax rates for the year
in which the differences are expected to reverse. Significant judgment is required by management to determine our provision
for income taxes, our deferred tax assets and liabilities, and any associated valuation allowances recorded against our net
deferred tax assets, which are based on complex and evolving tax regulations. Deferred tax assets (“DTA”) and other tax
benefits are recorded when they are more likely than not to be realized. On a quarterly basis, we assess the need for valuation
allowance on our DTAs, weighing all positive and negative evidence, to assess if it is more-likely-than-not that some or all of
our DTAs will be realized.

Segment Information

As a result of the acquisition of Antares, we assessed the organization of our business and concluded that we continue to
operate our business in one operating segment, which includes all activities related to the research, development and
commercialization of our proprietary enzymes and devices. This segment also includes revenues and expenses related to
(i) research and development and manufacturing activities conducted under our collaborative agreements with third parties, and
(ii) product sales of proprietary and products. The chief operating decision-maker reviews the operating results on an aggregate
basis and manages the operations as a single operating segment.

F-19

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Adoption and Pending Adoption of Recent Accounting Pronouncements

The following table provides a brief description of recently issued accounting standards, those adopted in the current

period and those not yet adopted:

Standard

Description

Effective Date

In October 2021, the
FASB issued ASU
2021-08, Business
Combinations (Topic
805): Accounting for
Contract Assets and
Contract Liabilities
from contracts with
customers

The new guidance requires an
acquirer to recognize and
measure contract assets and
contract liabilities acquired in
a business combination in
accordance with Topic 606 as
if it had originated the
contracts.

January 1, 2023
(Early adoption
is permitted,
including
adoption in an
interim period)

Effect on the Financial
Statements or Other Significant Matters

We early adopted ASU 2021-08 on April 1,
2022. The adoption did not have a material
impact on our condensed consolidated financial
position or results of operations.

F-20

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

3. Business Combination

On May 24, 2022, we acquired all outstanding equity interests of Antares Pharma, Inc. according to the terms and
conditions of the Agreement and Plan of Merger, dated as of April 12, 2022 (the “Merger Agreement”). Antares is a specialty
pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and
technologies that address patient needs in targeted therapeutic areas. We acquired Antares as a part of our strategy to expand as
a drug delivery company and include specialty products.

The total purchase consideration of Antares was $1,045.7 million. Each share of Antares common stock issued and
outstanding was converted into the right to receive $5.60 in cash without interest, less any applicable withholding taxes
(“Merger Consideration”). Additionally, in connection with the transaction, each Antares equity award granted and outstanding
as of May 24, 2022 under the Antares’ equity compensation plans was converted into the right to receive Merger Consideration.
Other components of purchase consideration include cash paid at closing to settle Antares existing debt of $19.7 million and
seller transaction costs paid by us on behalf of Antares of $22.9 million.

The acquisition of Antares was funded by cash on hand and borrowings under the new credit agreement with Bank of
America, N.A. (“BofA”) and other lenders that provides for (i) a $350 million revolving credit facility (the “Revolving Credit
Facility”) and (ii) a $250 million term loan facility (the “Term Facility”, collectively with the Revolving Credit Facility, the
“2022 Facility”) as described in Note 8. We recognized transaction costs of $21.9 million in the twelve months ended
December 31, 2022. These costs are reported in selling, general and administrative expenses in our condensed consolidated
statements of income. Transaction costs include, but are not limited to, investment banker, advisory, legal, and other
professional fees.

Purchase Consideration

The total purchase consideration was comprised of the following (in thousands):

Cash consideration for Antares shares outstanding as of May 24, 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 956,886
45,828
Consideration for Antares equity compensation awards (a) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
22,906
Consideration for seller transaction costs paid by Halozyme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19,683
Consideration related to Antares closing indebtedness settled by Halozyme . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash consideration related to cash bonus awards paid by Halozyme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
365
Total purchase consideration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 1,045,668

(a) Consideration for Antares equity compensation awards consists of $32.2 million paid for vested equity awards as well as $13.6 million paid for the pre-
combination portion of unvested equity awards that were accelerated as part of the Merger Agreement. The fair value of the unvested equity awards attributable
to the post-combination period of $8.7 million is included in our consolidated statements of income in twelve months ended December 31, 2022.

Fair Value of Assets Acquired and Liabilities Assumed

The acquisition of Antares has been accounted for using the acquisition method of accounting in accordance with ASC
805, Business Combinations, with Halozyme treated as the accounting acquirer, which requires, among other things, that the
assets acquired and liabilities assumed be recognized at their fair value on the acquisition date. Acquisition accounting is
dependent upon certain valuations and other studies that have yet to commence or progress to a stage where there is sufficient
information for a definitive measurement. The process for estimating the fair values of identifiable intangible assets and certain
tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.

The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition
date based on valuations and management estimates. Fair value estimates are based on a complex series of judgments about
future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated
fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our
results of operations. We are still finalizing the allocation of the purchase price, therefore, the fair value estimates assigned to
intangible assets, goodwill and the related tax impacts of the acquisition, among other items, are subject to change as additional
information is received to complete our analysis and certain tax returns are finalized. As a result, the preliminary estimates may
be revised during the measurement period. These differences could change the value of the intangible assets acquired, the
contingent liability assumed, and the tax impacts related to the acquisition and could have a material impact on our results of
operations and financial position.

F-21

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Amounts
recognized as of
Acquisition date
(as initially
reported)

Total purchase consideration, net of $46,548 cash acquired . $
Assets:
Short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, net . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other assets . . . . . . . . . . . . . . . . . . . . .
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . .
Intangibles, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Liabilities:
Accounts Payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue, current portion . . . . . . . . . . . . . . . . . . . . .
Deferred revenue, net of current portion . . . . . . . . . . . . . . . .
Deferred tax liabilities, net . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net assets acquired, excluding goodwill . . . . . . . . . . . . . . $
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

999,120

498
82,160
34,379
5,241
28,661
987,500

7,197
33,705
2,509
1,207
159,094
135,088
799,639
199,481

Amounts (in thousands)

Measurement
period adjustment
—
$

Amounts
recognized as of
Acquisition date
(as adjusted )

999,120

—
—
(6,311)
—
—
(397,700)

—
7,949
—
—
(88,092)
(114,300)
(209,568) $
$
209,568

498
82,160
28,068
5,241
28,661
589,800
—
7,197
41,654
2,509
1,207
71,002
20,788
590,071
409,049

$
$

Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue
and cost synergies of the combined company and assembled workforce. Goodwill will be allocated entirely to the single
reportable unit. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.

A contingent liability with a preliminary value of $130.0 million was assumed related to TLANDO. We assumed an
obligation to pay development milestone payments as well as commercial milestone payments and minimum tiered royalty
payments based on TLANDO net sales which are contingent upon future events. The acquisition date fair value was measured
using the income approach, specifically the probability weighted expected return method for the development milestone
payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments and
royalty payments.

We recorded measurement period adjustments in fourth quarter of 2022 to decrease intangible assets as a result of revised
future cash flow estimates from the initial purchase price allocation and adjustments to accrued expenses. These measurement
period adjustments were made to reflect facts and circumstances that existed as of the acquisition date. We also recorded a
measurement period adjustment in the fourth quarter of 2022 to reduce the acquisition-date fair value of contingent liability by
$114.3 million as a result of revised future cash flow estimates. The measurement period adjustment has been recorded to
reflect facts and circumstances that existed as of the acquisition date.

Identifiable Intangible Assets

The estimated fair values of identifiable intangible assets were prepared using the excess earnings method which
calculates the present value of the incremental after-tax cash flows attributable solely to each intangible asset. The estimated
useful lives are based on forecasted periods of benefit for each intangible asset which consider commercialization dates, the
estimated revenue cycle based on the products’ competitiveness in the market, and the loss of exclusivity timing with
subsequent trending down of revenue. For the ATRS-1902 IPR&D, the useful life is considered indefinite as the asset has not
been placed into service. As such, the ATRS-1902 IPR&D will be tested annually for impairment and will not be amortized.
Useful lives and preliminary values are presented in the table below.

F-22

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Auto-Injector technology platform . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
XYOSTED proprietary product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
TLANDO product rights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ATRS-1902 (IPR&D) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Estimated fair value of intangible assets acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

402,000
136,200
2,900
48,700
589,800

Amount (in
thousands)

Useful life
(years)
7
10
10
Indefinite

Unaudited Pro Forma Results

Our consolidated financial statements include Antares’ results of operations from the date of acquisition on May 24, 2022
through December 31, 2022. Total revenues and net loss after taxes attributable to Antares during this period and included in
our consolidated financial statements for the twelve months ended December 31, 2022 total $112.7 million and $67.6 million,
respectively.

The following unaudited pro forma financial information summarizes combined results of operations of Halozyme and

Antares as if the companies had been combined as of the beginning of our fiscal year 2021.

Twelve Months Ended
December 31,

2022

2021

Total Revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 712,683 $ 627,292

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 218,723 $ 295,634

The unaudited pro forma financial information for all periods presented includes the business combination accounting
effects resulting from this acquisition. The unaudited pro forma results include adjustments to reflect the amortization of the
inventory step-up and the incremental intangible asset amortization to be incurred based on preliminary valuations of assets as
well as certain material non-recurring transaction adjustments related to the acquisition. Adjustments to interest expense,
financing costs and investment income were made to reflect the capital structure of the combined entity. Adjustments to income
tax expense also were made to reflect the anticipated effective tax rate of the combined entity. The unaudited pro forma
financial information as presented is for informational purposes only and is not necessarily indicative of the results of
operations that would have been achieved if the acquisition had taken place at the beginning of fiscal year 2021, nor is it
necessarily an indication of trends in future results for a number of reasons, including, but not limited to, differences between
the assumptions used to prepare the pro forma information, cost savings from operating efficiencies, potential synergies, and the
impact of incremental costs incurred in integrating the businesses.

F-23

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

4. Fair Value Measurement

Available-for-sale marketable securities consisted of the following (in thousands):

December 31, 2022

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Estimated
Fair Value

Asset-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Corporate debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. Treasury securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Agency bonds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Commercial paper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,146 $
7,139
111,469
2,783
7,004
$ 129,541 $

— $
—
—
2
—
2 $

— $
(9)
(934)
(1)
—

1,146
7,130
110,535
2,784
7,004
(944) $ 128,599

December 31, 2021

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Estimated
Fair Value

Asset-backed securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

32,745 $

— $

(53) $

32,692

Corporate debt securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

U.S. Treasury securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Non-U.S. Government Securities . . . . . . . . . . . . . . . . . . . . . . . .

Commercial paper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

58,885

231,230

17,232

282,731

—

(86)

58,799

(469)

230,761

(12)

17,220

—

282,731

$ 622,823 $

— $

(620) $ 622,203

As of December 31, 2022, 20 available-for-sale marketable securities with a fair market value of $117.2 million were in a
gross unrealized loss position of $0.9 million. Based on our review of these marketable securities, we believe none of the
unrealized loss is as a result of a credit loss as of December 31, 2022, because we do not intend to sell these securities and it is
not more-likely-than-not that we will be required to sell these securities before the recovery of their amortized cost basis.

The estimated fair value of our contractual maturities of available-for-sale debt securities are as follows (in thousands):

Due within one year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

After one but within five years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

114,353 $

14,246
128,599 $

500,965

121,238
622,203

December 31, 2022

December 31, 2021

F-24

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

The following table summarizes, by major security type, our cash equivalents and available-for-sale marketable securities

that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy (in thousands):

December 31, 2022

December 31, 2021

Level 1

Level 2

Total
estimated
fair value

Level 1

Level 2

Total
estimated
fair value

Cash equivalents:

Money market funds . . . . . . . . . . $ 191,704 $

— $ 191,704

$ 118,707 $

— $ 118,707

Available-for-sale marketable
securities:

Asset-backed securities . . . . . . . .

—

1,146

—

Corporate debt securities . . . . . . .
U.S. Treasury securities . . . . . . . .
Non-US Government securities . .
Agency bonds . . . . . . . . . . . . . . .
Commercial paper . . . . . . . . . . . .

—
110,535
—
2,784
—

7,130
110,535
—
2,784
7,004
$ 305,023 $ 15,280 $ 320,303

7,130
—
—
—
7,004

—
230,761
—

32,692

58,799
—
17,220

32,692

58,799
230,761
17,220

—

282,731
282,731
$ 349,468 $ 391,442 $ 740,910

We had no available for sale securities that were classified within Level 3 as of December 31, 2022 and 2021.

A contingent liability with a value of $15.7 million was assumed related to TLANDO. The acquisition date fair value was
measured using the income approach, specifically the probability weighted expected return method for the development
milestone payments and the option pricing methodology using the Monte Carlo simulation for commercial milestone payments
and royalty payments. We will remeasure the fair value of the contingent liability on a quarterly basis. Estimates and
assumptions used in the Monte Carlo simulation include forecasted revenues, cost of debt, risk free rate, weighted average cost
of capital, revenue market price risk and revenue volatility. Estimates and assumptions used in the income approach include the
probability of achieving certain milestones and a discount rate. These unobservable inputs represent a Level 3 measurement
because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in
the fair value subsequent to the acquisition date is recognized in our consolidated statements of income.

F-25

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

5. Revenue

Our disaggregated revenues were as follows (in thousands):

Royalties

Product sales, net

Sales of bulk rHuPH20

Sale of proprietary products

Sale of Device Partnered Products

Total product sales, net

Revenues under collaborative agreements:
Upfront license and target nomination fees
Event-based development milestones and regulatory milestone and other fees
Sales-based milestones
Device Licensing and development revenue
Total revenues under collaborative agreements

Year Ended December 31,

2022

2021

2020

$ 360,475 $ 203,900 $ 88,596

82,084

80,960

38,956

72,849

23,264

17,031

36,097

—

$ 191,030 $ 104,224 $ 55,987

30,000
59,000
10,000
9,611

37,264
69,500
15,000
1,247
$ 108,611 $ 135,186 $ 123,011

42,000
42,000
50,000
1,186

Total revenue

$ 660,116 $ 443,310 $ 267,594

During the year ended December 31, 2022 we recognized revenue related to licenses granted to collaboration partners in
prior periods in the amount of $429.5 million. This amount represents royalties and sales milestone earned in the current period,
as well as $59.0 million of variable consideration in the contracts where uncertainties have been resolved and the development
milestones are probable of being achieved or were achieved. We also recognized revenue of $2.0 million during the year ended
December 31, 2022 that had been included in deferred revenues at December 31, 2021. We did not recognize any adjustments
to reduce sales reserves and allowances liability related to Hylenex recombinant sales in prior periods.

Accounts receivable, other contract assets and deferred revenues (contract liabilities) from contracts with customers,

including collaboration partners, consisted of the following (in thousands):

Accounts receivable, net
Other contract assets
Deferred revenues

December
31, 2022

December
31, 2021

$ 186,970 $ 90,975
—
$ 44,102 $
4,276
5,499 $
$

As of December 31, 2022, the amounts included in the transaction price of our contracts with customers, including
collaboration partners, and allocated to goods and services not yet provided were $80.7 million of which $75.2 million relates to
unfulfilled product purchase orders and $5.5 million has been collected and reported as deferred revenues. The unfulfilled
product purchase orders are estimated to be delivered in 2023. Of the total deferred revenues of $5.5 million, $3.2 million is
expected to be used by our customers within the next 12 months.

We recognized contract assets of $44.1 million as of December 31, 2022, which related to development milestones
deemed probable of receipt for intellectual property licenses granted to partners in prior periods and for goods or services when
control has transferred to the customer, and corresponding revenue is recognized on an over time basis but is not yet billable to
the customer in accordance with the terms of the contract.

F-26

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

6. Certain Balance Sheet Items

Accounts receivable consisted of the following (in thousands):

December 31,
2022

December 31,
2021

Accounts receivable from product sales to partners . . . . . . . . . . . . . . . . . . . . . . . . . . $
Accounts receivable from revenues under collaborative agreements . . . . . . . . . . . . .
Accounts receivable from royalty payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable from other product sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Contract assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Subtotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Allowance for distribution fees and discounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

62,979
18,776
100,900
6,229
44,102
232,986
(1,914)
231,072

18,504
5,422
63,555
4,634
—
92,115
(1,140)
90,975

Inventories consisted of the following (in thousands):

Raw materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Work-in-process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finished goods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

13,792
40,361
45,970
100,123

10,672
17,451
25,785
53,908

December 31,
2022

December 31,
2021

Prepaid expenses and other assets consisted of the following (in thousands):

Prepaid manufacturing expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Other prepaid expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total prepaid expenses and other assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Less long-term portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total prepaid expenses and other assets, current . . . . . . . . . . . . . . . . . . . . . . . . . . $

51,694
4,647
14,984
71,325
(26,301)
45,024

47,991
3,809
2,096
53,896
(13,414)
40,482

December 31,
2022

December 31,
2021

Prepaid manufacturing expenses include raw materials, slot reservation fees and other amounts paid to contract
manufacturing organizations. Such amounts are reclassified to work-in-process inventory as materials are used or the contract
manufacturing organization services are complete.

F-27

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Property and equipment, net consisted of the following (in thousands):

December 31,
2022

December 31,
2021

Research equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Manufacturing equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer and office equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Subtotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Accumulated depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Subtotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Right of use of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

7,380
27,893
7,855
6,729
49,857
(14,756)
35,101
40,469
75,570

7,174
5,719
5,370
1,628
19,891
(13,100)
6,791
2,003
8,794

Depreciation and amortization expense was approximately $6.5 million, $3.0 million, and $3.3 million, inclusive of ROU
asset amortization of $3.0 million, $1.6 million and $1.7 million for the years ended December 31, 2022, 2021 and 2020,
respectively.

Accrued expenses consisted of the following (in thousands):

December 31,
2022

December 31,
2021

Accrued compensation and payroll taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Accrued outsourced manufacturing expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Product returns and sales allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lease liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Less long-term portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total accrued expenses, current . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

19,939
12,190
—
30,261
29,771
34,788
126,949
(30,433)
96,516

9,858
6,514
1,439
706
3,648
2,820
24,985
(544)
24,441

Expense associated with the accretion of the lease liabilities was approximately $0.5 million, $0.3 million and $0.5
million for the twelve months ended December 31, 2022, 2021 and 2020, respectively. Total lease expense for the twelve
months ended December 31, 2022, 2021 and 2020 was $3.3 million, $1.9 million and $2.2 million, respectively.

Cash paid for amounts related to leases for the twelve months ended December 31, 2022, 2021 and 2020 was $4.2 million,

$2.7 million and $3.2 million, respectively.

F-28

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

7. Goodwill and Intangible Assets

Goodwill

On May 24, 2022, we acquired all outstanding equity interests of Antares. A Goodwill balance of $409.0 million was
recognized for the excess of the consideration transferred over the net assets acquired and represents the expected revenue and
cost synergies of the combined company and assembled workforce.

A summary of the activity impacting goodwill is presented below (in thousands):

Balance as of December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Goodwill acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Balance as of December 31, 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

—
409,049
409,049

Intangible Assets

Our acquired intangible assets are amortized using the straight-line method over their estimated useful lives of seven to
ten years. The following table shows the cost, accumulated amortization and weighted average remaining life in years for our
acquired intangible assets as of December 31, 2022 (in thousands).

Auto-Injector technology platform . . . . . . . . . . . . . . .
XYOSTED proprietary product . . . . . . . . . . . . . . . . . .
TLANDO product rights . . . . . . . . . . . . . . . . . . . . . . .

Total definite-lived intangibles, net

ATRS-1902 (IPR&D)

Total Intangibles, net

Weighted average
remaining life (in
years)
7
10
10

Indefinite

Gross
Carrying
Value

Accumulated
Amortization

Net Carrying
Value

$ 402,000 $
136,200
2,900
$ 541,100 $

34,735 $ 367,265
127,962
8,238
2,725
175
43,148 $ 497,952
48,700
$ 546,652

The estimated future annual amortization of finite-lived intangible assets is shown in the following table. Actual amortization
expense to be reported in future periods could differ from these estimates as a result of acquisitions, divestitures, and asset
impairments, among other factors.

Amortization (in
thousands)

71,339

71,339
71,339

71,339
141,257

497,952

Year:
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F-29

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

8. Long-Term Debt, Net

1.00% Convertible Notes due 2028

Holders may convert their 2028 Convertible Notes at their option only in the following circumstances: (1) during any
calendar quarter commencing after the calendar quarter ending on December 31, 2022, if the last reported sale price per share of
common stock exceeds 130% of the conversion price for each of at least 20 trading days during the 30 consecutive trading days
ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five consecutive
business days immediately after any five consecutive trading day period (such five consecutive trading day period, the
“measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement
period was less than 98% of the product of the last reported sale price per share of our common stock on such trading day and
the conversion rate on such trading day; (3) upon the occurrence of certain corporate events or distributions on our common
stock, as described in the offering memorandum for the 2028 Convertible Notes; (4) if we call such notes for redemption; and
(5) at any time from, and including, February 15, 2028 until the close of business on the second scheduled trading day
immediately before the maturity date. As of December 31, 2022, the 2028 Convertible Notes are not convertible.

As of December 31, 2022, we were in compliance with all covenants and there was no material adverse change in our

business, operations or financial condition.

Capped Call Transactions

In connection with the offering of the 2028 Convertible Notes, we entered into capped call transactions with certain
counterparties (the “Capped Call Transactions”). The Capped Call Transactions are expected generally to reduce potential
dilution to holders of our common stock upon conversion of the 2028 Convertible Notes or at our election (subject to certain
conditions) offset any cash payments we are required to make in excess of the principal amount of such converted 2028
Convertible Notes. The cap price of the Capped Call Transactions is initially $75.4075 per share of common stock, representing
a premium of 75% above the last reported sale price of $43.09 per share of common stock on August 15, 2022, and is subject to
certain adjustments under the terms of the Capped Call Transactions. As of December 31, 2022, no capped calls have been
exercised.

Pursuant to their terms, the capped calls qualify for classification within stockholders’ equity in the condensed
consolidated balance sheets, and their fair value is not remeasured and adjusted as long as they continue to qualify for
stockholders’ equity classification. We paid approximately $69.1 million for the Capped Calls, including applicable transaction
costs, which was recorded as a reduction to additional paid-in capital in the Condensed Consolidated Balance Sheets. The
Capped Call Transactions are separate transactions entered into by us with the capped call Counterparties, are not part of the
terms of the Convertible Notes, and do not affect any holder’s rights under the Convertible Notes. Holders of the Convertible
Notes do not have any rights with respect to the Capped Call Transactions.

0.25% Convertible Notes due 2027

F-30

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

$20.1 million, was approximately $784.9 million. We also incurred additional debt issuance costs totaling $0.4 million. Debt
issuance costs and the initial purchasers’ fee are presented as a debt discount.

Upon conversion, we will pay cash for the settlement of principal and for the premium, if applicable, we will pay cash,
deliver shares of common stock or a combination of cash and shares of common stock, at our election. The initial conversion
rate for the 2027 Convertible Notes will be 12.9576 shares of common stock per $1,000 in principal amount of 2027
Convertible Notes, equivalent to a conversion price of approximately $77.17 per share of our common stock. The conversion
rate is subject to adjustment.

As of December 31, 2022, we were in compliance with all covenants and there was no material adverse change in our

business, operations or financial condition.

1.25% Convertible Notes due 2024

F-31

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

In January 2021 we notified the note holders of our irrevocable election to settle the principal of the 2024 Convertible
Notes in cash and for the premium, if applicable, to deliver shares of common stock. The conversion rate for the 2024
Convertible Notes will be 41.9208 shares of common stock per $1,000 in principal amount of 2024 Convertible Notes,
equivalent to a conversion price of approximately $23.85 per share of our common stock. The conversion rate is subject to
adjustment.

In January 2023, we issued a notice for the redemption of 2024 Convertible Notes, and we expect to make cash payment

of $13.5 million to effect the redemption in March 2023.

As of December 31, 2022, we were in compliance with all covenants and there was no material adverse change in our

business, operations or financial condition.

F-32

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Net Carrying Amounts of the Convertible Notes

The carrying amount and fair value of our Convertible Notes were as follows as of the dates indicated (amount in

thousands).

Principal amount:

December 31,
2022

December 31,
2021

2024 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
2027 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2028 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Principal Amount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

13,483
805,000
720,000
1,538,483

90,936
805,000
—
895,936

Unamortized debt discount:

Total unamortized debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

(149) $

(14,359)
(17,875)
(32,383) $

(1,517)
(17,745)
—
(19,262)

Carrying amount:

Total carrying amount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Fair value based on trading levels (Level 2):

Total fair value of outstanding notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

13,334
790,641
702,125
1,506,100

32,176
784,770
849,823
1,666,769

Remaining amortization per period of debt discount (in years):

2024 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2027 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2028 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1.9
4.2
5.6

89,419
787,255
—
876,674

159,678
718,889
—
878,567

2.9
5.2
n/a

F-33

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

The following table summarizes the components of interest expense and the effective interest rates for each of our

Convertible Notes for the periods shown (in thousands).

Twelve Months Ended
December 31,

2022

2021

Coupon Interest:

2024 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
2027 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2028 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Coupon Interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

Amortization of debt discount:

Total amortization of debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

771
2,013
2,660
5,444

357
3,386
1,124
4,867

Interest expense:

Total interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

1,128
5,399
3,784
10,311

1,906
1,677
—
3,583

838
2,804
—
3,642

2,744
4,481
—
7,225

Effective interest rates:

2024 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2027 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2028 Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1.8 %
0.7 %
1.5 %

1.8 %
0.7 %
n/a

Revolving Credit and Term Loan Facilities (May 2022)

In May 2022, in connection with the closing of the Antares acquisition, we entered into a credit agreement, which was
subsequently amended, with Bank of America, N.A., as Administrative Agent, Swing Line Lender and an L/C Issuer, and the
other lenders and L/C Issuers party thereto (the “2022 Credit Agreement), evidencing a credit facility (the “2022 Facility”) that
provides for (i) a $350 million revolving credit facility (the “Revolving Credit Facility”) and (ii) a $250 million term loan
facility (the “Term Facility”). Proceeds from a $120 million draw on the Revolving Credit Facility and the $250 million Term
Facility were used to fund a portion of the Antares acquisition, repay Antares’ existing debt and pay fees and expenses in
connection with the acquisition. The 2022 Credit Agreement contains an expansion feature, which allows us, subject to certain
conditions, to increase the aggregate principal amount of the 2022 Facility, provided we remain in compliance with underlying
financial covenants on a pro forma basis including the consolidated interest coverage ratio and the consolidated net leverage
ratio covenants set forth in the 2022 Credit Agreement. The 2022 Facility will mature on November 30, 2026 unless either the
Revolving Credit Facility or the Term Facility is extended prior to such date in accordance with the 2022 Credit Agreement.

F-34

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

In August 2022, we entered into Amendment No. 1 to the Credit Agreement (the “Amendment”) among the Company,
the Guarantors (as defined in the Credit Agreement), each L/C Issuer from time to time party thereto, Bank of America, N.A.,
as Administrative Agent (in such capacity, the “Administrative Agent”) and swing line lender (in such capacity, the “Swing
Line Lender”), and each lender party thereto, which amends the Credit Agreement dated as of May 24, 2022 (the “Credit
Agreement”) among the Company, the Guarantors, the Administrative Agent, the Swing Line Lender, each Lender and the L/C
Issuers. The Amendment, among other things, increased the size of the revolving credit facility from $350 million to
$575 million. The terms of the Revolving Credit Facility are otherwise unchanged. Concurrently with the entry into the
Amendment, we repaid the entire outstanding Term Loan Facility and repaid all outstanding loans under the Revolving Credit
Facility under the 2022 Credit Agreement.

As of December 31, 2022, the Revolving Credit Facility was undrawn. We incurred a total of $3.6 million in third-party
costs related to the 2022 Credit Agreement which is recorded as debt issuance cost within prepaid expenses and other assets in
the condensed consolidated balance sheets. As of December 31, 2022, the unamortized debt issuance cost related to the
revolving credit facility was $3.1 million.

Future maturities and interest payments of long-term debt as of December 31, 2022, are as follows (in thousands):

2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

22,745

2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9,213

812,535

724,480

Total minimum payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 1,587,399

Less amount representing coupon interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(48,916)

Gross balance of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 1,538,483

Less unamortized debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Carrying value of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(32,383)
$ 1,506,100

Less current portion of long-term debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt, less current portion and unamortized debt discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(13,334)
$ 1,492,766

F-35

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

9. Share-based Compensation

We currently grant stock options, restricted stock awards, performance stock units and restricted stock units under the
Amended and Restated 2021 Stock Plan (“2021 Stock Plan”), which was approved by the stockholders on May 5, 2021 and
provides for the grant of up to 17.8 million shares of common stock to selected employees, consultants and non-employee
members of our Board of Directors as stock options, stock appreciation rights, restricted stock awards, restricted stock unit
awards and performance awards. Awards are subject to terms and conditions established by the Compensation Committee of
our Board of Directors. During the year ended December 31, 2022, we granted share-based awards under the 2021 Stock Plan.
At December 31, 2022, 6,550,075 shares were subject to outstanding awards and 14,764,481 shares were available for future
grants of share-based awards.

Total share-based compensation expense related to share-based awards excluding the acceleration of Antares equity

awards was comprised of the following (in thousands):

Year Ended December 31,

2022

2021

2020

Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . .

9,903 $

6,992 $

14,494

13,828

Share-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . $

24,397 $

20,820 $

5,484

11,720

17,204

Share-based compensation expense by type of share-based award (in thousands):

Stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
RSAs, RSUs, PSUs and ESPP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2022

2021

2020

10,973 $

10,252 $

13,424

10,568

8,955

8,249

Total unrecognized estimated compensation cost by type of award and the weighted-average remaining requisite service

period over which such expense is expected to be recognized (in thousands, unless otherwise noted):

24,397 $

20,820 $

17,204

December 31, 2022

Stock options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
RSUs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
PSUs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
ESPP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

26,730
26,488
3,986
247

Unrecognized
Expense

Remaining
Weighted-
Average
Recognition
Period
(years)

2.66
2.32
1.91
0.45

In February 2021, our Board of Directors approved our 2021 ESPP and our stockholders approved the plan in May 2021.
The ESPP enables eligible employees to purchase shares of our common stock at the end of each offering period at a price
equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period,
whichever is lower. Share purchases are funded through payroll deduction of at least 1% and up to 15% of an employee’s
compensation for each payroll period, and no employee may purchase shares under the ESPP that exceeds $25,000 worth of our
common stock for a calendar year. As of December 31, 2022, 2,650,103 shares were available for future purchase. The offering
period is generally for a six-months period and the first offering period commenced on June 16, 2021. Offering periods shall
commence on or about the sixteenth day of June and December of each year and end on or about the fifteenth day of the next
December and June respectively, occurring thereafter. During the twelve months ended December 31, 2022, 32,124 shares were
issued pursuant to the ESPP.

F-36

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Stock Options. Options granted under the Plans must have an exercise price equal to at least 100% of the fair market value
of our common stock on the date of grant. The options generally have a maximum contractual term of ten years and vest at the
rate of one-fourth of the shares on the first anniversary of the date of grant and 1/48 of the shares monthly thereafter. Certain
option awards provide for accelerated vesting if there is a change in control (as defined in the Plans).

A summary of our stock option award activity as of and for the year ended December 31, 2022 is as follows:

Shares
Underlying
Stock Options

Weighted
Average Exercise
Price per Share

Weighted
Average
Remaining
Contractual
Term (years)

Aggregate
Intrinsic
Value (in
Millions)

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . .

4,965,374

Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,773,912

Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Canceled/forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(789,870)

(581,191)

Outstanding at December 31, 2022 . . . . . . . . . . . . . . . . .

5,368,225

Vested and expected to vest at December 31, 2022 . . . .

5,368,225

Exercisable at December 31, 2022 . . . . . . . . . . . . . . . . .

3,176,691

$20.76

$37.25

$19.40

$33.87

$24.99

$17.22

6.48

4.92

$171.3

$126.0

The weighted average grant date fair values of options granted during the years ended December 31, 2022, 2021 and 2020
were $14.22 per share, $18.21 per share and $20.74 per share, respectively. The total intrinsic value of options exercised during
the years ended December 31, 2022, 2021 and 2020 was approximately $21.6 million, $33.5 million and $49.7 million,
respectively. Cash received from stock option exercises for the years ended December 31, 2022, 2021 and 2020 was
approximately $15.3 million, $16.6 million and $66.2 million, respectively.

The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair
value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model (“Black-
Scholes model”). Expected volatility is based on historical volatility of our common stock. The expected term of options
granted is based on analyses of historical employee termination rates and option exercises. The risk-free interest rate is based on
the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The
dividend yield assumption is based on the expectation of no future dividend payments. The assumptions used in the Black-
Scholes model were as follows:

Expected volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Average expected term (in years) . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Risk-free interest rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

39.91-50.81%
4.7

41.01-46.45%
4.7

47.57-51.82%
5.1

1.37-4.27%
—

0.36-1.20%
—

0.22-1.67%
—

Year Ended December 31,

2022

2021

2020

F-37

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

Restricted Stock Units. A RSU is a promise by us to issue a share of our common stock upon vesting of the unit. The

RSUs will generally vest at the rate of one-fourth of the shares on each anniversary of the date of grant.

The following table summarizes our RSU activity during the year ended December 31, 2022:

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Outstanding at December 31, 2022 . . . . . . . . . . . . . . . . . . . .

Number of
Shares
858,742
706,096
(320,767)
(204,690)
1,039,381

Weighted
Average
Grant Date
Fair Value
$29.54
$39.18
$26.68
$35.69
$35.76

Weighted
Average
Remaining
Contractual
Term (yrs)

Aggregate
Intrinsic
Value (in
Millions)

1.25

$59.1

The estimated fair value of the RSUs was based on the closing market value of our common stock on the date of grant.
The total grant date fair value of RSUs vested during the years ended December 31, 2022, 2021 and 2020 was approximately
$8.6 million, $6.6 million and $10.1 million, respectively. The fair value of RSUs vested during the years ended December 31,
2022, 2021 and 2020 was approximately $11.3 million, $19.0 million and $14.0 million, respectively.

Performance Stock Units. A PSU is a promise by us to issue a share of our common stock upon achievement of a specific

performance condition.

The following table summarizes our PSU activity during the year ended December 31, 2022:

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Number of
Shares

69,382

129,773

(2,565)

(53,746)

142,844

Weighted
Average
Grant Date
Fair Value

$40.66

$41.42

$63.41

$27.20

$46.01

The estimated fair value of the PSUs was based on the closing market value of our common stock on the date of grant.
The fair value of PSUs vested during the years ended December 31, 2022 and 2021 was $0.2 million and $0.1 million,
respectively.

F-38

10. Stockholders’ Equity

During the years ended December 31, 2022, 2021 and 2020, we issued an aggregate of 789,870, 1,179,032 and 4,705,843
shares of common stock, respectively, in connection with the exercises of stock options, for net proceeds of approximately
$15.3 million, $16.6 million and $66.2 million, respectively. For the years ended December 31, 2022, 2021 and 2020, we issued
254,907, 299,958 and 571,963 shares of common stock, respectively, upon vesting of certain RSUs and PSUs for which the
RSU holders surrendered 68,425, 94,795 and 142,905 RSUs, respectively, to pay for minimum withholding taxes totaling
approximately $4.4 million, $8.2 million and $5.5 million, respectively. Stock options and unvested restricted units totaling
approximately 6.6 million, 5.9 million and 6.7 million shares of our common stock were outstanding as of December 31, 2022,
2021 and 2020, respectively.

Share Repurchases

In November 2019, the Board of Directors authorized a capital return program to repurchase up to $550.0 million of
outstanding common stock over a three-year period. During 2020, we repurchased 6.5 million shares of common stock for
$150.0 million at an average price of $23.05. During 2021, we repurchased 4.6 million shares of common stock for
$200.0 million at an average price of $43.02 under the program. The shares were purchased through open market transactions
and through an ASR agreement. The $550.0 million share repurchase program was completed in October 2021 having
repurchased a total of 22.3 million shares at an average price of $24.72.

In December 2021, the Board of Directors authorized a second capital return program to repurchase up to $750.0 million
of outstanding stock over a three-year period. Also in December 2021, as part of the second capital return program, we entered
into an ASR agreement to repurchase $150.0 million of common stock. At inception pursuant to the agreement, we paid
$150.0 million and took initial delivery of 3.5 million shares. In June 2022, we finalized the transaction and received an
additional 0.4 million shares.

In August 2022, concurrent with the sale of 2028 Convertible Notes and the 2022 Induced Conversion, we repurchased
2.1 million shares of common stock in open market purchases for $90.2 million. Also, in August 2022, we entered into an ASR
agreement to repurchase $109.8 million of our common stock. At inception, pursuant to the agreement, we paid $109.8 million
and took an initial delivery of 2.0 million shares. In December 2022, we finalized the transaction and received an additional
0.4 million shares. We retired the repurchased shares and they resumed their status of authorized and unissued shares.

We had the following activity under the approved share repurchase programs (dollars in thousands, except share and per

share data)

First quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Second quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Third quarter(2) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fourth quarter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Number of Shares
Purchased

2022

Weighted
Average Price
paid Per Share

—

—
4,500,216

$0.00

$0.00
$44.44

Total Cost(1)

$0
$200,000

(1) Included in the total cost of shares purchased is a commission fee of $0.02 per share.
(2) Included is 0.4 million shares delivered in December 2022 upon completion of the ASR.

F-39

11. Net Income per share

Basic net income per common share is computed by dividing net income for the period by the weighted average number
of common shares outstanding during the period, without consideration for common stock equivalents. Outstanding stock
options, unvested RSAs, unvested RSUs, unvested PSUs, common shares expected to be issued under our ESPP and the
Convertible Notes are considered common stock equivalents and are only included in the calculation of diluted earnings per
common share when net income is reported and their effect is dilutive.

Potentially dilutive common shares issuable upon vesting of stock options, RSAs, RSUs and PSUs are determined using
the average share price for each period under the treasury stock method. Potentially dilutive common shares issuable upon
conversion of our Convertible Notes are determined using the if-converted method. Since we have committed to settle the
principal amount of the Convertible Notes in cash upon conversion only, the number of shares for the conversion spread will be
included as a dilutive common stock equivalent.

A reconciliation of the numerators and the denominators of the basic and diluted net income per common share

computations is as follows (in thousands, except per share amounts):

Twelve Months Ended
December 31,

2022

2021

2020

Numerator:

Net income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 202,129 $ 402,710 $ 129,085

Denominator:

Weighted average common shares outstanding for basic net
income per share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dilutive potential common stock outstanding:

Stock Options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

RSAs, RSUs, PSUs and ESPP . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Convertible Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Weighted average common shares outstanding for diluted net
income per share . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

136,844

140,646

136,206

2,265

422

1,077

2,737

555

2,858

2,317

627

2,313

140,608

146,796

141,463

Net income per share:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $

1.48 $
1.44 $

2.86 $
2.74 $

0.95
0.91

Shares which have been excluded from the calculation of diluted net income per common share because their effect was

anti-dilutive, include the following (shares in millions):

Anti-dilutive securities (1)

Twelve Months Ended
December 31,

2022

2021

2020

20.7

13.8

18.6

(1). The anti-dilutive securities include outstanding stock options, unvested RSUs, unvested PSUs, common shares expected to
be issued under our ESPP and Convertible Notes.

F-40

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

12. Commitments and Contingencies

Operating Leases

Our properties consist of leased office, laboratory, warehouse and manufacturing facilities. Our administrative offices and
research facilities are located in San Diego, California. In addition, we have an office in Ewing, New Jersey. We also lease a
building in Minnetonka, Minnesota consisting of office, laboratory, manufacturing and warehousing space. We lease an
aggregate of approximately 194,000 square feet of space.

In March 2022, we entered into an agreement for assignment and assumption of lease with Seismic Software, Inc.
pursuant to which effective January 1, 2023, we assumed Seismic’s office lease, as amended with Kilroy Realty L.P. for
approximately 73,238 square feet of space in office and research facilities which commenced on December 1, 2022.

We also pay a pro rata share of operating costs, insurance costs, utilities and real property taxes.

Additionally, we lease certain office equipment under operating leases. Total rent expense was approximately $3.3

million, $2.0 million and $2.3 million for the years ended December 31, 2022, 2021 and 2020, respectively.

Approximate annual future minimum operating lease payments as of December 31, 2022 are as follows (in thousands):

Year:
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total minimum lease payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Less imputed interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Operating
Leases

7,800

6,173

5,464

5,149

5,296

17,133

47,015

(12,227)

Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

34,788

The weighted-average remaining lease term of our operating leases is approximately 7.64 years.

Legal Contingencies

F-41

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

13. Income Taxes

Total income (loss) before income taxes summarized by region were as follows (in thousands):

Year Ended December 31,

2022

2021

2020

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

248,918

248,071

130,427

Foreign . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

447

(1,125)

Net income before income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

248,918

248,518

129,302

Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands).

December 31,

2022

2021

Deferred tax assets:

Net operating loss carryforwards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

32,887

42,182

Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Research and development and orphan drug credits . . . . . . . . . . . . . . . . . . . . . . . . . .

Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ASC 842 lease liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Capitalized research expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Transaction related expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Inventory related reserves . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Interest expense limitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Valuation allowance for deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Deferred tax assets, net of valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Deferred tax liabilities:

837

96,133

6,353

2,480

10,168

2,354

18,395

—

3,054

909

109,041

1,814

600

—

3,449

172,661

157,995

(707)

(500)

171,954

157,495

Non-deductible book amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Convertible note . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ASC 842 right of use asset . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Net deferred tax asset . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(115,578)

(2,559)

—

(9,061)

(330)
(127,528) $
$
44,426

$
$

(1,185)

(17)

(426)

(433)
(2,061)
155,434

A valuation allowance of $0.7 million and $0.5 million has been established to offset the net deferred tax assets as of

December 31, 2022 and 2021, respectively, as realization of such assets is uncertain.

On a periodic basis, we reassess the valuation allowance of our DTAs, weighing all positive and negative evidence, to
assess if it is more-likely-than-not that some or all of our DTAs will be realized. In 2021, we have demonstrated profitability
and cumulative pretax income and are forecasting income growth. After assessing both the positive and negative evidence, we
determined that it was more likely than not that our DTAs would be realized and released the valuation allowance in 2021.

F-42

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

On May 24, 2022, we acquired the outstanding shares of Antares Pharma Inc. This transaction was treated as a non-
taxable acquisition, we have increased our deferred tax liabilities by approximately $119.7 million related to acquired
intellectual property and a step-up to the value of inventory the amortization of which will not be tax deductible.

Income tax (benefit) expense was comprised of the following components (in thousands):

Year Ended December 31,

2022

2021

2020

Current - federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6,157

(9) $

Current - state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Deferred - federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Deferred - state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,525

44,757

(6,650)

1,251

(117,925)

(37,509)

46,789

(154,192) $

(11)

228

—

217

The provision for income taxes on earnings subject to income taxes differs from the statutory federal income tax rate due

to the following:

Federal income tax expense (benefit) at 21% . . . . . . . . . . . . . . . . . . . . .

State income tax expense (benefit), net of federal income tax impact . .

(Decrease) increase in valuation allowance . . . . . . . . . . . . . . . . . . . . . . .

Worthless stock deduction of international subsidiary . . . . . . . . . . . . . .

Foreign income subject to tax at other than federal statutory rate . . . . . .

Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Executive compensation limitation . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Non-deductible expenses and other . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Foreign-derived intangible income . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Transaction costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2022
21.00 %

0.82 %

(0.39) %

— %

(0.66) %

2.61 %

(0.40) %

(5.06) %

0.88 %

2021
21.00 %

2.67 %

(84.92) %

— %

0.02 %

(2.50) %

2.32 %

0.54 %

(1.18) %

— %

18.80 %

(62.05) %

2020
21.00 %

(1.59) %

34.59 %

(52.07) %

0.16 %

(1.89) %

1.61 %

(1.64) %

— %

0.17 %

At December 31, 2022, our unrecognized tax benefit and uncertain tax positions were $19.5 million, which will impact
the effective tax rate when resolved. Of the unrecognized tax benefits, we do not expect any significant changes to occur in the
next 12 months. Interest and/or penalties related to uncertain income tax positions are recognized by us as a component of
income tax expense. For the years ended December 31, 2022, 2021 and 2020, we recognized an immaterial amount of interest
and penalties.

F-43

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

The following table summarizes the activity related to our unrecognized tax benefits (in thousands):

Year Ended December 31,

2022

2021

2020

Gross unrecognized tax benefits at beginning of period . . . . . . . . . . . . .

17,692

19,167

21,483

Increases in tax positions for prior years . . . . . . . . . . . . . . . . . . . . . . . . .
Decreases in tax positions for prior years and lapse in statue of
limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Increases in tax positions related to business acquisition . . . . . . . . . . . .

Increases in tax positions for current year . . . . . . . . . . . . . . . . . . . . . . .

—

(1,148)

2,151

787

(1,496)

(2,357)

—

Gross unrecognized tax benefits at end of period . . . . . . . . . . . . . . . . . .

19,482

17,692

19,167

At December 31, 2022, we had federal, California and other state tax net operating loss carryforwards of approximately
$31.2 million, $237.4 million and $63.4 million, respectively. The California and Minnesota net operating loss carryforwards
begin to expire in 2028 and 2022, respectively.

As a result of the acquisition of Antares, we acquired federal and Minnesota research and development credits of
approximately $7.4 million and $0.72 million, respectively. We expect to be able to fully utilize these attributes without
limitation.

At December 31, 2022, we had federal, California and Minnesota research and development tax credit carryforwards of
approximately $30.8 million, $17.0 million and $0.7 million, respectively. The federal research and development tax credits
will begin to expire in 2030 unless previously utilized. The California research and development tax credits will carryforward
indefinitely until utilized. The Minnesota research and development credit will begin to expire in 2023 unless previously
utilized. Additionally, we had Orphan Drug Credit carryforwards of $70.0 million which will begin to expire in 2034.

Pursuant to Internal Revenue Code Section 382, the annual use of the net operating loss carryforwards and research and
development tax credits could be limited by any greater than 50% ownership change during any three year testing period. As a
result of any such ownership change, portions of our net operating loss carryforwards and research and development tax credits
are subject to annual limitations. We completed an updated Section 382 analysis regarding the limitation of the net operating
losses and research and development credits as of December 31, 2020. Based upon the analysis, we determined that ownership
changes occurred in prior years; however, the annual limitations on net operating loss and research and development tax credit
carryforwards will not have a material impact on the future utilization of such carryforwards.

We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiary as it is our intention to
utilize those earnings in the foreign operations for an indefinite period of time. At December 31, 2022 and 2021, there were no
undistributed earnings in foreign subsidiaries.

We are subject to taxation in the U.S. and in various state and foreign jurisdictions. Our tax years for 2008 and forward
are subject to examination by the U.S. and California tax authorities due to the carryforward of unutilized net operating losses
and research and development credits.

F-44

Halozyme Therapeutics, Inc.

Notes to Consolidated Financial Statements — (Continued)

14. Employee Savings Plan

We have an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code. All employees are eligible to
participate, provided they meet the requirements of the plan. We are not required to make matching contributions under the
plan. However, we voluntarily contributed to the plan approximately $2.6 million, $1.1 million and $1.1 million for the years
ended December 31, 2022, 2021 and 2020, respectively.

Halozyme Therapeutics, Inc.

Schedule II

Valuation and Qualifying Accounts
(in thousands)

Balance at
Beginning of
Period

Acquired

Additions

Deductions

Balance at
End of Period

For the year ended December 31, 2022
Accounts receivable allowances (1)
For the year ended December 31, 2021
Accounts receivable allowances (1)
For the year ended December 31, 2020
Accounts receivable allowances (1)

. . . . . . . $

1,140 $

924 $

5,946 $

(6,096) $

1,914

1,003 $

— $

8,131 $

(7,994) $

1,140

797 $

— $

13,276 $

(13,070) $

1,003

_______________

(1) Allowances are for chargebacks, prompt payment discounts and distribution fees related to proprietary product sales.

F-45

Halozyme Therapeutics, Inc.
12390 El Camino Real
San Diego, CA 92130
858-794-8889
info@halozyme.com
www.halozyme.com